[
  {
    "alterations": [
      2
    ], 
    "assertion_id": 2, 
    "created_on": null, 
    "description": "ALK rearrangement, notably with EML4, may suggest sensitivity to Crizotinib as a first or subsequent line of therapy. See NCCN guidelines for more details in the case of resistance to Crizotinib in the presence of ALK rearrangement.", 
    "disease": "Non-Small Cell Lung Cancer", 
    "favorable_prognosis": null, 
    "last_updated": "2017-11-03 14:38:58.792337", 
    "old_disease": "Non-Small Cell Lung Cancer", 
    "oncotree_code": "NSCLC", 
    "predictive_implication": "Level A", 
    "sources": [
      2
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "ALK Inhibitors", 
    "therapy_sensitivity": true, 
    "therapy_type": "Drug Class", 
    "validated": true
  }, 
  {
    "alterations": [
      3
    ], 
    "assertion_id": 3, 
    "created_on": null, 
    "description": "T315I mutant ABL1 in p210 BCR-ABL cells resulted in retained high levels of phosphotyrosine at increasing concentrations of inhibitor STI-571, whereas wildtype appropriately received inhibition.", 
    "disease": "Chronic Myelogenous Leukemia", 
    "favorable_prognosis": null, 
    "last_updated": "2017-11-03 14:38:58.806761", 
    "old_disease": "Chronic Myeloid Leukemia", 
    "oncotree_code": "CML", 
    "predictive_implication": "Level D", 
    "sources": [
      3
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "STI-571", 
    "therapy_sensitivity": false, 
    "therapy_type": "Targeted Drug", 
    "validated": true
  }, 
  {
    "alterations": [
      4
    ], 
    "assertion_id": 4, 
    "created_on": null, 
    "description": "Secondary mutations in BCR-ABL may suggest resistance to imatinib in CML.", 
    "disease": "Chronic Myelogenous Leukemia", 
    "favorable_prognosis": null, 
    "last_updated": "2017-11-03 14:38:58.819859", 
    "old_disease": "Chronic Myeloid Leukemia", 
    "oncotree_code": "CML", 
    "predictive_implication": "Level B", 
    "sources": [
      4
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "Imatinib", 
    "therapy_sensitivity": false, 
    "therapy_type": "Targeted Drug", 
    "validated": true
  }, 
  {
    "alterations": [
      5
    ], 
    "assertion_id": 5, 
    "created_on": null, 
    "description": "Secondary mutations in BCR-ABL may suggest resistance to imatinib in CML. ABL [T315I, V299L, T315A, F317L/V/I/C] are known to be less sensitive to dasatinib.", 
    "disease": "Chronic Myelogenous Leukemia", 
    "favorable_prognosis": null, 
    "last_updated": "2017-11-03 14:38:58.835129", 
    "old_disease": "Chronic Myeloid Leukemia", 
    "oncotree_code": "CML", 
    "predictive_implication": "Level B", 
    "sources": [
      4
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "Dasatinib", 
    "therapy_sensitivity": false, 
    "therapy_type": "Targeted Drug", 
    "validated": true
  }, 
  {
    "alterations": [
      6
    ], 
    "assertion_id": 6, 
    "created_on": null, 
    "description": "Secondary mutations in BCR-ABL may suggest resistance to imatinib in CML. ABL [T315I, V299L, T315A, F317L/V/I/C] are known to be less sensitive to dasatinib.", 
    "disease": "Chronic Myelogenous Leukemia", 
    "favorable_prognosis": null, 
    "last_updated": "2017-11-03 14:38:58.851434", 
    "old_disease": "Chronic Myeloid Leukemia", 
    "oncotree_code": "CML", 
    "predictive_implication": "Level B", 
    "sources": [
      4
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "Dasatinib", 
    "therapy_sensitivity": false, 
    "therapy_type": "Targeted Drug", 
    "validated": true
  }, 
  {
    "alterations": [
      3
    ], 
    "assertion_id": 7, 
    "created_on": null, 
    "description": "Secondary mutations in BCR-ABL may suggest resistance to imatinib in CML. ABL [T315I, V299L, T315A, F317L/V/I/C] are known to be less sensitive to dasatinib.", 
    "disease": "Chronic Myelogenous Leukemia", 
    "favorable_prognosis": null, 
    "last_updated": "2017-11-03 14:38:58.864625", 
    "old_disease": "Chronic Myeloid Leukemia", 
    "oncotree_code": "CML", 
    "predictive_implication": "Level B", 
    "sources": [
      4
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "Dasatinib", 
    "therapy_sensitivity": false, 
    "therapy_type": "Targeted Drug", 
    "validated": true
  }, 
  {
    "alterations": [
      7
    ], 
    "assertion_id": 8, 
    "created_on": null, 
    "description": "Secondary mutations in BCR-ABL may suggest resistance to imatinib in CML. ABL [T315I, V299L, T315A, F317L/V/I/C] are known to be less sensitive to dasatinib.", 
    "disease": "Chronic Myelogenous Leukemia", 
    "favorable_prognosis": null, 
    "last_updated": "2017-11-03 14:38:58.879454", 
    "old_disease": "Chronic Myeloid Leukemia", 
    "oncotree_code": "CML", 
    "predictive_implication": "Level B", 
    "sources": [
      4
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "Dasatinib", 
    "therapy_sensitivity": false, 
    "therapy_type": "Targeted Drug", 
    "validated": true
  }, 
  {
    "alterations": [
      8
    ], 
    "assertion_id": 9, 
    "created_on": null, 
    "description": "Secondary mutations in BCR-ABL may suggest resistance to imatinib in CML. ABL [T315I, V299L, T315A, F317L/V/I/C] are known to be less sensitive to dasatinib.", 
    "disease": "Chronic Myelogenous Leukemia", 
    "favorable_prognosis": null, 
    "last_updated": "2017-11-03 14:38:58.896239", 
    "old_disease": "Chronic Myeloid Leukemia", 
    "oncotree_code": "CML", 
    "predictive_implication": "Level B", 
    "sources": [
      4
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "Dasatinib", 
    "therapy_sensitivity": false, 
    "therapy_type": "Targeted Drug", 
    "validated": true
  }, 
  {
    "alterations": [
      9
    ], 
    "assertion_id": 10, 
    "created_on": null, 
    "description": "Secondary mutations in BCR-ABL may suggest resistance to imatinib in CML. ABL [T315I, V299L, T315A, F317L/V/I/C] are known to be less sensitive to dasatinib.", 
    "disease": "Chronic Myelogenous Leukemia", 
    "favorable_prognosis": null, 
    "last_updated": "2017-11-03 14:38:58.912589", 
    "old_disease": "Chronic Myeloid Leukemia", 
    "oncotree_code": "CML", 
    "predictive_implication": "Level B", 
    "sources": [
      4
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "Dasatinib", 
    "therapy_sensitivity": false, 
    "therapy_type": "Targeted Drug", 
    "validated": true
  }, 
  {
    "alterations": [
      10
    ], 
    "assertion_id": 11, 
    "created_on": null, 
    "description": "Secondary mutations in BCR-ABL may suggest resistance to imatinib in CML. ABL [T315I, V299L, T315A, F317L/V/I/C] are known to be less sensitive to dasatinib.", 
    "disease": "Chronic Myelogenous Leukemia", 
    "favorable_prognosis": null, 
    "last_updated": "2017-11-03 14:38:58.926407", 
    "old_disease": "Chronic Myeloid Leukemia", 
    "oncotree_code": "CML", 
    "predictive_implication": "Level B", 
    "sources": [
      4
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "Dasatinib", 
    "therapy_sensitivity": false, 
    "therapy_type": "Targeted Drug", 
    "validated": true
  }, 
  {
    "alterations": [
      11
    ], 
    "assertion_id": 12, 
    "created_on": null, 
    "description": "Secondary mutations in BCR-ABL may suggest resistance to imatinib in CML. ABL [E255K/V, Y253H, F359V/C/I] are known to be less sensitive to Nilotinib.", 
    "disease": "Chronic Myelogenous Leukemia", 
    "favorable_prognosis": null, 
    "last_updated": "2017-11-03 14:38:58.942510", 
    "old_disease": "Chronic Myeloid Leukemia", 
    "oncotree_code": "CML", 
    "predictive_implication": "Level B", 
    "sources": [
      4
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "Nilotinib", 
    "therapy_sensitivity": false, 
    "therapy_type": "Targeted Drug", 
    "validated": true
  }, 
  {
    "alterations": [
      12
    ], 
    "assertion_id": 13, 
    "created_on": null, 
    "description": "Secondary mutations in BCR-ABL may suggest resistance to imatinib in CML. ABL [E255K/V, Y253H, F359V/C/I] are known to be less sensitive to Nilotinib.", 
    "disease": "Chronic Myelogenous Leukemia", 
    "favorable_prognosis": null, 
    "last_updated": "2017-11-03 14:38:58.958837", 
    "old_disease": "Chronic Myeloid Leukemia", 
    "oncotree_code": "CML", 
    "predictive_implication": "Level B", 
    "sources": [
      4
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "Nilotinib", 
    "therapy_sensitivity": false, 
    "therapy_type": "Targeted Drug", 
    "validated": true
  }, 
  {
    "alterations": [
      13
    ], 
    "assertion_id": 14, 
    "created_on": null, 
    "description": "Secondary mutations in BCR-ABL may suggest resistance to imatinib in CML. ABL [E255K/V, Y253H, F359V/C/I] are known to be less sensitive to Nilotinib.", 
    "disease": "Chronic Myelogenous Leukemia", 
    "favorable_prognosis": null, 
    "last_updated": "2017-11-03 14:38:58.975431", 
    "old_disease": "Chronic Myeloid Leukemia", 
    "oncotree_code": "CML", 
    "predictive_implication": "Level B", 
    "sources": [
      4
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "Nilotinib", 
    "therapy_sensitivity": false, 
    "therapy_type": "Targeted Drug", 
    "validated": true
  }, 
  {
    "alterations": [
      14
    ], 
    "assertion_id": 15, 
    "created_on": null, 
    "description": "Secondary mutations in BCR-ABL may suggest resistance to imatinib in CML. ABL [E255K/V, Y253H, F359V/C/I] are known to be less sensitive to Nilotinib.", 
    "disease": "Chronic Myelogenous Leukemia", 
    "favorable_prognosis": null, 
    "last_updated": "2017-11-03 14:38:59.002625", 
    "old_disease": "Chronic Myeloid Leukemia", 
    "oncotree_code": "CML", 
    "predictive_implication": "Level B", 
    "sources": [
      4
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "Nilotinib", 
    "therapy_sensitivity": false, 
    "therapy_type": "Targeted Drug", 
    "validated": true
  }, 
  {
    "alterations": [
      15
    ], 
    "assertion_id": 16, 
    "created_on": null, 
    "description": "Secondary mutations in BCR-ABL may suggest resistance to imatinib in CML. ABL [E255K/V, Y253H, F359V/C/I] are known to be less sensitive to Nilotinib.", 
    "disease": "Chronic Myelogenous Leukemia", 
    "favorable_prognosis": null, 
    "last_updated": "2017-11-03 14:38:59.022069", 
    "old_disease": "Chronic Myeloid Leukemia", 
    "oncotree_code": "CML", 
    "predictive_implication": "Level B", 
    "sources": [
      4
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "Nilotinib", 
    "therapy_sensitivity": false, 
    "therapy_type": "Targeted Drug", 
    "validated": true
  }, 
  {
    "alterations": [
      16
    ], 
    "assertion_id": 17, 
    "created_on": null, 
    "description": "Secondary mutations in BCR-ABL may suggest resistance to imatinib in CML. ABL [E255K/V, Y253H, F359V/C/I] are known to be less sensitive to Nilotinib.", 
    "disease": "Chronic Myelogenous Leukemia", 
    "favorable_prognosis": null, 
    "last_updated": "2017-11-03 14:38:59.036715", 
    "old_disease": "Chronic Myeloid Leukemia", 
    "oncotree_code": "CML", 
    "predictive_implication": "Level B", 
    "sources": [
      4
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "Nilotinib", 
    "therapy_sensitivity": false, 
    "therapy_type": "Targeted Drug", 
    "validated": true
  }, 
  {
    "alterations": [
      17
    ], 
    "assertion_id": 18, 
    "created_on": null, 
    "description": "Activating mutations in AKT may predict sensitivity to direct inhibition or downstream inhibition of the PI3K/mTOR pathway", 
    "disease": "", 
    "favorable_prognosis": null, 
    "last_updated": "2017-11-03 14:38:59.052229", 
    "old_disease": "", 
    "oncotree_code": "", 
    "predictive_implication": "Level D", 
    "sources": [
      5
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "MK-2206", 
    "therapy_sensitivity": true, 
    "therapy_type": "Targeted Drug", 
    "validated": true
  }, 
  {
    "alterations": [
      18
    ], 
    "assertion_id": 19, 
    "created_on": null, 
    "description": "Activating mutations in AKT may predict sensitivity to direct inhibition or downstream inhibition of the PI3K/mTOR pathway", 
    "disease": "", 
    "favorable_prognosis": null, 
    "last_updated": "2017-11-03 14:38:59.069377", 
    "old_disease": "", 
    "oncotree_code": "", 
    "predictive_implication": "Level D", 
    "sources": [
      5
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "MK-2206", 
    "therapy_sensitivity": true, 
    "therapy_type": "Targeted Drug", 
    "validated": true
  }, 
  {
    "alterations": [
      19
    ], 
    "assertion_id": 20, 
    "created_on": null, 
    "description": "Activating mutations in AKT may predict sensitivity to direct inhibition or downstream inhibition of the PI3K/mTOR pathway", 
    "disease": "", 
    "favorable_prognosis": null, 
    "last_updated": "2017-11-03 14:38:59.084982", 
    "old_disease": "", 
    "oncotree_code": "", 
    "predictive_implication": "Level D", 
    "sources": [
      5
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "MK-2206", 
    "therapy_sensitivity": true, 
    "therapy_type": "Targeted Drug", 
    "validated": true
  }, 
  {
    "alterations": [
      20
    ], 
    "assertion_id": 21, 
    "created_on": null, 
    "description": "Activating mutations in AKT may predict sensitivity to direct inhibition or downstream inhibition of the PI3K/mTOR pathway", 
    "disease": "", 
    "favorable_prognosis": null, 
    "last_updated": "2017-11-03 14:38:59.098247", 
    "old_disease": "", 
    "oncotree_code": "", 
    "predictive_implication": "Level D", 
    "sources": [
      5
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "MK-2206", 
    "therapy_sensitivity": true, 
    "therapy_type": "Targeted Drug", 
    "validated": true
  }, 
  {
    "alterations": [
      21
    ], 
    "assertion_id": 22, 
    "created_on": null, 
    "description": "Ceritinib (LDK378), an ALK TKI, was evaluated in the context of crizotinib resistant ALK rearrangement positive non-small cell lung cancers. It was found that Certinib potently overcame crizotinib-resistant mutations. In particular, L1196M, G1269A, I1171T, S1206Y but it was not able to overcome G1202R and F1174C.", 
    "disease": "Non-Small Cell Lung Cancer", 
    "favorable_prognosis": null, 
    "last_updated": "2017-11-03 14:38:59.113454", 
    "old_disease": "Non-Small Cell Lung Cancer", 
    "oncotree_code": "NSCLC", 
    "predictive_implication": "Level D", 
    "sources": [
      6
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "Certinib", 
    "therapy_sensitivity": true, 
    "therapy_type": "Targeted Drug", 
    "validated": true
  }, 
  {
    "alterations": [
      22
    ], 
    "assertion_id": 23, 
    "created_on": null, 
    "description": "Ceritinib (LDK378), an ALK TKI, was evaluated in the context of crizotinib resistant ALK rearrangement positive non-small cell lung cancers. It was found that Certinib potently overcame crizotinib-resistant mutations. In particular, L1196M, G1269A, I1171T, S1206Y but it was not able to overcome G1202R and F1174C.", 
    "disease": "Non-Small Cell Lung Cancer", 
    "favorable_prognosis": null, 
    "last_updated": "2017-11-03 14:38:59.130252", 
    "old_disease": "Non-Small Cell Lung Cancer", 
    "oncotree_code": "NSCLC", 
    "predictive_implication": "Level D", 
    "sources": [
      6
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "Certinib", 
    "therapy_sensitivity": true, 
    "therapy_type": "Targeted Drug", 
    "validated": true
  }, 
  {
    "alterations": [
      23
    ], 
    "assertion_id": 24, 
    "created_on": null, 
    "description": "Ceritinib (LDK378), an ALK TKI, was evaluated in the context of crizotinib resistant ALK rearrangement positive non-small cell lung cancers. It was found that Certinib potently overcame crizotinib-resistant mutations. In particular, L1196M, G1269A, I1171T, S1206Y but it was not able to overcome G1202R and F1174C.", 
    "disease": "Non-Small Cell Lung Cancer", 
    "favorable_prognosis": null, 
    "last_updated": "2017-11-03 14:38:59.144878", 
    "old_disease": "Non-Small Cell Lung Cancer", 
    "oncotree_code": "NSCLC", 
    "predictive_implication": "Level D", 
    "sources": [
      6
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "Certinib", 
    "therapy_sensitivity": true, 
    "therapy_type": "Targeted Drug", 
    "validated": true
  }, 
  {
    "alterations": [
      24
    ], 
    "assertion_id": 25, 
    "created_on": null, 
    "description": "Ceritinib (LDK378), an ALK TKI, was evaluated in the context of crizotinib resistant ALK rearrangement positive non-small cell lung cancers. It was found that Certinib potently overcame crizotinib-resistant mutations. In particular, L1196M, G1269A, I1171T, S1206Y but it was not able to overcome G1202R and F1174C.", 
    "disease": "Non-Small Cell Lung Cancer", 
    "favorable_prognosis": null, 
    "last_updated": "2017-11-03 14:38:59.160087", 
    "old_disease": "Non-Small Cell Lung Cancer", 
    "oncotree_code": "NSCLC", 
    "predictive_implication": "Level D", 
    "sources": [
      6
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "Certinib", 
    "therapy_sensitivity": false, 
    "therapy_type": "Targeted Drug", 
    "validated": true
  }, 
  {
    "alterations": [
      25
    ], 
    "assertion_id": 26, 
    "created_on": null, 
    "description": "Ceritinib (LDK378), an ALK TKI, was evaluated in the context of crizotinib resistant ALK rearrangement positive non-small cell lung cancers. It was found that Certinib potently overcame crizotinib-resistant mutations. In particular, L1196M, G1269A, I1171T, S1206Y but it was not able to overcome G1202R and F1174C.", 
    "disease": "Non-Small Cell Lung Cancer", 
    "favorable_prognosis": null, 
    "last_updated": "2017-11-03 14:38:59.175981", 
    "old_disease": "Non-Small Cell Lung Cancer", 
    "oncotree_code": "NSCLC", 
    "predictive_implication": "Level D", 
    "sources": [
      6
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "Certinib", 
    "therapy_sensitivity": false, 
    "therapy_type": "Targeted Drug", 
    "validated": true
  }, 
  {
    "alterations": [
      26
    ], 
    "assertion_id": 27, 
    "created_on": null, 
    "description": "Androgen receptor mutation may predict resistance to second generation androgen deprivation or direct androgen inhibitors.", 
    "disease": "Prostate Adenocarcinoma", 
    "favorable_prognosis": null, 
    "last_updated": "2017-11-03 14:38:59.191703", 
    "old_disease": "Prostate Cancer", 
    "oncotree_code": "PRAD", 
    "predictive_implication": "Level B", 
    "sources": [
      7
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "Androgen Deprivation Therapy", 
    "therapy_sensitivity": false, 
    "therapy_type": "Drug Class", 
    "validated": true
  }, 
  {
    "alterations": [
      27
    ], 
    "assertion_id": 28, 
    "created_on": null, 
    "description": "Androgen receptor mutation may predict resistance to second generation androgen deprivation or direct androgen inhibitors.", 
    "disease": "Prostate Adenocarcinoma", 
    "favorable_prognosis": null, 
    "last_updated": "2017-11-03 14:38:59.205160", 
    "old_disease": "Prostate Cancer", 
    "oncotree_code": "PRAD", 
    "predictive_implication": "Level B", 
    "sources": [
      7
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "Androgen Deprivation Therapy", 
    "therapy_sensitivity": false, 
    "therapy_type": "Drug Class", 
    "validated": true
  }, 
  {
    "alterations": [
      28
    ], 
    "assertion_id": 29, 
    "created_on": null, 
    "description": "Androgen receptor activation may predict sensitivity to second generation androgen deprivation or direct androgen inhibitors.", 
    "disease": "Prostate Adenocarcinoma", 
    "favorable_prognosis": null, 
    "last_updated": "2017-11-03 14:38:59.220478", 
    "old_disease": "Prostate Cancer", 
    "oncotree_code": "PRAD", 
    "predictive_implication": "FDA-Approved", 
    "sources": [
      8
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "Abiraterone", 
    "therapy_sensitivity": true, 
    "therapy_type": "Targeted Drug", 
    "validated": true
  }, 
  {
    "alterations": [
      28
    ], 
    "assertion_id": 30, 
    "created_on": null, 
    "description": "Androgen receptor activation is a potential mechanism of recurrence of prostate cancer during androgen deprivation therapy.", 
    "disease": "Prostate Adenocarcinoma", 
    "favorable_prognosis": null, 
    "last_updated": "2017-11-03 14:38:59.236555", 
    "old_disease": "Prostate Cancer", 
    "oncotree_code": "PRAD", 
    "predictive_implication": "Level A", 
    "sources": [
      8
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "Androgen Deprivation Therapy", 
    "therapy_sensitivity": false, 
    "therapy_type": "Drug Class", 
    "validated": true
  }, 
  {
    "alterations": [
      28
    ], 
    "assertion_id": 31, 
    "created_on": null, 
    "description": "Androgen receptor activation may predict sensitivity to second generation androgen deprivation or direct androgen inhibitors.", 
    "disease": "Prostate Adenocarcinoma", 
    "favorable_prognosis": null, 
    "last_updated": "2017-11-03 14:38:59.248534", 
    "old_disease": "Prostate Cancer", 
    "oncotree_code": "PRAD", 
    "predictive_implication": "FDA-Approved", 
    "sources": [
      8
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "Enzalutamide", 
    "therapy_sensitivity": true, 
    "therapy_type": "Targeted Drug", 
    "validated": true
  }, 
  {
    "alterations": [
      29
    ], 
    "assertion_id": 32, 
    "created_on": null, 
    "description": "Activating mutations in ARAF may predict sensitivity to sorafenib or other RAF inhibitors. Patient received 5 year response to sorafenib with ARAF S214C.", 
    "disease": "Non-Small Cell Lung Cancer", 
    "favorable_prognosis": null, 
    "last_updated": "2017-11-03 14:38:59.262386", 
    "old_disease": "Non-Small Cell Lung Cancer", 
    "oncotree_code": "NSCLC", 
    "predictive_implication": "Level B", 
    "sources": [
      9
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "Sorafenib", 
    "therapy_sensitivity": true, 
    "therapy_type": "Targeted Drug", 
    "validated": true
  }, 
  {
    "alterations": [
      30
    ], 
    "assertion_id": 33, 
    "created_on": null, 
    "description": "ARID1A mutations were associated with poorer prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors.", 
    "disease": "Pancreatic Adenocarcinoma", 
    "favorable_prognosis": false, 
    "last_updated": "2017-11-03 14:38:59.277530", 
    "old_disease": "Pancreatic Cancer", 
    "oncotree_code": "PAAD", 
    "predictive_implication": "Level B", 
    "sources": [
      10
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "", 
    "therapy_sensitivity": null, 
    "therapy_type": "", 
    "validated": true
  }, 
  {
    "alterations": [
      31
    ], 
    "assertion_id": 34, 
    "created_on": null, 
    "description": "Most frequent in Chronic Myelomonocytic Leukemia.", 
    "disease": "Myelodysplasia ", 
    "favorable_prognosis": false, 
    "last_updated": "2017-11-03 14:38:59.294549", 
    "old_disease": "Myelodysplastic Syndromes", 
    "oncotree_code": "MDS", 
    "predictive_implication": "Level B", 
    "sources": [
      11
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "", 
    "therapy_sensitivity": null, 
    "therapy_type": "", 
    "validated": true
  }, 
  {
    "alterations": [
      32
    ], 
    "assertion_id": 35, 
    "created_on": null, 
    "description": "Most frequent in Chronic Myelomonocytic Leukemia.", 
    "disease": "Myelodysplasia ", 
    "favorable_prognosis": false, 
    "last_updated": "2017-11-03 14:38:59.309873", 
    "old_disease": "Myelodysplastic Syndromes", 
    "oncotree_code": "MDS", 
    "predictive_implication": "Level B", 
    "sources": [
      11
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "", 
    "therapy_sensitivity": null, 
    "therapy_type": "", 
    "validated": true
  }, 
  {
    "alterations": [
      33
    ], 
    "assertion_id": 36, 
    "created_on": null, 
    "description": "Downmodulation of TPX2 and AURKA in the presence of 20q copy gain was shown to tumor growth", 
    "disease": "Colorectal Adenocarcinoma", 
    "favorable_prognosis": false, 
    "last_updated": "2017-11-03 14:38:59.324697", 
    "old_disease": "Colorectal Cancer", 
    "oncotree_code": "COADREAD", 
    "predictive_implication": "Level D", 
    "sources": [
      12
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "", 
    "therapy_sensitivity": null, 
    "therapy_type": "", 
    "validated": true
  }, 
  {
    "alterations": [
      33
    ], 
    "assertion_id": 37, 
    "created_on": null, 
    "description": "Neuroendocrine prostate cancer (NEPC) cell lines shows enhanced sensitivity to pan-Aurora kinase inhibitor therapy, specifically to PHA-739358 (Danusertib)", 
    "disease": "Prostate Neuroendocrine Cancer", 
    "favorable_prognosis": null, 
    "last_updated": "2017-11-03 14:38:59.342060", 
    "old_disease": "Prostate Cancer", 
    "oncotree_code": "PRNE", 
    "predictive_implication": "Level D", 
    "sources": [
      13
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "Danusertib", 
    "therapy_sensitivity": true, 
    "therapy_type": "Targeted Drug", 
    "validated": true
  }, 
  {
    "alterations": [
      34
    ], 
    "assertion_id": 38, 
    "created_on": null, 
    "description": "MYC amplified small cell lung cancer", 
    "disease": "Small Cell Lung Cancer", 
    "favorable_prognosis": null, 
    "last_updated": "2017-11-03 14:38:59.359272", 
    "old_disease": "Small-Cell Lung Cancer", 
    "oncotree_code": "SCLC", 
    "predictive_implication": "Level D", 
    "sources": [
      14
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "Barasertib", 
    "therapy_sensitivity": true, 
    "therapy_type": "Targeted Drug", 
    "validated": true
  }, 
  {
    "alterations": [
      35
    ], 
    "assertion_id": 39, 
    "created_on": null, 
    "description": "Somatic homologous recombination mutations werepredictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.", 
    "disease": "Ovarian Cancer, Other", 
    "favorable_prognosis": null, 
    "last_updated": "2017-11-03 14:38:59.376074", 
    "old_disease": "Ovarian Cancer", 
    "oncotree_code": "OOVC", 
    "predictive_implication": "Level E", 
    "sources": [
      15
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "Platinum", 
    "therapy_sensitivity": true, 
    "therapy_type": "Chemotherapy", 
    "validated": true
  }, 
  {
    "alterations": [
      36
    ], 
    "assertion_id": 40, 
    "created_on": null, 
    "description": "Germline homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas. Mutant cases also had better overall survival than wild type.", 
    "disease": "Ovarian Cancer, Other", 
    "favorable_prognosis": true, 
    "last_updated": "2017-11-03 14:38:59.393622", 
    "old_disease": "Ovarian Cancer", 
    "oncotree_code": "OOVC", 
    "predictive_implication": "Level E", 
    "sources": [
      15
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "Platinum", 
    "therapy_sensitivity": null, 
    "therapy_type": "Chemotherapy", 
    "validated": true
  }, 
  {
    "alterations": [
      35
    ], 
    "assertion_id": 41, 
    "created_on": null, 
    "description": "Somatic homologous recombination mutations werepredictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.", 
    "disease": "Ovarian Cancer, Other", 
    "favorable_prognosis": true, 
    "last_updated": "2017-11-03 14:38:59.407483", 
    "old_disease": "Ovarian Cancer", 
    "oncotree_code": "OOVC", 
    "predictive_implication": "Level E", 
    "sources": [
      15
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "Platinum", 
    "therapy_sensitivity": null, 
    "therapy_type": "Chemotherapy", 
    "validated": true
  }, 
  {
    "alterations": [
      36
    ], 
    "assertion_id": 42, 
    "created_on": null, 
    "description": "Germline homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas. Mutant cases also had better overall survival than wild type.", 
    "disease": "Ovarian Cancer, Other", 
    "favorable_prognosis": true, 
    "last_updated": "2017-11-03 14:38:59.420955", 
    "old_disease": "Ovarian Cancer", 
    "oncotree_code": "OOVC", 
    "predictive_implication": "Level E", 
    "sources": [
      15
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "Platinum", 
    "therapy_sensitivity": null, 
    "therapy_type": "Chemotherapy", 
    "validated": true
  }, 
  {
    "alterations": [
      35
    ], 
    "assertion_id": 43, 
    "created_on": null, 
    "description": "Somatic homologous recombination mutations werepredictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.", 
    "disease": "Peritoneal Mesothelioma", 
    "favorable_prognosis": null, 
    "last_updated": "2017-11-03 14:38:59.433824", 
    "old_disease": "Peritoneal Carcinoma", 
    "oncotree_code": "PEMESO", 
    "predictive_implication": "Level E", 
    "sources": [
      15
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "Platinum", 
    "therapy_sensitivity": true, 
    "therapy_type": "Chemotherapy", 
    "validated": true
  }, 
  {
    "alterations": [
      36
    ], 
    "assertion_id": 44, 
    "created_on": null, 
    "description": "Germline homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas. Mutant cases also had better overall survival than wild type.", 
    "disease": "Peritoneal Mesothelioma", 
    "favorable_prognosis": true, 
    "last_updated": "2017-11-03 14:38:59.448563", 
    "old_disease": "Peritoneal Carcinoma", 
    "oncotree_code": "PEMESO", 
    "predictive_implication": "Level E", 
    "sources": [
      15
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "Platinum", 
    "therapy_sensitivity": null, 
    "therapy_type": "Chemotherapy", 
    "validated": true
  }, 
  {
    "alterations": [
      35
    ], 
    "assertion_id": 45, 
    "created_on": null, 
    "description": "Somatic homologous recombination mutations werepredictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.", 
    "disease": "Peritoneal Mesothelioma", 
    "favorable_prognosis": true, 
    "last_updated": "2017-11-03 14:38:59.461638", 
    "old_disease": "Peritoneal Carcinoma", 
    "oncotree_code": "PEMESO", 
    "predictive_implication": "Level E", 
    "sources": [
      15
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "Platinum", 
    "therapy_sensitivity": null, 
    "therapy_type": "Chemotherapy", 
    "validated": true
  }, 
  {
    "alterations": [
      36
    ], 
    "assertion_id": 46, 
    "created_on": null, 
    "description": "Germline homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas. Mutant cases also had better overall survival than wild type.", 
    "disease": "Peritoneal Mesothelioma", 
    "favorable_prognosis": true, 
    "last_updated": "2017-11-03 14:38:59.474270", 
    "old_disease": "Peritoneal Carcinoma", 
    "oncotree_code": "PEMESO", 
    "predictive_implication": "Level E", 
    "sources": [
      15
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "Platinum", 
    "therapy_sensitivity": null, 
    "therapy_type": "Chemotherapy", 
    "validated": true
  }, 
  {
    "alterations": [
      35
    ], 
    "assertion_id": 47, 
    "created_on": null, 
    "description": "Somatic homologous recombination mutations werepredictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.", 
    "disease": "Serous Ovarian Cancer", 
    "favorable_prognosis": null, 
    "last_updated": "2017-11-03 14:38:59.486431", 
    "old_disease": "Fallopian Tube Carcinoma", 
    "oncotree_code": "SOC", 
    "predictive_implication": "Level E", 
    "sources": [
      15
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "Platinum", 
    "therapy_sensitivity": true, 
    "therapy_type": "Chemotherapy", 
    "validated": true
  }, 
  {
    "alterations": [
      36
    ], 
    "assertion_id": 48, 
    "created_on": null, 
    "description": "Germline homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas. Mutant cases also had better overall survival than wild type.", 
    "disease": "Serous Ovarian Cancer", 
    "favorable_prognosis": true, 
    "last_updated": "2017-11-03 14:38:59.497445", 
    "old_disease": "Fallopian Tube Carcinoma", 
    "oncotree_code": "SOC", 
    "predictive_implication": "Level E", 
    "sources": [
      15
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "Platinum", 
    "therapy_sensitivity": null, 
    "therapy_type": "Chemotherapy", 
    "validated": true
  }, 
  {
    "alterations": [
      35
    ], 
    "assertion_id": 49, 
    "created_on": null, 
    "description": "Somatic homologous recombination mutations werepredictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.", 
    "disease": "Serous Ovarian Cancer", 
    "favorable_prognosis": true, 
    "last_updated": "2017-11-03 14:38:59.513534", 
    "old_disease": "Fallopian Tube Carcinoma", 
    "oncotree_code": "SOC", 
    "predictive_implication": "Level E", 
    "sources": [
      15
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "Platinum", 
    "therapy_sensitivity": null, 
    "therapy_type": "Chemotherapy", 
    "validated": true
  }, 
  {
    "alterations": [
      36
    ], 
    "assertion_id": 50, 
    "created_on": null, 
    "description": "Germline homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas. Mutant cases also had better overall survival than wild type.", 
    "disease": "Serous Ovarian Cancer", 
    "favorable_prognosis": true, 
    "last_updated": "2017-11-03 14:38:59.527505", 
    "old_disease": "Fallopian Tube Carcinoma", 
    "oncotree_code": "SOC", 
    "predictive_implication": "Level E", 
    "sources": [
      15
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "Platinum", 
    "therapy_sensitivity": null, 
    "therapy_type": "Chemotherapy", 
    "validated": true
  }, 
  {
    "alterations": [
      37
    ], 
    "assertion_id": 51, 
    "created_on": null, 
    "description": "More frequent in Chronic Myelomonocytic Leukemia.", 
    "disease": "Myelodysplasia ", 
    "favorable_prognosis": false, 
    "last_updated": "2017-11-03 14:38:59.541551", 
    "old_disease": "Myelodysplastic Syndromes", 
    "oncotree_code": "MDS", 
    "predictive_implication": "Level B", 
    "sources": [
      11
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "", 
    "therapy_sensitivity": null, 
    "therapy_type": "", 
    "validated": true
  }, 
  {
    "alterations": [
      38
    ], 
    "assertion_id": 52, 
    "created_on": null, 
    "description": "More frequent in Chronic Myelomonocytic Leukemia.", 
    "disease": "Myelodysplasia ", 
    "favorable_prognosis": false, 
    "last_updated": "2017-11-03 14:38:59.559042", 
    "old_disease": "Myelodysplastic Syndromes", 
    "oncotree_code": "MDS", 
    "predictive_implication": "Level B", 
    "sources": [
      11
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "", 
    "therapy_sensitivity": null, 
    "therapy_type": "", 
    "validated": true
  }, 
  {
    "alterations": [
      39
    ], 
    "assertion_id": 53, 
    "created_on": null, 
    "description": "More frequent in Chronic Myelomonocytic Leukemia.", 
    "disease": "Myelodysplasia ", 
    "favorable_prognosis": false, 
    "last_updated": "2017-11-03 14:38:59.573883", 
    "old_disease": "Myelodysplastic Syndromes", 
    "oncotree_code": "MDS", 
    "predictive_implication": "Level B", 
    "sources": [
      11
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "", 
    "therapy_sensitivity": null, 
    "therapy_type": "", 
    "validated": true
  }, 
  {
    "alterations": [
      40
    ], 
    "assertion_id": 54, 
    "created_on": null, 
    "description": "More frequent in Chronic Myelomonocytic Leukemia.", 
    "disease": "Myelodysplasia ", 
    "favorable_prognosis": false, 
    "last_updated": "2017-11-03 14:38:59.586552", 
    "old_disease": "Myelodysplastic Syndromes", 
    "oncotree_code": "MDS", 
    "predictive_implication": "Level B", 
    "sources": [
      16
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "", 
    "therapy_sensitivity": null, 
    "therapy_type": "", 
    "validated": true
  }, 
  {
    "alterations": [
      41
    ], 
    "assertion_id": 55, 
    "created_on": null, 
    "description": "Secondary mutations in BCR-ABL may suggest resistance to imatinib in CML.", 
    "disease": "Chronic Myelogenous Leukemia", 
    "favorable_prognosis": null, 
    "last_updated": "2017-11-03 14:38:59.602795", 
    "old_disease": "Chronic Myeloid Leukemia", 
    "oncotree_code": "CML", 
    "predictive_implication": "Level B", 
    "sources": [
      4
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "Imatinib", 
    "therapy_sensitivity": false, 
    "therapy_type": "Targeted Drug", 
    "validated": true
  }, 
  {
    "alterations": [
      42
    ], 
    "assertion_id": 56, 
    "created_on": null, 
    "description": "Translocations predict sensitivity to tyrosine kinase inhibitors such as imatinib, dasatinib, and nilotinib. Secondary mutations can cause resistance to these agents. Nilotinib or Bosutinib are second-line and subsequent therapies for cytogenetic or hematologic resistance to TKIs", 
    "disease": "Chronic Myelogenous Leukemia", 
    "favorable_prognosis": null, 
    "last_updated": "2017-11-03 14:38:59.621311", 
    "old_disease": "Chronic Myeloid Leukemia", 
    "oncotree_code": "CML", 
    "predictive_implication": "FDA-Approved", 
    "sources": [
      17
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "Dasatinib", 
    "therapy_sensitivity": true, 
    "therapy_type": "Targeted Drug", 
    "validated": true
  }, 
  {
    "alterations": [
      42
    ], 
    "assertion_id": 57, 
    "created_on": null, 
    "description": "Translocations predict sensitivity to tyrosine kinase inhibitors such as imatinib, dasatinib, and nilotinib. Secondary mutations can cause resistance to these agents. Dasatinib, Nilotinib, or Bosutinib are second-line and subsequent therapies for cytogenetic or hematologic resistance to TKIs", 
    "disease": "Chronic Myelogenous Leukemia", 
    "favorable_prognosis": null, 
    "last_updated": "2017-11-03 14:38:59.633970", 
    "old_disease": "Chronic Myeloid Leukemia", 
    "oncotree_code": "CML", 
    "predictive_implication": "FDA-Approved", 
    "sources": [
      17
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "Imatinib", 
    "therapy_sensitivity": true, 
    "therapy_type": "Targeted Drug", 
    "validated": true
  }, 
  {
    "alterations": [
      42
    ], 
    "assertion_id": 58, 
    "created_on": null, 
    "description": "Translocations predict sensitivity to tyrosine kinase inhibitors such as imatinib, dasatinib, and nilotinib. Secondary mutations can cause resistance to these agents. Dasatinib or Bosutinib are second-line and subsequent therapies for cytogenetic or hematologic resistance to TKIs", 
    "disease": "Chronic Myelogenous Leukemia", 
    "favorable_prognosis": null, 
    "last_updated": "2017-11-03 14:38:59.648235", 
    "old_disease": "Chronic Myeloid Leukemia", 
    "oncotree_code": "CML", 
    "predictive_implication": "FDA-Approved", 
    "sources": [
      17
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "Nilotinib", 
    "therapy_sensitivity": true, 
    "therapy_type": "Targeted Drug", 
    "validated": true
  }, 
  {
    "alterations": [
      43
    ], 
    "assertion_id": 59, 
    "created_on": null, 
    "description": "BLM may indicate a predisposition for early onset of colorectal cancer, although with a low-moderate penetrance.", 
    "disease": "Colorectal Adenocarcinoma", 
    "favorable_prognosis": false, 
    "last_updated": "2017-11-03 14:38:59.664922", 
    "old_disease": "Colorectal Cancer", 
    "oncotree_code": "COADREAD", 
    "predictive_implication": "Level B", 
    "sources": [
      18
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "", 
    "therapy_sensitivity": null, 
    "therapy_type": "", 
    "validated": true
  }, 
  {
    "alterations": [
      44
    ], 
    "assertion_id": 60, 
    "created_on": null, 
    "description": "Activating BRAF mutations are associated with an increased sensitivity to BRAF inhibitors. Co-administration with a MEK inhibitor may potentiate the effects of BRAF inhibitors.", 
    "disease": "Anaplastic Thyroid Cancer", 
    "favorable_prognosis": null, 
    "last_updated": "2017-11-03 14:38:59.679336", 
    "old_disease": "Anaplastic Thyroid Cancer", 
    "oncotree_code": "THAP", 
    "predictive_implication": "Level A", 
    "sources": [
      19
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "BRAF Inhibitors", 
    "therapy_sensitivity": true, 
    "therapy_type": "Drug Class", 
    "validated": true
  }, 
  {
    "alterations": [
      44
    ], 
    "assertion_id": 61, 
    "created_on": null, 
    "description": "Activating BRAF mutations are associated with an increased sensitivity to BRAF inhibitors. Co-administration with a MEK inhibitor may potentiate the effects of BRAF inhibitors.", 
    "disease": "Cholangiocarcinoma", 
    "favorable_prognosis": null, 
    "last_updated": "2017-11-03 14:38:59.694799", 
    "old_disease": "Cholangiocarcinoma", 
    "oncotree_code": "CHOL", 
    "predictive_implication": "Level A", 
    "sources": [
      19
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "BRAF Inhibitors", 
    "therapy_sensitivity": true, 
    "therapy_type": "Drug Class", 
    "validated": true
  }, 
  {
    "alterations": [
      45
    ], 
    "assertion_id": 62, 
    "created_on": null, 
    "description": "BRAF V600E mutant colorectal cancer cell lines were cultured in increasing concentrations of the MEK inhibitor AZD6244 (Selumetinib). FISH analysis marked increase in BRAF gene copies in resistant cells.", 
    "disease": "Colorectal Adenocarcinoma", 
    "favorable_prognosis": null, 
    "last_updated": "2017-11-03 14:38:59.709573", 
    "old_disease": "Colorectal Cancer", 
    "oncotree_code": "COADREAD", 
    "predictive_implication": "Level D", 
    "sources": [
      20
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "Selumetinib", 
    "therapy_sensitivity": false, 
    "therapy_type": "Targeted Drug", 
    "validated": true
  }, 
  {
    "alterations": [
      46
    ], 
    "assertion_id": 63, 
    "created_on": null, 
    "description": "BRAF V600E alterations predict resistance to treatment with Cetuximab, both alone and in combination with alkylating chemotherapy.", 
    "disease": "Colorectal Adenocarcinoma", 
    "favorable_prognosis": null, 
    "last_updated": "2017-11-03 14:38:59.725711", 
    "old_disease": "Colorectal Cancer", 
    "oncotree_code": "COADREAD", 
    "predictive_implication": "Level B", 
    "sources": [
      21
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "Cetuximab", 
    "therapy_sensitivity": false, 
    "therapy_type": "Targeted Drug", 
    "validated": true
  }, 
  {
    "alterations": [
      46
    ], 
    "assertion_id": 64, 
    "created_on": null, 
    "description": "BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.", 
    "disease": "Colorectal Adenocarcinoma", 
    "favorable_prognosis": false, 
    "last_updated": "2017-11-03 14:38:59.737137", 
    "old_disease": "Colorectal Cancer", 
    "oncotree_code": "COADREAD", 
    "predictive_implication": "Level B", 
    "sources": [
      21
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "Cetuximab", 
    "therapy_sensitivity": null, 
    "therapy_type": "Targeted Drug", 
    "validated": true
  }, 
  {
    "alterations": [
      46
    ], 
    "assertion_id": 65, 
    "created_on": null, 
    "description": "BRAF V600E alterations predict resistance to treatment with Panitumumab, both alone and in combination with alkylating chemotherapy.chemotherapy.", 
    "disease": "Colorectal Adenocarcinoma", 
    "favorable_prognosis": null, 
    "last_updated": "2017-11-03 14:38:59.751356", 
    "old_disease": "Colorectal Cancer", 
    "oncotree_code": "COADREAD", 
    "predictive_implication": "Level B", 
    "sources": [
      21
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "Panitumumab", 
    "therapy_sensitivity": false, 
    "therapy_type": "Targeted Drug", 
    "validated": true
  }, 
  {
    "alterations": [
      46
    ], 
    "assertion_id": 66, 
    "created_on": null, 
    "description": "BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.", 
    "disease": "Colorectal Adenocarcinoma", 
    "favorable_prognosis": false, 
    "last_updated": "2017-11-03 14:38:59.764571", 
    "old_disease": "Colorectal Cancer", 
    "oncotree_code": "COADREAD", 
    "predictive_implication": "Level B", 
    "sources": [
      21
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "Panitumumab", 
    "therapy_sensitivity": null, 
    "therapy_type": "Targeted Drug", 
    "validated": true
  }, 
  {
    "alterations": [
      44
    ], 
    "assertion_id": 67, 
    "created_on": null, 
    "description": "Activating BRAF mutations are associated with an increased sensitivity to BRAF inhibitors. Co-administration with a MEK inhibitor may potentiate the effects of BRAF inhibitors.", 
    "disease": "Langerhans Cell Histiocytosis", 
    "favorable_prognosis": null, 
    "last_updated": "2017-11-03 14:38:59.779329", 
    "old_disease": "Langerhans Cell Histiocytosis", 
    "oncotree_code": "LCH", 
    "predictive_implication": "Level A", 
    "sources": [
      19
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "BRAF Inhibitors", 
    "therapy_sensitivity": true, 
    "therapy_type": "Drug Class", 
    "validated": true
  }, 
  {
    "alterations": [
      46
    ], 
    "assertion_id": 68, 
    "created_on": null, 
    "description": "The combination of ipilimumab and vemurafenib in a sequencing strategy showed limited efficacy in a phase II study.", 
    "disease": "Melanoma", 
    "favorable_prognosis": null, 
    "last_updated": "2017-11-03 14:38:59.794948", 
    "old_disease": "Melanoma", 
    "oncotree_code": "MEL", 
    "predictive_implication": "Level A", 
    "sources": [
      22, 
      23
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "Ipilimumab+Vemurafenib", 
    "therapy_sensitivity": true, 
    "therapy_type": "Targeted Drug", 
    "validated": true
  }, 
  {
    "alterations": [
      46
    ], 
    "assertion_id": 69, 
    "created_on": null, 
    "description": "Administration of bevacizumab in a dabrafenib-resistant cell line counteracted the tumor growth stimulating effect of administering dabrafenib post-resistance.", 
    "disease": "Melanoma", 
    "favorable_prognosis": null, 
    "last_updated": "2017-11-03 14:38:59.808720", 
    "old_disease": "Melanoma", 
    "oncotree_code": "MEL", 
    "predictive_implication": "Level D", 
    "sources": [
      24
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "Bevacizumab", 
    "therapy_sensitivity": true, 
    "therapy_type": "Targeted Drug", 
    "validated": true
  }, 
  {
    "alterations": [
      46
    ], 
    "assertion_id": 70, 
    "created_on": null, 
    "description": "Administration of GSK2126458A, a PI3K/AKT/mTOR pathway inhibitor, in a dabrafenib-resistant cell line counteracted the tumor growth stimulating effect of administering dabrafenib post-resistance.", 
    "disease": "Melanoma", 
    "favorable_prognosis": null, 
    "last_updated": "2017-11-03 14:38:59.823187", 
    "old_disease": "Melanoma", 
    "oncotree_code": "MEL", 
    "predictive_implication": "Level D", 
    "sources": [
      24
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "GSK2126458A", 
    "therapy_sensitivity": true, 
    "therapy_type": "Targeted Drug", 
    "validated": true
  }, 
  {
    "alterations": [
      46
    ], 
    "assertion_id": 71, 
    "created_on": null, 
    "description": "The combination of bleomycin, electrochemotherapy (ECT), and vemurafenib was found to be effective in two human melanoma cell lines.", 
    "disease": "Melanoma", 
    "favorable_prognosis": null, 
    "last_updated": "2017-11-03 14:38:59.845385", 
    "old_disease": "Melanoma", 
    "oncotree_code": "MEL", 
    "predictive_implication": "Level D", 
    "sources": [
      25
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "Bleomycin+Electrochemotherapy+Vemurafenib", 
    "therapy_sensitivity": true, 
    "therapy_type": "Targeted Drug", 
    "validated": true
  }, 
  {
    "alterations": [
      47
    ], 
    "assertion_id": 72, 
    "created_on": null, 
    "description": "Treating mutant BRAF melanoma cell with both Selumetinib and PLX4720, a predecessor to Vemurafenib, prevented emergence of resistant clones.", 
    "disease": "Melanoma", 
    "favorable_prognosis": null, 
    "last_updated": "2017-11-03 14:38:59.862873", 
    "old_disease": "Melanoma", 
    "oncotree_code": "MEL", 
    "predictive_implication": "Level D", 
    "sources": [
      26
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "Vemurafenib+Selumetinib", 
    "therapy_sensitivity": true, 
    "therapy_type": "Targeted Drug", 
    "validated": true
  }, 
  {
    "alterations": [
      46
    ], 
    "assertion_id": 73, 
    "created_on": null, 
    "description": "Three human melanoma cell lines displayed sensitivity to bleomycin, particularly when co-administered with human interferon-beta gene or herpes simplex virus thymidine kinase/ganciclovir suicide gene lipofection.", 
    "disease": "Melanoma", 
    "favorable_prognosis": null, 
    "last_updated": "2017-11-03 14:38:59.876858", 
    "old_disease": "Melanoma", 
    "oncotree_code": "MEL", 
    "predictive_implication": "Level D", 
    "sources": [
      27
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "Bleomycin", 
    "therapy_sensitivity": true, 
    "therapy_type": "Targeted Drug", 
    "validated": true
  }, 
  {
    "alterations": [
      46
    ], 
    "assertion_id": 74, 
    "created_on": null, 
    "description": "Mitochondria-targeted metabolism-interferring agent mito-CP (mitochondria-targeted carboxy-proxyl) demonstrated a tumor-suppressing effect in BRAF V600E-mutated melanoma mouse models, including models that had developed resistance to vemurafenib.", 
    "disease": "Melanoma", 
    "favorable_prognosis": null, 
    "last_updated": "2017-11-03 14:38:59.898460", 
    "old_disease": "Melanoma", 
    "oncotree_code": "MEL", 
    "predictive_implication": "Level D", 
    "sources": [
      28
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "Mito-CP", 
    "therapy_sensitivity": true, 
    "therapy_type": "Targeted Drug", 
    "validated": true
  }, 
  {
    "alterations": [
      46
    ], 
    "assertion_id": 75, 
    "created_on": null, 
    "description": "Study of a patient-derived orthotopic xenograft (PDOX) model suggests some vemurafenib-resistant BRAF-V600E-mutated melanomas may be sensitive to trametinib (but not cobimetinib) treatment.", 
    "disease": "Melanoma", 
    "favorable_prognosis": null, 
    "last_updated": "2017-11-03 14:38:59.913725", 
    "old_disease": "Melanoma", 
    "oncotree_code": "MEL", 
    "predictive_implication": "Level D", 
    "sources": [
      29
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "Trametinib", 
    "therapy_sensitivity": true, 
    "therapy_type": "Targeted Drug", 
    "validated": true
  }, 
  {
    "alterations": [
      44
    ], 
    "assertion_id": 76, 
    "created_on": null, 
    "description": "Activating BRAF mutations are associated with an increased sensitivity to BRAF inhibitors. Co-administration with a MEK inhibitor may potentiate the effects of BRAF inhibitors.", 
    "disease": "Melanoma", 
    "favorable_prognosis": null, 
    "last_updated": "2017-11-03 14:38:59.929343", 
    "old_disease": "Melanoma", 
    "oncotree_code": "MEL", 
    "predictive_implication": "FDA-Approved", 
    "sources": [
      30
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "BRAF Inhibitors", 
    "therapy_sensitivity": true, 
    "therapy_type": "Drug Class", 
    "validated": true
  }, 
  {
    "alterations": [
      44
    ], 
    "assertion_id": 77, 
    "created_on": null, 
    "description": "Activating BRAF mutations are associated with an increased sensitivity to BRAF inhibitors. Co-administration with a MEK inhibitor may potentiate the effects of BRAF inhibitors.", 
    "disease": "Melanoma", 
    "favorable_prognosis": null, 
    "last_updated": "2017-11-03 14:38:59.941663", 
    "old_disease": "Melanoma", 
    "oncotree_code": "MEL", 
    "predictive_implication": "FDA-Approved", 
    "sources": [
      30
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "Dabrafenib+Trametinib", 
    "therapy_sensitivity": true, 
    "therapy_type": "Targeted Drug", 
    "validated": true
  }, 
  {
    "alterations": [
      44
    ], 
    "assertion_id": 78, 
    "created_on": null, 
    "description": "Activating BRAF mutations are associated with an increased sensitivity to BRAF inhibitors. Co-administration with a MEK inhibitor may potentiate the effects of BRAF inhibitors.", 
    "disease": "Melanoma", 
    "favorable_prognosis": null, 
    "last_updated": "2017-11-03 14:38:59.958895", 
    "old_disease": "Melanoma", 
    "oncotree_code": "MEL", 
    "predictive_implication": "FDA-Approved", 
    "sources": [
      30
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "Vemurafenib+Cobimetinib", 
    "therapy_sensitivity": true, 
    "therapy_type": "Targeted Drug", 
    "validated": true
  }, 
  {
    "alterations": [
      46
    ], 
    "assertion_id": 79, 
    "created_on": null, 
    "description": "Preclinical evidence suggests the combination of proteasome inhibitor ixazomib with interferon-alpha may negatively impact tumor cell viability in melanoma, particularly in patients with BRAF V600E mutations.", 
    "disease": "Melanoma", 
    "favorable_prognosis": null, 
    "last_updated": "2017-11-03 14:38:59.977409", 
    "old_disease": "Melanoma", 
    "oncotree_code": "MEL", 
    "predictive_implication": "Level D", 
    "sources": [
      31
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "Ixazomib+Interferon-alpha", 
    "therapy_sensitivity": true, 
    "therapy_type": "Targeted Drug", 
    "validated": true
  }, 
  {
    "alterations": [
      46
    ], 
    "assertion_id": 80, 
    "created_on": null, 
    "description": "Loss of tumor cell viability was observed in nine cell lines after administration of GANT61, a GLI1/GLI2 inhibitor (targeting the Hedgehog/GLI pathway). Co-administration of GANT61 with obatoclax, a BCL2 family inhibitor, increased treatment effectiveness.", 
    "disease": "Melanoma", 
    "favorable_prognosis": null, 
    "last_updated": "2017-11-03 14:38:59.991859", 
    "old_disease": "Melanoma", 
    "oncotree_code": "MEL", 
    "predictive_implication": "Level D", 
    "sources": [
      32
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "GANT61", 
    "therapy_sensitivity": true, 
    "therapy_type": "Targeted Drug", 
    "validated": true
  }, 
  {
    "alterations": [
      46
    ], 
    "assertion_id": 81, 
    "created_on": null, 
    "description": "Loss of tumor cell viability was observed in nine cell lines after administration of GANT61, a GLI1/GLI2 inhibitor (targeting the Hedgehog/GLI pathway). Co-administration of GANT61 with obatoclax, a BCL2 family inhibitor, increased treatment effectiveness.", 
    "disease": "Melanoma", 
    "favorable_prognosis": null, 
    "last_updated": "2017-11-03 14:39:00.011078", 
    "old_disease": "Melanoma", 
    "oncotree_code": "MEL", 
    "predictive_implication": "Level D", 
    "sources": [
      32
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "GANT61+Obtaoclax", 
    "therapy_sensitivity": true, 
    "therapy_type": "Targeted Drug", 
    "validated": true
  }, 
  {
    "alterations": [
      47
    ], 
    "assertion_id": 82, 
    "created_on": null, 
    "description": "Targeted agents, such as vemurafenib, that inhibit effector kinases of the mitogen-activated protein kinase (MAPK) signaling cascade, including BRAF, have improved progression-free survival and overall survival when used as a monotherapy in BRAF-mutant melanoma.", 
    "disease": "Melanoma", 
    "favorable_prognosis": null, 
    "last_updated": "2017-11-03 14:39:00.027776", 
    "old_disease": "Melanoma", 
    "oncotree_code": "MEL", 
    "predictive_implication": "Level B", 
    "sources": [
      33
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "Vemurafenib", 
    "therapy_sensitivity": true, 
    "therapy_type": "Targeted Drug", 
    "validated": true
  }, 
  {
    "alterations": [
      47
    ], 
    "assertion_id": 83, 
    "created_on": null, 
    "description": "Targeted agents, such as dabrafenib, that inhibit effector kinases of the mitogen-activated protein kinase (MAPK) signaling cascade, including BRAF, have improved progression-free survival and overall survival when used as a monotherapy in BRAF-mutant melanoma.", 
    "disease": "Melanoma", 
    "favorable_prognosis": null, 
    "last_updated": "2017-11-03 14:39:00.042348", 
    "old_disease": "Melanoma", 
    "oncotree_code": "MEL", 
    "predictive_implication": "Level B", 
    "sources": [
      33
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "Dabrafenib", 
    "therapy_sensitivity": true, 
    "therapy_type": "Targeted Drug", 
    "validated": true
  }, 
  {
    "alterations": [
      47
    ], 
    "assertion_id": 84, 
    "created_on": null, 
    "description": "Targeted agents, such as tremetinib, that inhibit effector kinases of the mitogen-activated protein kinase (MAPK) signaling cascade, including MEK1 and MEK2, have improved progression-free survival and overall survival when used as a monotherapy in BRAF-mutant melanoma.", 
    "disease": "Melanoma", 
    "favorable_prognosis": null, 
    "last_updated": "2017-11-03 14:39:00.058699", 
    "old_disease": "Melanoma", 
    "oncotree_code": "MEL", 
    "predictive_implication": "Level B", 
    "sources": [
      33
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "Tremetinib", 
    "therapy_sensitivity": true, 
    "therapy_type": "Targeted Drug", 
    "validated": true
  }, 
  {
    "alterations": [
      47
    ], 
    "assertion_id": 85, 
    "created_on": null, 
    "description": "Combination therapy of dabrafenib and tremetinib improved progression-free survival, objective response, and duration of response relative to dabrafenib monotherapy in a phase I/II trial.", 
    "disease": "Melanoma", 
    "favorable_prognosis": null, 
    "last_updated": "2017-11-03 14:39:00.070749", 
    "old_disease": "Melanoma", 
    "oncotree_code": "MEL", 
    "predictive_implication": "Level B", 
    "sources": [
      33
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "Dabrafenib+Trametinib", 
    "therapy_sensitivity": true, 
    "therapy_type": "Targeted Drug", 
    "validated": true
  }, 
  {
    "alterations": [
      45
    ], 
    "assertion_id": 86, 
    "created_on": null, 
    "description": "Amplification of BRAF may predict resistance to RAF inhibition", 
    "disease": "Melanoma", 
    "favorable_prognosis": null, 
    "last_updated": "2017-11-03 14:39:00.083235", 
    "old_disease": "Melanoma", 
    "oncotree_code": "MEL", 
    "predictive_implication": "Level B", 
    "sources": [
      33
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "Vemurafenib", 
    "therapy_sensitivity": false, 
    "therapy_type": "Targeted Drug", 
    "validated": true
  }, 
  {
    "alterations": [
      44
    ], 
    "assertion_id": 87, 
    "created_on": null, 
    "description": "Activating BRAF mutations are associated with an increased sensitivity to BRAF inhibitors. Co-administration with a MEK inhibitor may potentiate the effects of BRAF inhibitors.", 
    "disease": "Non-Langerhans Cell Histiocytosis/Erdheim-Chester Disease", 
    "favorable_prognosis": null, 
    "last_updated": "2017-11-03 14:39:00.095890", 
    "old_disease": "Erdheim-Chester Disease", 
    "oncotree_code": "ECD", 
    "predictive_implication": "Level A", 
    "sources": [
      19
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "BRAF Inhibitors", 
    "therapy_sensitivity": true, 
    "therapy_type": "Drug Class", 
    "validated": true
  }, 
  {
    "alterations": [
      44
    ], 
    "assertion_id": 88, 
    "created_on": null, 
    "description": "Activating BRAF mutations are associated with an increased sensitivity to BRAF inhibitors. Co-administration with a MEK inhibitor may potentiate the effects of BRAF inhibitors.", 
    "disease": "Non-Small Cell Lung Cancer", 
    "favorable_prognosis": null, 
    "last_updated": "2017-11-03 14:39:00.110622", 
    "old_disease": "Non-Small Cell Lung Cancer", 
    "oncotree_code": "NSCLC", 
    "predictive_implication": "Level A", 
    "sources": [
      19
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "BRAF Inhibitors", 
    "therapy_sensitivity": true, 
    "therapy_type": "Drug Class", 
    "validated": true
  }, 
  {
    "alterations": [
      44
    ], 
    "assertion_id": 89, 
    "created_on": null, 
    "description": "Activating BRAF mutations are associated with an increased sensitivity to BRAF inhibitors. Co-administration with a MEK inhibitor may potentiate the effects of BRAF inhibitors.", 
    "disease": "Ovarian Cancer, Other", 
    "favorable_prognosis": null, 
    "last_updated": "2017-11-03 14:39:00.122687", 
    "old_disease": "Ovarian Cancer", 
    "oncotree_code": "OOVC", 
    "predictive_implication": "Level A", 
    "sources": [
      19
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "BRAF Inhibitors", 
    "therapy_sensitivity": true, 
    "therapy_type": "Drug Class", 
    "validated": true
  }, 
  {
    "alterations": [
      48
    ], 
    "assertion_id": 90, 
    "created_on": null, 
    "description": "BRAF V600E mutations were associated with sensitivity to the BRAF inhibitor PLX-4032 in a study of 109 microdissected pancreatic ductal adenocarcinoma patients.", 
    "disease": "Pancreatic Adenocarcinoma", 
    "favorable_prognosis": null, 
    "last_updated": "2017-11-03 14:39:00.138406", 
    "old_disease": "Pancreatic Cancer", 
    "oncotree_code": "PAAD", 
    "predictive_implication": "Level B", 
    "sources": [
      10
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "Vemurafenib", 
    "therapy_sensitivity": true, 
    "therapy_type": "Targeted Drug", 
    "validated": true
  }, 
  {
    "alterations": [
      44
    ], 
    "assertion_id": 91, 
    "created_on": null, 
    "description": "Activating BRAF mutations are associated with an increased sensitivity to BRAF inhibitors. Co-administration with a MEK inhibitor may potentiate the effects of BRAF inhibitors.", 
    "disease": "Pleomorphic Xanthoastrocytoma", 
    "favorable_prognosis": null, 
    "last_updated": "2017-11-03 14:39:00.152648", 
    "old_disease": "Pleomorphic Xanthoastrocytoma", 
    "oncotree_code": "PXA", 
    "predictive_implication": "Level A", 
    "sources": [
      19
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "BRAF Inhibitors", 
    "therapy_sensitivity": true, 
    "therapy_type": "Drug Class", 
    "validated": true
  }, 
  {
    "alterations": [
      44
    ], 
    "assertion_id": 92, 
    "created_on": null, 
    "description": "Activating BRAF mutations are associated with an increased sensitivity to BRAF inhibitors. Co-administration with a MEK inhibitor may potentiate the effects of BRAF inhibitors.", 
    "disease": "Salivary Duct Carcinoma", 
    "favorable_prognosis": null, 
    "last_updated": "2017-11-03 14:39:00.169886", 
    "old_disease": "Salivary-Duct Cancer", 
    "oncotree_code": "SDCA", 
    "predictive_implication": "Level A", 
    "sources": [
      19
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "BRAF Inhibitors", 
    "therapy_sensitivity": true, 
    "therapy_type": "Drug Class", 
    "validated": true
  }, 
  {
    "alterations": [
      46
    ], 
    "assertion_id": 93, 
    "created_on": null, 
    "description": "BRAF V600E mutations in pediatric glioma patients may sensitize a response to BRAF inhibitors. A clinical trial testing response to dabrafenib in pediatric glioma patients is underway.", 
    "disease": "Glioma", 
    "favorable_prognosis": null, 
    "last_updated": "2017-11-03 14:39:00.184942", 
    "old_disease": "Glioma", 
    "oncotree_code": "GNOS", 
    "predictive_implication": "Level A", 
    "sources": [
      34
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "Dabrafenib", 
    "therapy_sensitivity": true, 
    "therapy_type": "Targeted Drug", 
    "validated": true
  }, 
  {
    "alterations": [
      44
    ], 
    "assertion_id": 94, 
    "created_on": null, 
    "description": "Activating BRAF mutations are associated with an increased sensitivity to BRAF inhibitors. Co-administration with a MEK inhibitor may potentiate the effects of BRAF inhibitors.", 
    "disease": "Clear Cell Sarcoma", 
    "favorable_prognosis": null, 
    "last_updated": "2017-11-03 14:39:00.199785", 
    "old_disease": "Clear-Cell Sarcoma", 
    "oncotree_code": "CSS", 
    "predictive_implication": "Level A", 
    "sources": [
      19
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "BRAF Inhibitors", 
    "therapy_sensitivity": true, 
    "therapy_type": "Drug Class", 
    "validated": true
  }, 
  {
    "alterations": [
      46
    ], 
    "assertion_id": 95, 
    "created_on": null, 
    "description": "Two patients with metastatic colorectal neuroendocrine tumors refractory to treatment exhibited a durable response to combined BRAF-MEK inhibition.", 
    "disease": "Gastrointestinal Neuroendocrine Tumors", 
    "favorable_prognosis": null, 
    "last_updated": "2017-11-03 14:39:00.215686", 
    "old_disease": "Colorectal Neuroendocrine Tumors", 
    "oncotree_code": "GINET", 
    "predictive_implication": "Level D", 
    "sources": [
      35
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "BRAF Inhibitors+MEK Inhibitors", 
    "therapy_sensitivity": true, 
    "therapy_type": "Drug Class", 
    "validated": true
  }, 
  {
    "alterations": [
      46
    ], 
    "assertion_id": 96, 
    "created_on": null, 
    "description": "BRAF V600E mutations in pediatric glioma patients may sensitize a response to BRAF inhibitors. A clinical trial testing response to vemurafenib in pediatric glioma patients is underway.", 
    "disease": "Glioma", 
    "favorable_prognosis": null, 
    "last_updated": "2017-11-03 14:39:00.235309", 
    "old_disease": "Glioma", 
    "oncotree_code": "GNOS", 
    "predictive_implication": "Level A", 
    "sources": [
      36
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "Vemurafenib", 
    "therapy_sensitivity": true, 
    "therapy_type": "Targeted Drug", 
    "validated": true
  }, 
  {
    "alterations": [
      49
    ], 
    "assertion_id": 97, 
    "created_on": null, 
    "description": "Rearrangements in BRAF are rare but may result in dependencies that can be targeted with MAPK inhibition", 
    "disease": "", 
    "favorable_prognosis": null, 
    "last_updated": "2017-11-03 14:39:00.250917", 
    "old_disease": "", 
    "oncotree_code": "", 
    "predictive_implication": "Level D", 
    "sources": [
      37
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "RAF-MEK inhibitors", 
    "therapy_sensitivity": true, 
    "therapy_type": "Drug Class", 
    "validated": true
  }, 
  {
    "alterations": [
      46
    ], 
    "assertion_id": 98, 
    "created_on": null, 
    "description": "Vemurafenib monotherapy is efficacious in preclinical models of pediatric gliomas harboring BRAF V600E mutations, but resistance quickly develops. EGFR inhibition appears to rescue the effects of vemurafenib in these models.", 
    "disease": "Glioma", 
    "favorable_prognosis": null, 
    "last_updated": "2017-11-03 14:39:00.263580", 
    "old_disease": "Glioma", 
    "oncotree_code": "GNOS", 
    "predictive_implication": "Level D", 
    "sources": [
      38
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "Vemurafenib+EGFR Inhibitor", 
    "therapy_sensitivity": true, 
    "therapy_type": "Targeted Drug", 
    "validated": true
  }, 
  {
    "alterations": [
      50
    ], 
    "assertion_id": 99, 
    "created_on": null, 
    "description": "Mutations in BRCA1 or BRCA2 may predict sensitivity to PARP inhibition in ovarian cancer", 
    "disease": "Ovarian Cancer, Other", 
    "favorable_prognosis": null, 
    "last_updated": "2017-11-03 14:39:00.281286", 
    "old_disease": "Ovarian Cancer", 
    "oncotree_code": "OOVC", 
    "predictive_implication": "FDA-Approved", 
    "sources": [
      39
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "PARP Inhibitors", 
    "therapy_sensitivity": true, 
    "therapy_type": "Targeted Drug", 
    "validated": true
  }, 
  {
    "alterations": [
      50
    ], 
    "assertion_id": 100, 
    "created_on": null, 
    "description": "Secondary mutations in BRCA1 may confer resistance to PARP inhibition in ovarian cancer", 
    "disease": "Ovarian Cancer, Other", 
    "favorable_prognosis": null, 
    "last_updated": "2017-11-03 14:39:00.292143", 
    "old_disease": "Ovarian Cancer", 
    "oncotree_code": "OOVC", 
    "predictive_implication": "FDA-Approved", 
    "sources": [
      40
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "PARP Inhibitors", 
    "therapy_sensitivity": false, 
    "therapy_type": "Targeted Drug", 
    "validated": true
  }, 
  {
    "alterations": [
      51
    ], 
    "assertion_id": 101, 
    "created_on": null, 
    "description": "Patients with chemotherapy-refractory ovarian cancer have higher response rates to PARP inhibitor therapy in the presence of BRCA1 and BRCA2 mutations, particularly concomittant with platinum-sensitive disease. Platinum-resistant disease partially abrogates olaparib sensitvity in the setting of BRCA1 and BRCA2 mutations.", 
    "disease": "Ovarian Cancer, Other", 
    "favorable_prognosis": null, 
    "last_updated": "2017-11-03 14:39:00.302781", 
    "old_disease": "Ovarian Cancer", 
    "oncotree_code": "OOVC", 
    "predictive_implication": "FDA-Approved", 
    "sources": [
      41
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "Olaparib", 
    "therapy_sensitivity": true, 
    "therapy_type": "Targeted Drug", 
    "validated": true
  }, 
  {
    "alterations": [
      51
    ], 
    "assertion_id": 102, 
    "created_on": null, 
    "description": "Patients with chemotherapy-refractory ovarian cancer have higher response rates to PARP inhibitor therapy in the presence of BRCA1 and BRCA2 mutations, particularly concomittant with platinum-sensitive disease. Platinum-resistant disease partially abrogates olaparib sensitvity in the setting of BRCA1 and BRCA2 mutations.", 
    "disease": "Ovarian Cancer, Other", 
    "favorable_prognosis": null, 
    "last_updated": "2017-11-03 14:39:00.313382", 
    "old_disease": "Ovarian Cancer", 
    "oncotree_code": "OOVC", 
    "predictive_implication": "FDA-Approved", 
    "sources": [
      41
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "PARP Inhibitors", 
    "therapy_sensitivity": true, 
    "therapy_type": "Drug Class", 
    "validated": true
  }, 
  {
    "alterations": [
      51
    ], 
    "assertion_id": 103, 
    "created_on": null, 
    "description": "Pazopanib may increase PFS in patients whose disease does not progress following first-line treatment.", 
    "disease": "Ovarian Cancer, Other", 
    "favorable_prognosis": null, 
    "last_updated": "2017-11-03 14:39:00.324275", 
    "old_disease": "Ovarian Cancer", 
    "oncotree_code": "OOVC", 
    "predictive_implication": "Level A", 
    "sources": [
      41
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "Pazopanib", 
    "therapy_sensitivity": true, 
    "therapy_type": "Targeted Drug", 
    "validated": true
  }, 
  {
    "alterations": [
      50
    ], 
    "assertion_id": 104, 
    "created_on": null, 
    "description": "The presence of alterations in BRCA mutated pancreatic tumors is associated with increased sensitivity to PARP inhibitors.", 
    "disease": "Pancreatic Adenocarcinoma", 
    "favorable_prognosis": null, 
    "last_updated": "2017-11-03 14:39:00.334105", 
    "old_disease": "Pancreatic Cancer", 
    "oncotree_code": "PAAD", 
    "predictive_implication": "Level A", 
    "sources": [
      42
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "PARP Inhibitors", 
    "therapy_sensitivity": true, 
    "therapy_type": "Drug Class", 
    "validated": true
  }, 
  {
    "alterations": [
      50
    ], 
    "assertion_id": 105, 
    "created_on": null, 
    "description": "When present alongside genomic instability, the inactivation of DNA maintenance genes (BRCA1, BRCA2, or PALB2) was associated with increased sensitivity to platinum therapy in pancreatic cancer patients.", 
    "disease": "Pancreatic Adenocarcinoma", 
    "favorable_prognosis": null, 
    "last_updated": "2017-11-03 14:39:00.342206", 
    "old_disease": "Pancreatic Cancer", 
    "oncotree_code": "PAAD", 
    "predictive_implication": "Level A", 
    "sources": [
      43
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "Platins", 
    "therapy_sensitivity": true, 
    "therapy_type": "Drug Class", 
    "validated": true
  }, 
  {
    "alterations": [
      52
    ], 
    "assertion_id": 106, 
    "created_on": null, 
    "description": "Mutations in BRCA1 or BRCA2 may predict sensitivity to PARP inhibition in ovarian cancer", 
    "disease": "Ovarian Cancer, Other", 
    "favorable_prognosis": null, 
    "last_updated": "2017-11-03 14:39:00.351750", 
    "old_disease": "Ovarian Cancer", 
    "oncotree_code": "OOVC", 
    "predictive_implication": "FDA-Approved", 
    "sources": [
      39
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "PARP Inhibitors", 
    "therapy_sensitivity": true, 
    "therapy_type": "Targeted Drug", 
    "validated": true
  }, 
  {
    "alterations": [
      52
    ], 
    "assertion_id": 107, 
    "created_on": null, 
    "description": "Secondary mutations in BRCA2 may confer resistance to PARP inhibition in ovarian cancer", 
    "disease": "Ovarian Cancer, Other", 
    "favorable_prognosis": null, 
    "last_updated": "2017-11-03 14:39:00.363205", 
    "old_disease": "Ovarian Cancer", 
    "oncotree_code": "OOVC", 
    "predictive_implication": "FDA-Approved", 
    "sources": [
      40
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "PARP Inhibitors", 
    "therapy_sensitivity": false, 
    "therapy_type": "Targeted Drug", 
    "validated": true
  }, 
  {
    "alterations": [
      53
    ], 
    "assertion_id": 108, 
    "created_on": null, 
    "description": "Patients with chemotherapy-refractory ovarian cancer have higher response rates to PARP inhibitor therapy in the presence of BRCA1 and BRCA2 mutations, particularly concomittant with platinum-sensitive disease. Platinum-resistant disease partially abrogates olaparib sensitvity in the setting of BRCA1 and BRCA2 mutations.", 
    "disease": "Ovarian Cancer, Other", 
    "favorable_prognosis": null, 
    "last_updated": "2017-11-03 14:39:00.373042", 
    "old_disease": "Ovarian Cancer", 
    "oncotree_code": "OOVC", 
    "predictive_implication": "FDA-Approved", 
    "sources": [
      41
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "Olaparib", 
    "therapy_sensitivity": true, 
    "therapy_type": "Targeted Drug", 
    "validated": true
  }, 
  {
    "alterations": [
      53
    ], 
    "assertion_id": 109, 
    "created_on": null, 
    "description": "Patients with chemotherapy-refractory ovarian cancer have higher response rates to PARP inhibitor therapy in the presence of BRCA1 and BRCA2 mutations, particularly concomittant with platinum-sensitive disease. Platinum-resistant disease partially abrogates olaparib sensitvity in the setting of BRCA1 and BRCA2 mutations.", 
    "disease": "Ovarian Cancer, Other", 
    "favorable_prognosis": null, 
    "last_updated": "2017-11-03 14:39:00.385963", 
    "old_disease": "Ovarian Cancer", 
    "oncotree_code": "OOVC", 
    "predictive_implication": "FDA-Approved", 
    "sources": [
      41
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "PARP Inhibitors", 
    "therapy_sensitivity": true, 
    "therapy_type": "Drug Class", 
    "validated": true
  }, 
  {
    "alterations": [
      53
    ], 
    "assertion_id": 110, 
    "created_on": null, 
    "description": "Pazopanib may increase PFS in patients whose disease does not progress following first-line treatment.", 
    "disease": "Ovarian Cancer, Other", 
    "favorable_prognosis": null, 
    "last_updated": "2017-11-03 14:39:00.393994", 
    "old_disease": "Ovarian Cancer", 
    "oncotree_code": "OOVC", 
    "predictive_implication": "Level A", 
    "sources": [
      41
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "Pazopanib", 
    "therapy_sensitivity": true, 
    "therapy_type": "Targeted Drug", 
    "validated": true
  }, 
  {
    "alterations": [
      52
    ], 
    "assertion_id": 111, 
    "created_on": null, 
    "description": "The presence of alterations in BRCA mutated pancreatic tumors is associated with increased sensitivity to PARP inhibitors.", 
    "disease": "Pancreatic Adenocarcinoma", 
    "favorable_prognosis": null, 
    "last_updated": "2017-11-03 14:39:00.401360", 
    "old_disease": "Pancreatic Cancer", 
    "oncotree_code": "PAAD", 
    "predictive_implication": "Level A", 
    "sources": [
      42
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "PARP Inhibitors", 
    "therapy_sensitivity": true, 
    "therapy_type": "Drug Class", 
    "validated": true
  }, 
  {
    "alterations": [
      52
    ], 
    "assertion_id": 112, 
    "created_on": null, 
    "description": "When present alongside genomic instability, the inactivation of DNA maintenance genes (BRCA1, BRCA2, or PALB2) was associated with increased sensitivity to platinum therapy in pancreatic cancer patients.", 
    "disease": "Pancreatic Adenocarcinoma", 
    "favorable_prognosis": null, 
    "last_updated": "2017-11-03 14:39:00.408824", 
    "old_disease": "Pancreatic Cancer", 
    "oncotree_code": "PAAD", 
    "predictive_implication": "Level A", 
    "sources": [
      43
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "Platins", 
    "therapy_sensitivity": true, 
    "therapy_type": "Drug Class", 
    "validated": true
  }, 
  {
    "alterations": [
      52
    ], 
    "assertion_id": 113, 
    "created_on": null, 
    "description": "Patients with chemotherapy-refractory prostate cancer have higher response rates to PARP inhibitor therapy in the presence of DNA repair mutations, particularly concomittant with platinum-sensitive disease. Platinum-resistant disease partially abrogates olaparib sensitvity in the setting of BRCA1 and BRCA2 mutations.", 
    "disease": "Prostate Adenocarcinoma", 
    "favorable_prognosis": null, 
    "last_updated": "2017-11-03 14:39:00.418894", 
    "old_disease": "Prostate Cancer", 
    "oncotree_code": "PRAD", 
    "predictive_implication": "Level A", 
    "sources": [
      44
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "Olaparib", 
    "therapy_sensitivity": true, 
    "therapy_type": "Targeted Drug", 
    "validated": true
  }, 
  {
    "alterations": [
      53
    ], 
    "assertion_id": 114, 
    "created_on": null, 
    "description": "Patients with chemotherapy-refractory prostate cancer have higher response rates to PARP inhibitor therapy in the presence of DNA repair mutations, particularly concomittant with platinum-sensitive disease. Platinum-resistant disease partially abrogates olaparib sensitvity in the setting of BRCA1 and BRCA2 mutations.", 
    "disease": "Prostate Adenocarcinoma", 
    "favorable_prognosis": null, 
    "last_updated": "2017-11-03 14:39:00.427304", 
    "old_disease": "Prostate Cancer", 
    "oncotree_code": "PRAD", 
    "predictive_implication": "Level A", 
    "sources": [
      44
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "Olaparib", 
    "therapy_sensitivity": true, 
    "therapy_type": "Targeted Drug", 
    "validated": true
  }, 
  {
    "alterations": [
      54
    ], 
    "assertion_id": 115, 
    "created_on": null, 
    "description": "Patients with chemotherapy-refractory prostate cancer have higher response rates to PARP inhibitor therapy in the presence of DNA repair mutations, particularly concomittant with platinum-sensitive disease. Platinum-resistant disease partially abrogates olaparib sensitvity in the setting of BRCA1 and BRCA2 mutations.", 
    "disease": "Prostate Adenocarcinoma", 
    "favorable_prognosis": null, 
    "last_updated": "2017-11-03 14:39:00.439957", 
    "old_disease": "Prostate Cancer", 
    "oncotree_code": "PRAD", 
    "predictive_implication": "Level A", 
    "sources": [
      44
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "Olaparib", 
    "therapy_sensitivity": true, 
    "therapy_type": "Targeted Drug", 
    "validated": true
  }, 
  {
    "alterations": [
      55
    ], 
    "assertion_id": 116, 
    "created_on": null, 
    "description": "BET inhibition was found to have an antitumor effect in a murine model of squamous cell carcinoma.", 
    "disease": "Squamous Cell Carcinoma, NOS", 
    "favorable_prognosis": null, 
    "last_updated": "2017-11-03 14:39:00.452753", 
    "old_disease": "Squamous Cell Carcinoma", 
    "oncotree_code": "SCCNOS", 
    "predictive_implication": "Level D", 
    "sources": [
      45, 
      46
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "BET Inhibitors", 
    "therapy_sensitivity": true, 
    "therapy_type": "Drug Class", 
    "validated": true
  }, 
  {
    "alterations": [
      56
    ], 
    "assertion_id": 117, 
    "created_on": null, 
    "description": "Somatic homologous recombination mutations werepredictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.", 
    "disease": "Ovarian Cancer, Other", 
    "favorable_prognosis": true, 
    "last_updated": "2017-11-03 14:39:00.461006", 
    "old_disease": "Ovarian Cancer", 
    "oncotree_code": "OOVC", 
    "predictive_implication": "Level E", 
    "sources": [
      15
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "Platinum", 
    "therapy_sensitivity": null, 
    "therapy_type": "Chemotherapy", 
    "validated": true
  }, 
  {
    "alterations": [
      56
    ], 
    "assertion_id": 118, 
    "created_on": null, 
    "description": "Somatic homologous recombination mutations werepredictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.", 
    "disease": "Ovarian Cancer, Other", 
    "favorable_prognosis": true, 
    "last_updated": "2017-11-03 14:39:00.468276", 
    "old_disease": "Ovarian Cancer", 
    "oncotree_code": "OOVC", 
    "predictive_implication": "Level E", 
    "sources": [
      15
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "Platinum", 
    "therapy_sensitivity": null, 
    "therapy_type": "Chemotherapy", 
    "validated": true
  }, 
  {
    "alterations": [
      56
    ], 
    "assertion_id": 119, 
    "created_on": null, 
    "description": "Somatic homologous recombination mutations werepredictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.", 
    "disease": "Peritoneal Mesothelioma", 
    "favorable_prognosis": true, 
    "last_updated": "2017-11-03 14:39:00.477134", 
    "old_disease": "Peritoneal Carcinoma", 
    "oncotree_code": "PEMESO", 
    "predictive_implication": "Level E", 
    "sources": [
      15
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "Platinum", 
    "therapy_sensitivity": null, 
    "therapy_type": "Chemotherapy", 
    "validated": true
  }, 
  {
    "alterations": [
      56
    ], 
    "assertion_id": 120, 
    "created_on": null, 
    "description": "Somatic homologous recombination mutations werepredictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.", 
    "disease": "Peritoneal Mesothelioma", 
    "favorable_prognosis": true, 
    "last_updated": "2017-11-03 14:39:00.487123", 
    "old_disease": "Peritoneal Carcinoma", 
    "oncotree_code": "PEMESO", 
    "predictive_implication": "Level E", 
    "sources": [
      15
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "Platinum", 
    "therapy_sensitivity": null, 
    "therapy_type": "Chemotherapy", 
    "validated": true
  }, 
  {
    "alterations": [
      56
    ], 
    "assertion_id": 121, 
    "created_on": null, 
    "description": "Somatic homologous recombination mutations werepredictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.", 
    "disease": "Serous Ovarian Cancer", 
    "favorable_prognosis": true, 
    "last_updated": "2017-11-03 14:39:00.496015", 
    "old_disease": "Fallopian Tube Carcinoma", 
    "oncotree_code": "SOC", 
    "predictive_implication": "Level E", 
    "sources": [
      15
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "Platinum", 
    "therapy_sensitivity": null, 
    "therapy_type": "Chemotherapy", 
    "validated": true
  }, 
  {
    "alterations": [
      56
    ], 
    "assertion_id": 122, 
    "created_on": null, 
    "description": "Somatic homologous recombination mutations werepredictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.", 
    "disease": "Serous Ovarian Cancer", 
    "favorable_prognosis": true, 
    "last_updated": "2017-11-03 14:39:00.504122", 
    "old_disease": "Fallopian Tube Carcinoma", 
    "oncotree_code": "SOC", 
    "predictive_implication": "Level E", 
    "sources": [
      15
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "Platinum", 
    "therapy_sensitivity": null, 
    "therapy_type": "Chemotherapy", 
    "validated": true
  }, 
  {
    "alterations": [
      57
    ], 
    "assertion_id": 123, 
    "created_on": null, 
    "description": "Adult patients with a diagnosis of a solid tumor or hemotological malignancy, the identification of a CCND1 amplification, and who have received pre-treatment for recurrent, metastatic and/or locally advanced disease and have no remaining standard therapy options are eligible for a clinical trial of ribociclib.", 
    "disease": "Liposarcoma", 
    "favorable_prognosis": null, 
    "last_updated": "2017-11-03 14:39:00.513698", 
    "old_disease": "Liposarcoma", 
    "oncotree_code": "LIPO", 
    "predictive_implication": "Level A", 
    "sources": [
      47
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "Ribociclib", 
    "therapy_sensitivity": true, 
    "therapy_type": "Targeted Drug", 
    "validated": true
  }, 
  {
    "alterations": [
      57
    ], 
    "assertion_id": 124, 
    "created_on": null, 
    "description": "Adult patients with a diagnosis of a solid tumor or hemotological malignancy, the identification of a CCND1 amplification, and who have received pre-treatment for recurrent, metastatic and/or locally advanced disease and have no remaining standard therapy options are eligible for a clinical trial of ribociclib.", 
    "disease": "Melanoma", 
    "favorable_prognosis": null, 
    "last_updated": "2017-11-03 14:39:00.523457", 
    "old_disease": "Melanoma", 
    "oncotree_code": "MEL", 
    "predictive_implication": "Level A", 
    "sources": [
      47
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "Ribociclib", 
    "therapy_sensitivity": true, 
    "therapy_type": "Targeted Drug", 
    "validated": true
  }, 
  {
    "alterations": [
      58
    ], 
    "assertion_id": 125, 
    "created_on": null, 
    "description": "Palbociclib is predicted to have antitumor effects in multiple myeloma patients with t(11;14) resulting in CCND1 overexpression.", 
    "disease": "Multiple Myeloma", 
    "favorable_prognosis": null, 
    "last_updated": "2017-11-03 14:39:00.535550", 
    "old_disease": "Multiple Myeloma", 
    "oncotree_code": "MM", 
    "predictive_implication": "Level E", 
    "sources": [
      48
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "Palbociclib", 
    "therapy_sensitivity": true, 
    "therapy_type": "Targeted Drug", 
    "validated": true
  }, 
  {
    "alterations": [
      58
    ], 
    "assertion_id": 126, 
    "created_on": null, 
    "description": "In a meta-analysis of 1,661 patients, the t(11;14) translocation accompanied by CCND1 mutation was found to be associated with poor prognosis.", 
    "disease": "Multiple Myeloma", 
    "favorable_prognosis": false, 
    "last_updated": "2017-11-03 14:39:00.546999", 
    "old_disease": "Multiple Myeloma", 
    "oncotree_code": "MM", 
    "predictive_implication": "Level B", 
    "sources": [
      49
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "", 
    "therapy_sensitivity": null, 
    "therapy_type": "", 
    "validated": true
  }, 
  {
    "alterations": [
      58
    ], 
    "assertion_id": 127, 
    "created_on": null, 
    "description": "In a meta-analysis of 1,661 patients, the t(11;14) translocation accompanied by CCND1 mutation was found to be associated with poor prognosis.", 
    "disease": "Multiple Myeloma", 
    "favorable_prognosis": false, 
    "last_updated": "2017-11-03 14:39:00.554233", 
    "old_disease": "Multiple Myeloma", 
    "oncotree_code": "MM", 
    "predictive_implication": "Level B", 
    "sources": [
      49
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "", 
    "therapy_sensitivity": null, 
    "therapy_type": "", 
    "validated": true
  }, 
  {
    "alterations": [
      57
    ], 
    "assertion_id": 128, 
    "created_on": null, 
    "description": "CCND1 amplification was observed in a study of 109 microdissected pancreatic adenocarcinoma tumors, and is predicted to have antitumor effects in response to palbociclib.", 
    "disease": "Pancreatic Adenocarcinoma", 
    "favorable_prognosis": null, 
    "last_updated": "2017-11-03 14:39:00.561580", 
    "old_disease": "Pancreatic Cancer", 
    "oncotree_code": "PAAD", 
    "predictive_implication": "Level E", 
    "sources": [
      10
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "Palbociclib", 
    "therapy_sensitivity": true, 
    "therapy_type": "Targeted Drug", 
    "validated": true
  }, 
  {
    "alterations": [
      59
    ], 
    "assertion_id": 129, 
    "created_on": null, 
    "description": "CCND1 amplification showed reduced recurrence-free survival in a randomized control trial of postmenopausal breast cancer patients.", 
    "disease": "Invasive Breast Carcinoma", 
    "favorable_prognosis": false, 
    "last_updated": "2017-11-03 14:39:00.569444", 
    "old_disease": "Breast Cancer", 
    "oncotree_code": "BRCA", 
    "predictive_implication": "Level A", 
    "sources": [
      50
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "Tamoxifen", 
    "therapy_sensitivity": null, 
    "therapy_type": "Targeted Drug", 
    "validated": true
  }, 
  {
    "alterations": [
      57
    ], 
    "assertion_id": 130, 
    "created_on": null, 
    "description": "Adult patients with a diagnosis of a solid tumor or hemotological malignancy, the identification of a CCND1 amplification, and who have received pre-treatment for recurrent, metastatic and/or locally advanced disease and have no remaining standard therapy options are eligible for a clinical trial of ribociclib.", 
    "disease": "Prostate Adenocarcinoma", 
    "favorable_prognosis": null, 
    "last_updated": "2017-11-03 14:39:00.580125", 
    "old_disease": "Prostate Cancer", 
    "oncotree_code": "PRAD", 
    "predictive_implication": "Level A", 
    "sources": [
      47
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "Ribociclib", 
    "therapy_sensitivity": true, 
    "therapy_type": "Targeted Drug", 
    "validated": true
  }, 
  {
    "alterations": [
      60
    ], 
    "assertion_id": 131, 
    "created_on": null, 
    "description": "Adult patients with a diagnosis of a solid tumor or hemotological malignancy, the identification of a CCND3 amplification, and who have received pre-treatment for recurrent, metastatic and/or locally advanced disease and have no remaining standard therapy options are eligible for a clinical trial of ribociclib.", 
    "disease": "Liposarcoma", 
    "favorable_prognosis": null, 
    "last_updated": "2017-11-03 14:39:00.593337", 
    "old_disease": "Liposarcoma", 
    "oncotree_code": "LIPO", 
    "predictive_implication": "Level A", 
    "sources": [
      47
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "Ribociclib", 
    "therapy_sensitivity": true, 
    "therapy_type": "Targeted Drug", 
    "validated": true
  }, 
  {
    "alterations": [
      60
    ], 
    "assertion_id": 132, 
    "created_on": null, 
    "description": "Adult patients with a diagnosis of a solid tumor or hemotological malignancy, the identification of a CCND3 amplification, and who have received pre-treatment for recurrent, metastatic and/or locally advanced disease and have no remaining standard therapy options are eligible for a clinical trial of ribociclib.", 
    "disease": "Melanoma", 
    "favorable_prognosis": null, 
    "last_updated": "2017-11-03 14:39:00.605056", 
    "old_disease": "Melanoma", 
    "oncotree_code": "MEL", 
    "predictive_implication": "Level A", 
    "sources": [
      47
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "Ribociclib", 
    "therapy_sensitivity": true, 
    "therapy_type": "Targeted Drug", 
    "validated": true
  }, 
  {
    "alterations": [
      61
    ], 
    "assertion_id": 133, 
    "created_on": null, 
    "description": "Palbociclib is predicted to have antitumor effects in multiple myeloma patients with t(6;14) resulting in CCND3 overexpression.", 
    "disease": "Multiple Myeloma", 
    "favorable_prognosis": null, 
    "last_updated": "2017-11-03 14:39:00.613666", 
    "old_disease": "Multiple Myeloma", 
    "oncotree_code": "MM", 
    "predictive_implication": "Level E", 
    "sources": [
      48
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "Palbociclib", 
    "therapy_sensitivity": true, 
    "therapy_type": "Targeted Drug", 
    "validated": true
  }, 
  {
    "alterations": [
      60
    ], 
    "assertion_id": 134, 
    "created_on": null, 
    "description": "Adult patients with a diagnosis of a solid tumor or hemotological malignancy, the identification of a CCND3 amplification, and who have received pre-treatment for recurrent, metastatic and/or locally advanced disease and have no remaining standard therapy options are eligible for a clinical trial of ribociclib.", 
    "disease": "Prostate Adenocarcinoma", 
    "favorable_prognosis": null, 
    "last_updated": "2017-11-03 14:39:00.621061", 
    "old_disease": "Prostate Cancer", 
    "oncotree_code": "PRAD", 
    "predictive_implication": "Level A", 
    "sources": [
      47
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "Ribociclib", 
    "therapy_sensitivity": true, 
    "therapy_type": "Targeted Drug", 
    "validated": true
  }, 
  {
    "alterations": [
      62
    ], 
    "assertion_id": 135, 
    "created_on": null, 
    "description": "Sensitivity to Bortezomib was observed in ovarian cancer cell lines.", 
    "disease": "Ovarian Cancer, Other", 
    "favorable_prognosis": null, 
    "last_updated": "2017-11-03 14:39:00.632519", 
    "old_disease": "Ovarian Cancer", 
    "oncotree_code": "OOVC", 
    "predictive_implication": "Level D", 
    "sources": [
      51
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "Bortezomib", 
    "therapy_sensitivity": true, 
    "therapy_type": "Targeted Drug", 
    "validated": true
  }, 
  {
    "alterations": [
      63
    ], 
    "assertion_id": 136, 
    "created_on": null, 
    "description": "shRNA knockout in ovarian cancer suggests suggests sensitivity to PARP1/2 inhibition, specifically olaparib.", 
    "disease": "Ovarian Cancer, Other", 
    "favorable_prognosis": null, 
    "last_updated": "2017-11-03 14:39:00.645690", 
    "old_disease": "Ovarian Cancer", 
    "oncotree_code": "OOVC", 
    "predictive_implication": "Level D", 
    "sources": [
      52
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "Olaparib", 
    "therapy_sensitivity": true, 
    "therapy_type": "Targeted Drug", 
    "validated": true
  }, 
  {
    "alterations": [
      64
    ], 
    "assertion_id": 137, 
    "created_on": null, 
    "description": "siRNA knockout, \"gene depletion\", of CDK12 shows sensitivity to PARP inhibitor veliparib in ovarian cancer cell lines.", 
    "disease": "Ovarian Cancer, Other", 
    "favorable_prognosis": null, 
    "last_updated": "2017-11-03 14:39:00.658574", 
    "old_disease": "Ovarian Cancer", 
    "oncotree_code": "OOVC", 
    "predictive_implication": "Level D", 
    "sources": [
      53
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "Veliparib", 
    "therapy_sensitivity": true, 
    "therapy_type": "Targeted Drug", 
    "validated": true
  }, 
  {
    "alterations": [
      65
    ], 
    "assertion_id": 138, 
    "created_on": null, 
    "description": "Treatment with CDK4 inhibitor PD033299 showed favorable progression free survival for patients with CDK4 amplification.", 
    "disease": "Liposarcoma", 
    "favorable_prognosis": null, 
    "last_updated": "2017-11-03 14:39:00.668103", 
    "old_disease": "Liposarcoma", 
    "oncotree_code": "LIPO", 
    "predictive_implication": "Level A", 
    "sources": [
      54
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "PD033299", 
    "therapy_sensitivity": true, 
    "therapy_type": "Targeted Drug", 
    "validated": true
  }, 
  {
    "alterations": [
      65
    ], 
    "assertion_id": 139, 
    "created_on": null, 
    "description": "Adult patients with a diagnosis of a solid tumor or hemotological malignancy, the identification of a CDK4 aberration, and who have received pre-treatment for recurrent, metastatic and/or locally advanced disease and have no remaining standard therapy options are eligible for a clinical trial of ribociclib.", 
    "disease": "Liposarcoma", 
    "favorable_prognosis": null, 
    "last_updated": "2017-11-03 14:39:00.675071", 
    "old_disease": "Liposarcoma", 
    "oncotree_code": "LIPO", 
    "predictive_implication": "Level A", 
    "sources": [
      47
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "Ribociclib", 
    "therapy_sensitivity": true, 
    "therapy_type": "Targeted Drug", 
    "validated": true
  }, 
  {
    "alterations": [
      66
    ], 
    "assertion_id": 140, 
    "created_on": null, 
    "description": "Adult patients with a diagnosis of a solid tumor or hemotological malignancy, the identification of a CDK4 aberration, and who have received pre-treatment for recurrent, metastatic and/or locally advanced disease and have no remaining standard therapy options are eligible for a clinical trial of ribociclib.", 
    "disease": "Liposarcoma", 
    "favorable_prognosis": null, 
    "last_updated": "2017-11-03 14:39:00.684620", 
    "old_disease": "Liposarcoma", 
    "oncotree_code": "LIPO", 
    "predictive_implication": "Level A", 
    "sources": [
      47
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "Ribociclib", 
    "therapy_sensitivity": true, 
    "therapy_type": "Targeted Drug", 
    "validated": true
  }, 
  {
    "alterations": [
      65
    ], 
    "assertion_id": 141, 
    "created_on": null, 
    "description": "Adult patients with a diagnosis of a solid tumor or hemotological malignancy, the identification of a CDK4 aberration, and who have received pre-treatment for recurrent, metastatic and/or locally advanced disease and have no remaining standard therapy options are eligible for a clinical trial of ribociclib.", 
    "disease": "Melanoma", 
    "favorable_prognosis": null, 
    "last_updated": "2017-11-03 14:39:00.691945", 
    "old_disease": "Melanoma", 
    "oncotree_code": "MEL", 
    "predictive_implication": "Level A", 
    "sources": [
      47
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "Ribociclib", 
    "therapy_sensitivity": true, 
    "therapy_type": "Targeted Drug", 
    "validated": true
  }, 
  {
    "alterations": [
      66
    ], 
    "assertion_id": 142, 
    "created_on": null, 
    "description": "Adult patients with a diagnosis of a solid tumor or hemotological malignancy, the identification of a CDK4 aberration, and who have received pre-treatment for recurrent, metastatic and/or locally advanced disease and have no remaining standard therapy options are eligible for a clinical trial of ribociclib.", 
    "disease": "Melanoma", 
    "favorable_prognosis": null, 
    "last_updated": "2017-11-03 14:39:00.702192", 
    "old_disease": "Melanoma", 
    "oncotree_code": "MEL", 
    "predictive_implication": "Level A", 
    "sources": [
      47
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "Ribociclib", 
    "therapy_sensitivity": true, 
    "therapy_type": "Targeted Drug", 
    "validated": true
  }, 
  {
    "alterations": [
      65
    ], 
    "assertion_id": 143, 
    "created_on": null, 
    "description": "CDK4 amplification was observed in a study of 109 microdissected pancreatic adenocarcinoma tumors, and is predicted to have antitumor effects in response to palbociclib.", 
    "disease": "Pancreatic Adenocarcinoma", 
    "favorable_prognosis": null, 
    "last_updated": "2017-11-03 14:39:00.711926", 
    "old_disease": "Pancreatic Cancer", 
    "oncotree_code": "PAAD", 
    "predictive_implication": "Level E", 
    "sources": [
      10, 
      55
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "Palbociclib", 
    "therapy_sensitivity": true, 
    "therapy_type": "Targeted Drug", 
    "validated": true
  }, 
  {
    "alterations": [
      65
    ], 
    "assertion_id": 144, 
    "created_on": null, 
    "description": "Adult patients with a diagnosis of a solid tumor or hemotological malignancy, the identification of a CDK4 aberration, and who have received pre-treatment for recurrent, metastatic and/or locally advanced disease and have no remaining standard therapy options are eligible for a clinical trial of ribociclib.", 
    "disease": "Prostate Adenocarcinoma", 
    "favorable_prognosis": null, 
    "last_updated": "2017-11-03 14:39:00.720629", 
    "old_disease": "Prostate Cancer", 
    "oncotree_code": "PRAD", 
    "predictive_implication": "Level A", 
    "sources": [
      47
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "Ribociclib", 
    "therapy_sensitivity": true, 
    "therapy_type": "Targeted Drug", 
    "validated": true
  }, 
  {
    "alterations": [
      66
    ], 
    "assertion_id": 145, 
    "created_on": null, 
    "description": "Adult patients with a diagnosis of a solid tumor or hemotological malignancy, the identification of a CDK4 aberration, and who have received pre-treatment for recurrent, metastatic and/or locally advanced disease and have no remaining standard therapy options are eligible for a clinical trial of ribociclib.", 
    "disease": "Prostate Adenocarcinoma", 
    "favorable_prognosis": null, 
    "last_updated": "2017-11-03 14:39:00.728470", 
    "old_disease": "Prostate Cancer", 
    "oncotree_code": "PRAD", 
    "predictive_implication": "Level A", 
    "sources": [
      47
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "Ribociclib", 
    "therapy_sensitivity": true, 
    "therapy_type": "Targeted Drug", 
    "validated": true
  }, 
  {
    "alterations": [
      67
    ], 
    "assertion_id": 146, 
    "created_on": null, 
    "description": "Adult patients with a diagnosis of a solid tumor or hemotological malignancy, the identification of a CDK6 aberration, and who have received pre-treatment for recurrent, metastatic and/or locally advanced disease and have no remaining standard therapy options are eligible for a clinical trial of ribociclib.", 
    "disease": "Liposarcoma", 
    "favorable_prognosis": null, 
    "last_updated": "2017-11-03 14:39:00.739014", 
    "old_disease": "Liposarcoma", 
    "oncotree_code": "LIPO", 
    "predictive_implication": "Level A", 
    "sources": [
      47
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "Ribociclib", 
    "therapy_sensitivity": true, 
    "therapy_type": "Targeted Drug", 
    "validated": true
  }, 
  {
    "alterations": [
      68
    ], 
    "assertion_id": 147, 
    "created_on": null, 
    "description": "Adult patients with a diagnosis of a solid tumor or hemotological malignancy, the identification of a CDK6 aberration, and who have received pre-treatment for recurrent, metastatic and/or locally advanced disease and have no remaining standard therapy options are eligible for a clinical trial of ribociclib.", 
    "disease": "Liposarcoma", 
    "favorable_prognosis": null, 
    "last_updated": "2017-11-03 14:39:00.755706", 
    "old_disease": "Liposarcoma", 
    "oncotree_code": "LIPO", 
    "predictive_implication": "Level A", 
    "sources": [
      47
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "Ribociclib", 
    "therapy_sensitivity": true, 
    "therapy_type": "Targeted Drug", 
    "validated": true
  }, 
  {
    "alterations": [
      67
    ], 
    "assertion_id": 148, 
    "created_on": null, 
    "description": "Adult patients with a diagnosis of a solid tumor or hemotological malignancy, the identification of a CDK6 aberration, and who have received pre-treatment for recurrent, metastatic and/or locally advanced disease and have no remaining standard therapy options are eligible for a clinical trial of ribociclib.", 
    "disease": "Melanoma", 
    "favorable_prognosis": null, 
    "last_updated": "2017-11-03 14:39:00.764266", 
    "old_disease": "Melanoma", 
    "oncotree_code": "MEL", 
    "predictive_implication": "Level A", 
    "sources": [
      47
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "Ribociclib", 
    "therapy_sensitivity": true, 
    "therapy_type": "Targeted Drug", 
    "validated": true
  }, 
  {
    "alterations": [
      68
    ], 
    "assertion_id": 149, 
    "created_on": null, 
    "description": "Adult patients with a diagnosis of a solid tumor or hemotological malignancy, the identification of a CDK6 aberration, and who have received pre-treatment for recurrent, metastatic and/or locally advanced disease and have no remaining standard therapy options are eligible for a clinical trial of ribociclib.", 
    "disease": "Melanoma", 
    "favorable_prognosis": null, 
    "last_updated": "2017-11-03 14:39:00.772714", 
    "old_disease": "Melanoma", 
    "oncotree_code": "MEL", 
    "predictive_implication": "Level A", 
    "sources": [
      47
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "Ribociclib", 
    "therapy_sensitivity": true, 
    "therapy_type": "Targeted Drug", 
    "validated": true
  }, 
  {
    "alterations": [
      67
    ], 
    "assertion_id": 150, 
    "created_on": null, 
    "description": "Adult patients with a diagnosis of a solid tumor or hemotological malignancy, the identification of a CDK6 aberration, and who have received pre-treatment for recurrent, metastatic and/or locally advanced disease and have no remaining standard therapy options are eligible for a clinical trial of ribociclib.", 
    "disease": "Prostate Adenocarcinoma", 
    "favorable_prognosis": null, 
    "last_updated": "2017-11-03 14:39:00.780065", 
    "old_disease": "Prostate Cancer", 
    "oncotree_code": "PRAD", 
    "predictive_implication": "Level A", 
    "sources": [
      47
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "Ribociclib", 
    "therapy_sensitivity": true, 
    "therapy_type": "Targeted Drug", 
    "validated": true
  }, 
  {
    "alterations": [
      68
    ], 
    "assertion_id": 151, 
    "created_on": null, 
    "description": "Adult patients with a diagnosis of a solid tumor or hemotological malignancy, the identification of a CDK6 aberration, and who have received pre-treatment for recurrent, metastatic and/or locally advanced disease and have no remaining standard therapy options are eligible for a clinical trial of ribociclib.", 
    "disease": "Prostate Adenocarcinoma", 
    "favorable_prognosis": null, 
    "last_updated": "2017-11-03 14:39:00.786470", 
    "old_disease": "Prostate Cancer", 
    "oncotree_code": "PRAD", 
    "predictive_implication": "Level A", 
    "sources": [
      47
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "Ribociclib", 
    "therapy_sensitivity": true, 
    "therapy_type": "Targeted Drug", 
    "validated": true
  }, 
  {
    "alterations": [
      69
    ], 
    "assertion_id": 152, 
    "created_on": null, 
    "description": "Adult patients with a diagnosis of a solid tumor or hemotological malignancy, the identification of a CDKN2A amplification, and who have received pre-treatment for recurrent, metastatic and/or locally advanced disease and have no remaining standard therapy options are eligible for a clinical trial of ribociclib.", 
    "disease": "Liposarcoma", 
    "favorable_prognosis": null, 
    "last_updated": "2017-11-03 14:39:00.796205", 
    "old_disease": "Liposarcoma", 
    "oncotree_code": "LIPO", 
    "predictive_implication": "Level A", 
    "sources": [
      47
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "Ribociclib", 
    "therapy_sensitivity": true, 
    "therapy_type": "Targeted Drug", 
    "validated": true
  }, 
  {
    "alterations": [
      69
    ], 
    "assertion_id": 153, 
    "created_on": null, 
    "description": "Adult patients with a diagnosis of a solid tumor or hemotological malignancy, the identification of a CDKN2A amplification, and who have received pre-treatment for recurrent, metastatic and/or locally advanced disease and have no remaining standard therapy options are eligible for a clinical trial of ribociclib.", 
    "disease": "Melanoma", 
    "favorable_prognosis": null, 
    "last_updated": "2017-11-03 14:39:00.808991", 
    "old_disease": "Melanoma", 
    "oncotree_code": "MEL", 
    "predictive_implication": "Level A", 
    "sources": [
      47
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "Ribociclib", 
    "therapy_sensitivity": true, 
    "therapy_type": "Targeted Drug", 
    "validated": true
  }, 
  {
    "alterations": [
      70
    ], 
    "assertion_id": 154, 
    "created_on": null, 
    "description": "CDKN2A loss was observed in a study of 109 microdissected pancreatic adenocarcinoma tumors, and is predicted to have antitumor effects in response to palbociclib.", 
    "disease": "Pancreatic Adenocarcinoma", 
    "favorable_prognosis": null, 
    "last_updated": "2017-11-03 14:39:00.821579", 
    "old_disease": "Pancreatic Cancer", 
    "oncotree_code": "PAAD", 
    "predictive_implication": "Level E", 
    "sources": [
      10
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "Palbociclib", 
    "therapy_sensitivity": true, 
    "therapy_type": "Targeted Drug", 
    "validated": true
  }, 
  {
    "alterations": [
      70
    ], 
    "assertion_id": 155, 
    "created_on": null, 
    "description": "These deletions are typically codeleted with MTAP, which has enhanced dependency on PRMT5 for which there is an inhibitor in clincial development", 
    "disease": "", 
    "favorable_prognosis": null, 
    "last_updated": "2017-11-03 14:39:00.833034", 
    "old_disease": "", 
    "oncotree_code": "", 
    "predictive_implication": "Level D", 
    "sources": [
      56
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "EPZ015666", 
    "therapy_sensitivity": true, 
    "therapy_type": "Targeted Drug", 
    "validated": true
  }, 
  {
    "alterations": [
      69
    ], 
    "assertion_id": 156, 
    "created_on": null, 
    "description": "Adult patients with a diagnosis of a solid tumor or hemotological malignancy, the identification of a CDKN2A amplification, and who have received pre-treatment for recurrent, metastatic and/or locally advanced disease and have no remaining standard therapy options are eligible for a clinical trial of ribociclib.", 
    "disease": "Prostate Adenocarcinoma", 
    "favorable_prognosis": null, 
    "last_updated": "2017-11-03 14:39:00.843500", 
    "old_disease": "Prostate Cancer", 
    "oncotree_code": "PRAD", 
    "predictive_implication": "Level A", 
    "sources": [
      47
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "Ribociclib", 
    "therapy_sensitivity": true, 
    "therapy_type": "Targeted Drug", 
    "validated": true
  }, 
  {
    "alterations": [
      71
    ], 
    "assertion_id": 157, 
    "created_on": null, 
    "description": "These deletions are typically codeleted with MTAP, which has enhanced dependency on PRMT5 for which there is an inhibitor in clincial development", 
    "disease": "", 
    "favorable_prognosis": null, 
    "last_updated": "2017-11-03 14:39:00.853645", 
    "old_disease": "", 
    "oncotree_code": "", 
    "predictive_implication": "Level D", 
    "sources": [
      56
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "EPZ015666", 
    "therapy_sensitivity": true, 
    "therapy_type": "Targeted Drug", 
    "validated": true
  }, 
  {
    "alterations": [
      72
    ], 
    "assertion_id": 158, 
    "created_on": null, 
    "description": "Either hemizygous or homozygous CDKN2C loss, identified by FISH, resulted in worse overall survival relative to wild type in a study of 515 multiple myeloma patients.", 
    "disease": "Multiple Myeloma", 
    "favorable_prognosis": false, 
    "last_updated": "2017-11-03 14:39:00.866207", 
    "old_disease": "Multiple Myeloma", 
    "oncotree_code": "MM", 
    "predictive_implication": "Level A", 
    "sources": [
      57
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "", 
    "therapy_sensitivity": null, 
    "therapy_type": "", 
    "validated": true
  }, 
  {
    "alterations": [
      73
    ], 
    "assertion_id": 159, 
    "created_on": null, 
    "description": "Palbociclib is predicted to have antitumor effects in multiple myeloma patients with del(1p) resulting in loss of CDKN2C.", 
    "disease": "Multiple Myeloma", 
    "favorable_prognosis": null, 
    "last_updated": "2017-11-03 14:39:00.877463", 
    "old_disease": "Multiple Myeloma", 
    "oncotree_code": "MM", 
    "predictive_implication": "Level E", 
    "sources": [
      48
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "Palbociclib", 
    "therapy_sensitivity": true, 
    "therapy_type": "Targeted Drug", 
    "validated": true
  }, 
  {
    "alterations": [
      74
    ], 
    "assertion_id": 160, 
    "created_on": null, 
    "description": "Somatic homologous recombination mutations werepredictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.", 
    "disease": "Ovarian Cancer, Other", 
    "favorable_prognosis": null, 
    "last_updated": "2017-11-03 14:39:00.886510", 
    "old_disease": "Ovarian Cancer", 
    "oncotree_code": "OOVC", 
    "predictive_implication": "Level E", 
    "sources": [
      15
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "Platinum", 
    "therapy_sensitivity": true, 
    "therapy_type": "Chemotherapy", 
    "validated": true
  }, 
  {
    "alterations": [
      75
    ], 
    "assertion_id": 161, 
    "created_on": null, 
    "description": "Germline homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas. Mutant cases also had better overall survival than wild type.", 
    "disease": "Ovarian Cancer, Other", 
    "favorable_prognosis": true, 
    "last_updated": "2017-11-03 14:39:00.893975", 
    "old_disease": "Ovarian Cancer", 
    "oncotree_code": "OOVC", 
    "predictive_implication": "Level E", 
    "sources": [
      15
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "Platinum", 
    "therapy_sensitivity": null, 
    "therapy_type": "Chemotherapy", 
    "validated": true
  }, 
  {
    "alterations": [
      74
    ], 
    "assertion_id": 162, 
    "created_on": null, 
    "description": "Somatic homologous recombination mutations werepredictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.", 
    "disease": "Ovarian Cancer, Other", 
    "favorable_prognosis": true, 
    "last_updated": "2017-11-03 14:39:00.903164", 
    "old_disease": "Ovarian Cancer", 
    "oncotree_code": "OOVC", 
    "predictive_implication": "Level E", 
    "sources": [
      15
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "Platinum", 
    "therapy_sensitivity": null, 
    "therapy_type": "Chemotherapy", 
    "validated": true
  }, 
  {
    "alterations": [
      75
    ], 
    "assertion_id": 163, 
    "created_on": null, 
    "description": "Germline homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas. Mutant cases also had better overall survival than wild type.", 
    "disease": "Ovarian Cancer, Other", 
    "favorable_prognosis": true, 
    "last_updated": "2017-11-03 14:39:00.911253", 
    "old_disease": "Ovarian Cancer", 
    "oncotree_code": "OOVC", 
    "predictive_implication": "Level E", 
    "sources": [
      15
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "Platinum", 
    "therapy_sensitivity": null, 
    "therapy_type": "Chemotherapy", 
    "validated": true
  }, 
  {
    "alterations": [
      74
    ], 
    "assertion_id": 164, 
    "created_on": null, 
    "description": "Somatic homologous recombination mutations werepredictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.", 
    "disease": "Peritoneal Mesothelioma", 
    "favorable_prognosis": null, 
    "last_updated": "2017-11-03 14:39:00.923191", 
    "old_disease": "Peritoneal Carcinoma", 
    "oncotree_code": "PEMESO", 
    "predictive_implication": "Level E", 
    "sources": [
      15
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "Platinum", 
    "therapy_sensitivity": true, 
    "therapy_type": "Chemotherapy", 
    "validated": true
  }, 
  {
    "alterations": [
      75
    ], 
    "assertion_id": 165, 
    "created_on": null, 
    "description": "Germline homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas. Mutant cases also had better overall survival than wild type.", 
    "disease": "Peritoneal Mesothelioma", 
    "favorable_prognosis": true, 
    "last_updated": "2017-11-03 14:39:00.931472", 
    "old_disease": "Peritoneal Carcinoma", 
    "oncotree_code": "PEMESO", 
    "predictive_implication": "Level E", 
    "sources": [
      15
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "Platinum", 
    "therapy_sensitivity": null, 
    "therapy_type": "Chemotherapy", 
    "validated": true
  }, 
  {
    "alterations": [
      74
    ], 
    "assertion_id": 166, 
    "created_on": null, 
    "description": "Somatic homologous recombination mutations werepredictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.", 
    "disease": "Peritoneal Mesothelioma", 
    "favorable_prognosis": true, 
    "last_updated": "2017-11-03 14:39:00.939192", 
    "old_disease": "Peritoneal Carcinoma", 
    "oncotree_code": "PEMESO", 
    "predictive_implication": "Level E", 
    "sources": [
      15
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "Platinum", 
    "therapy_sensitivity": null, 
    "therapy_type": "Chemotherapy", 
    "validated": true
  }, 
  {
    "alterations": [
      75
    ], 
    "assertion_id": 167, 
    "created_on": null, 
    "description": "Germline homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas. Mutant cases also had better overall survival than wild type.", 
    "disease": "Peritoneal Mesothelioma", 
    "favorable_prognosis": true, 
    "last_updated": "2017-11-03 14:39:00.945604", 
    "old_disease": "Peritoneal Carcinoma", 
    "oncotree_code": "PEMESO", 
    "predictive_implication": "Level E", 
    "sources": [
      15
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "Platinum", 
    "therapy_sensitivity": null, 
    "therapy_type": "Chemotherapy", 
    "validated": true
  }, 
  {
    "alterations": [
      74
    ], 
    "assertion_id": 168, 
    "created_on": null, 
    "description": "Somatic homologous recombination mutations werepredictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.", 
    "disease": "Serous Ovarian Cancer", 
    "favorable_prognosis": null, 
    "last_updated": "2017-11-03 14:39:00.953028", 
    "old_disease": "Fallopian Tube Carcinoma", 
    "oncotree_code": "SOC", 
    "predictive_implication": "Level E", 
    "sources": [
      15
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "Platinum", 
    "therapy_sensitivity": true, 
    "therapy_type": "Chemotherapy", 
    "validated": true
  }, 
  {
    "alterations": [
      75
    ], 
    "assertion_id": 169, 
    "created_on": null, 
    "description": "Germline homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas. Mutant cases also had better overall survival than wild type.", 
    "disease": "Serous Ovarian Cancer", 
    "favorable_prognosis": true, 
    "last_updated": "2017-11-03 14:39:00.961225", 
    "old_disease": "Fallopian Tube Carcinoma", 
    "oncotree_code": "SOC", 
    "predictive_implication": "Level E", 
    "sources": [
      15
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "Platinum", 
    "therapy_sensitivity": null, 
    "therapy_type": "Chemotherapy", 
    "validated": true
  }, 
  {
    "alterations": [
      74
    ], 
    "assertion_id": 170, 
    "created_on": null, 
    "description": "Somatic homologous recombination mutations werepredictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.", 
    "disease": "Serous Ovarian Cancer", 
    "favorable_prognosis": true, 
    "last_updated": "2017-11-03 14:39:00.971416", 
    "old_disease": "Fallopian Tube Carcinoma", 
    "oncotree_code": "SOC", 
    "predictive_implication": "Level E", 
    "sources": [
      15
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "Platinum", 
    "therapy_sensitivity": null, 
    "therapy_type": "Chemotherapy", 
    "validated": true
  }, 
  {
    "alterations": [
      75
    ], 
    "assertion_id": 171, 
    "created_on": null, 
    "description": "Germline homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas. Mutant cases also had better overall survival than wild type.", 
    "disease": "Serous Ovarian Cancer", 
    "favorable_prognosis": true, 
    "last_updated": "2017-11-03 14:39:00.978956", 
    "old_disease": "Fallopian Tube Carcinoma", 
    "oncotree_code": "SOC", 
    "predictive_implication": "Level E", 
    "sources": [
      15
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "Platinum", 
    "therapy_sensitivity": null, 
    "therapy_type": "Chemotherapy", 
    "validated": true
  }, 
  {
    "alterations": [
      76
    ], 
    "assertion_id": 172, 
    "created_on": null, 
    "description": "Somatic homologous recombination mutations werepredictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.", 
    "disease": "Ovarian Cancer, Other", 
    "favorable_prognosis": null, 
    "last_updated": "2017-11-03 14:39:00.989142", 
    "old_disease": "Ovarian Cancer", 
    "oncotree_code": "OOVC", 
    "predictive_implication": "Level E", 
    "sources": [
      15
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "Platinum", 
    "therapy_sensitivity": true, 
    "therapy_type": "Chemotherapy", 
    "validated": true
  }, 
  {
    "alterations": [
      77
    ], 
    "assertion_id": 173, 
    "created_on": null, 
    "description": "Germline homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas. Mutant cases also had better overall survival than wild type.", 
    "disease": "Ovarian Cancer, Other", 
    "favorable_prognosis": true, 
    "last_updated": "2017-11-03 14:39:00.998832", 
    "old_disease": "Ovarian Cancer", 
    "oncotree_code": "OOVC", 
    "predictive_implication": "Level E", 
    "sources": [
      15
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "Platinum", 
    "therapy_sensitivity": null, 
    "therapy_type": "Chemotherapy", 
    "validated": true
  }, 
  {
    "alterations": [
      76
    ], 
    "assertion_id": 174, 
    "created_on": null, 
    "description": "Somatic homologous recombination mutations werepredictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.", 
    "disease": "Ovarian Cancer, Other", 
    "favorable_prognosis": true, 
    "last_updated": "2017-11-03 14:39:01.007830", 
    "old_disease": "Ovarian Cancer", 
    "oncotree_code": "OOVC", 
    "predictive_implication": "Level E", 
    "sources": [
      15
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "Platinum", 
    "therapy_sensitivity": null, 
    "therapy_type": "Chemotherapy", 
    "validated": true
  }, 
  {
    "alterations": [
      77
    ], 
    "assertion_id": 175, 
    "created_on": null, 
    "description": "Germline homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas. Mutant cases also had better overall survival than wild type.", 
    "disease": "Ovarian Cancer, Other", 
    "favorable_prognosis": true, 
    "last_updated": "2017-11-03 14:39:01.016623", 
    "old_disease": "Ovarian Cancer", 
    "oncotree_code": "OOVC", 
    "predictive_implication": "Level E", 
    "sources": [
      15
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "Platinum", 
    "therapy_sensitivity": null, 
    "therapy_type": "Chemotherapy", 
    "validated": true
  }, 
  {
    "alterations": [
      76
    ], 
    "assertion_id": 176, 
    "created_on": null, 
    "description": "Somatic homologous recombination mutations werepredictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.", 
    "disease": "Peritoneal Mesothelioma", 
    "favorable_prognosis": null, 
    "last_updated": "2017-11-03 14:39:01.028893", 
    "old_disease": "Peritoneal Carcinoma", 
    "oncotree_code": "PEMESO", 
    "predictive_implication": "Level E", 
    "sources": [
      15
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "Platinum", 
    "therapy_sensitivity": true, 
    "therapy_type": "Chemotherapy", 
    "validated": true
  }, 
  {
    "alterations": [
      77
    ], 
    "assertion_id": 177, 
    "created_on": null, 
    "description": "Germline homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas. Mutant cases also had better overall survival than wild type.", 
    "disease": "Peritoneal Mesothelioma", 
    "favorable_prognosis": true, 
    "last_updated": "2017-11-03 14:39:01.036342", 
    "old_disease": "Peritoneal Carcinoma", 
    "oncotree_code": "PEMESO", 
    "predictive_implication": "Level E", 
    "sources": [
      15
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "Platinum", 
    "therapy_sensitivity": null, 
    "therapy_type": "Chemotherapy", 
    "validated": true
  }, 
  {
    "alterations": [
      76
    ], 
    "assertion_id": 178, 
    "created_on": null, 
    "description": "Somatic homologous recombination mutations werepredictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.", 
    "disease": "Peritoneal Mesothelioma", 
    "favorable_prognosis": true, 
    "last_updated": "2017-11-03 14:39:01.043153", 
    "old_disease": "Peritoneal Carcinoma", 
    "oncotree_code": "PEMESO", 
    "predictive_implication": "Level E", 
    "sources": [
      15
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "Platinum", 
    "therapy_sensitivity": null, 
    "therapy_type": "Chemotherapy", 
    "validated": true
  }, 
  {
    "alterations": [
      77
    ], 
    "assertion_id": 179, 
    "created_on": null, 
    "description": "Germline homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas. Mutant cases also had better overall survival than wild type.", 
    "disease": "Peritoneal Mesothelioma", 
    "favorable_prognosis": true, 
    "last_updated": "2017-11-03 14:39:01.049713", 
    "old_disease": "Peritoneal Carcinoma", 
    "oncotree_code": "PEMESO", 
    "predictive_implication": "Level E", 
    "sources": [
      15
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "Platinum", 
    "therapy_sensitivity": null, 
    "therapy_type": "Chemotherapy", 
    "validated": true
  }, 
  {
    "alterations": [
      76
    ], 
    "assertion_id": 180, 
    "created_on": null, 
    "description": "Somatic homologous recombination mutations werepredictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.", 
    "disease": "Serous Ovarian Cancer", 
    "favorable_prognosis": null, 
    "last_updated": "2017-11-03 14:39:01.058736", 
    "old_disease": "Fallopian Tube Carcinoma", 
    "oncotree_code": "SOC", 
    "predictive_implication": "Level E", 
    "sources": [
      15
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "Platinum", 
    "therapy_sensitivity": true, 
    "therapy_type": "Chemotherapy", 
    "validated": true
  }, 
  {
    "alterations": [
      77
    ], 
    "assertion_id": 181, 
    "created_on": null, 
    "description": "Germline homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas. Mutant cases also had better overall survival than wild type.", 
    "disease": "Serous Ovarian Cancer", 
    "favorable_prognosis": true, 
    "last_updated": "2017-11-03 14:39:01.068398", 
    "old_disease": "Fallopian Tube Carcinoma", 
    "oncotree_code": "SOC", 
    "predictive_implication": "Level E", 
    "sources": [
      15
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "Platinum", 
    "therapy_sensitivity": null, 
    "therapy_type": "Chemotherapy", 
    "validated": true
  }, 
  {
    "alterations": [
      76
    ], 
    "assertion_id": 182, 
    "created_on": null, 
    "description": "Somatic homologous recombination mutations werepredictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.", 
    "disease": "Serous Ovarian Cancer", 
    "favorable_prognosis": true, 
    "last_updated": "2017-11-03 14:39:01.081238", 
    "old_disease": "Fallopian Tube Carcinoma", 
    "oncotree_code": "SOC", 
    "predictive_implication": "Level E", 
    "sources": [
      15
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "Platinum", 
    "therapy_sensitivity": null, 
    "therapy_type": "Chemotherapy", 
    "validated": true
  }, 
  {
    "alterations": [
      77
    ], 
    "assertion_id": 183, 
    "created_on": null, 
    "description": "Germline homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas. Mutant cases also had better overall survival than wild type.", 
    "disease": "Serous Ovarian Cancer", 
    "favorable_prognosis": true, 
    "last_updated": "2017-11-03 14:39:01.092015", 
    "old_disease": "Fallopian Tube Carcinoma", 
    "oncotree_code": "SOC", 
    "predictive_implication": "Level E", 
    "sources": [
      15
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "Platinum", 
    "therapy_sensitivity": null, 
    "therapy_type": "Chemotherapy", 
    "validated": true
  }, 
  {
    "alterations": [
      78
    ], 
    "assertion_id": 184, 
    "created_on": null, 
    "description": "Imatinib has shown clinical activity against localized and metastatic DFSP tumors containing t(17;22)(q22;q13).", 
    "disease": "Dermatofibrosarcoma Protuberans", 
    "favorable_prognosis": null, 
    "last_updated": "2017-11-03 14:39:01.101582", 
    "old_disease": "Dermatofibrosarcoma", 
    "oncotree_code": "DFSP", 
    "predictive_implication": "FDA-Approved", 
    "sources": [
      58
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "Imatinib", 
    "therapy_sensitivity": true, 
    "therapy_type": "Targeted Drug", 
    "validated": true
  }, 
  {
    "alterations": [
      79
    ], 
    "assertion_id": 185, 
    "created_on": null, 
    "description": "CPT1A is involved in fatty acid oxidation, a key component of some tumor's metabolic processes. CPT1A knockdown in some melanoma BRAF V600E cell lines resulted in decreased proliferation and tumorigenesis.", 
    "disease": "Melanoma", 
    "favorable_prognosis": true, 
    "last_updated": "2017-11-03 14:39:01.110201", 
    "old_disease": "Melanoma", 
    "oncotree_code": "MEL", 
    "predictive_implication": "Level D", 
    "sources": [
      59
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "", 
    "therapy_sensitivity": null, 
    "therapy_type": "", 
    "validated": true
  }, 
  {
    "alterations": [
      80
    ], 
    "assertion_id": 186, 
    "created_on": null, 
    "description": "CRKL amplification was observed in an EGFR inhibitor resistant tumor after researchers observed that cells from gefitinib-sensitive cell line (HCC827) overexpressing CRKL became resistant to gefitinib relative to controls.", 
    "disease": "Non-Small Cell Lung Cancer", 
    "favorable_prognosis": null, 
    "last_updated": "2017-11-03 14:39:01.121675", 
    "old_disease": "Non-Small Cell Lung Cancer", 
    "oncotree_code": "NSCLC", 
    "predictive_implication": "Level B", 
    "sources": [
      60
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "EGFR inhibitor", 
    "therapy_sensitivity": false, 
    "therapy_type": "Drug Class", 
    "validated": true
  }, 
  {
    "alterations": [
      81
    ], 
    "assertion_id": 187, 
    "created_on": null, 
    "description": "Associated with a poor prognosis in patients without mutations in SF3B1.", 
    "disease": "Myelodysplasia ", 
    "favorable_prognosis": false, 
    "last_updated": "2017-11-03 14:39:01.137675", 
    "old_disease": "Myelodysplastic Syndromes", 
    "oncotree_code": "MDS", 
    "predictive_implication": "Level B", 
    "sources": [
      11
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "", 
    "therapy_sensitivity": null, 
    "therapy_type": "", 
    "validated": true
  }, 
  {
    "alterations": [
      82
    ], 
    "assertion_id": 188, 
    "created_on": null, 
    "description": "Associated with a poor prognosis in patients without mutations in SF3B1.", 
    "disease": "Myelodysplasia ", 
    "favorable_prognosis": false, 
    "last_updated": "2017-11-03 14:39:01.149857", 
    "old_disease": "Myelodysplastic Syndromes", 
    "oncotree_code": "MDS", 
    "predictive_implication": "Level B", 
    "sources": [
      11
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "", 
    "therapy_sensitivity": null, 
    "therapy_type": "", 
    "validated": true
  }, 
  {
    "alterations": [
      83
    ], 
    "assertion_id": 189, 
    "created_on": null, 
    "description": "Associated with a poor prognosis in patients without mutations in SF3B1.", 
    "disease": "Myelodysplasia ", 
    "favorable_prognosis": false, 
    "last_updated": "2017-11-03 14:39:01.157492", 
    "old_disease": "Myelodysplastic Syndromes", 
    "oncotree_code": "MDS", 
    "predictive_implication": "Level B", 
    "sources": [
      11
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "", 
    "therapy_sensitivity": null, 
    "therapy_type": "", 
    "validated": true
  }, 
  {
    "alterations": [
      84
    ], 
    "assertion_id": 190, 
    "created_on": null, 
    "description": "Associated with a poor prognosis in patients without mutations in SF3B1.", 
    "disease": "Myelodysplasia ", 
    "favorable_prognosis": false, 
    "last_updated": "2017-11-03 14:39:01.166848", 
    "old_disease": "Myelodysplastic Syndromes", 
    "oncotree_code": "MDS", 
    "predictive_implication": "Level B", 
    "sources": [
      11
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "", 
    "therapy_sensitivity": null, 
    "therapy_type": "", 
    "validated": true
  }, 
  {
    "alterations": [
      85
    ], 
    "assertion_id": 191, 
    "created_on": null, 
    "description": "Durvalumab (a PD-L1 inhibitor), is being evaluated in combination with Osimertinib (an EGFR-TKI) in patients with sensitizing EGFR mutations or T790M.", 
    "disease": "Non-Small Cell Lung Cancer", 
    "favorable_prognosis": null, 
    "last_updated": "2017-11-03 14:39:01.176585", 
    "old_disease": "Non-Small Cell Lung Cancer", 
    "oncotree_code": "NSCLC", 
    "predictive_implication": "Level A", 
    "sources": [
      61
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "Durvalumab+Osimertinib", 
    "therapy_sensitivity": true, 
    "therapy_type": "Targeted Drug", 
    "validated": true
  }, 
  {
    "alterations": [
      86
    ], 
    "assertion_id": 192, 
    "created_on": null, 
    "description": "Durvalumab, a PD-L1 inhibitor, has shown clinical activity when given alongside gefitinib in patients with sensitizing EGFR mutations.", 
    "disease": "Non-Small Cell Lung Cancer", 
    "favorable_prognosis": null, 
    "last_updated": "2017-11-03 14:39:01.193930", 
    "old_disease": "Non-Small Cell Lung Cancer", 
    "oncotree_code": "NSCLC", 
    "predictive_implication": "Level A", 
    "sources": [
      62
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "Durvalumab+Gefitinib", 
    "therapy_sensitivity": true, 
    "therapy_type": "Targeted Drug", 
    "validated": true
  }, 
  {
    "alterations": [
      85
    ], 
    "assertion_id": 193, 
    "created_on": null, 
    "description": "HM61713 showed clinical activity in patients with an EGFR T790M mutation in a Phase I trial.", 
    "disease": "Non-Small Cell Lung Cancer", 
    "favorable_prognosis": null, 
    "last_updated": "2017-11-03 14:39:01.203267", 
    "old_disease": "Non-Small Cell Lung Cancer", 
    "oncotree_code": "NSCLC", 
    "predictive_implication": "Level A", 
    "sources": [
      63
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "HM61713", 
    "therapy_sensitivity": true, 
    "therapy_type": "Targeted Drug", 
    "validated": true
  }, 
  {
    "alterations": [
      87
    ], 
    "assertion_id": 194, 
    "created_on": null, 
    "description": "Dacomitinib is being evaluated in comparison with gefitinib for the treatment of locally advanced or metastatic non-small cell lung cancer.", 
    "disease": "Non-Small Cell Lung Cancer", 
    "favorable_prognosis": null, 
    "last_updated": "2017-11-03 14:39:01.213064", 
    "old_disease": "Non-Small Cell Lung Cancer", 
    "oncotree_code": "NSCLC", 
    "predictive_implication": "Level A", 
    "sources": [
      64
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "Dacomitinib", 
    "therapy_sensitivity": true, 
    "therapy_type": "Targeted Drug", 
    "validated": true
  }, 
  {
    "alterations": [
      85
    ], 
    "assertion_id": 195, 
    "created_on": null, 
    "description": "Osimertinib is being evaluated in patients who have progressed following treatment with an EGFR TKI.", 
    "disease": "Non-Small Cell Lung Cancer", 
    "favorable_prognosis": null, 
    "last_updated": "2017-11-03 14:39:01.220801", 
    "old_disease": "Non-Small Cell Lung Cancer", 
    "oncotree_code": "NSCLC", 
    "predictive_implication": "Level A", 
    "sources": [
      64
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "Osimertinib", 
    "therapy_sensitivity": true, 
    "therapy_type": "Targeted Drug", 
    "validated": true
  }, 
  {
    "alterations": [
      86
    ], 
    "assertion_id": 196, 
    "created_on": null, 
    "description": "AZD3759, a CNS-penetrant EGFR-TKI, is being evaluated in patients with activating EGFR mutations.", 
    "disease": "Non-Small Cell Lung Cancer", 
    "favorable_prognosis": null, 
    "last_updated": "2017-11-03 14:39:01.228128", 
    "old_disease": "Non-Small Cell Lung Cancer", 
    "oncotree_code": "NSCLC", 
    "predictive_implication": "Level A", 
    "sources": [
      64
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "AZD3759", 
    "therapy_sensitivity": true, 
    "therapy_type": "Targeted Drug", 
    "validated": true
  }, 
  {
    "alterations": [
      86
    ], 
    "assertion_id": 197, 
    "created_on": null, 
    "description": "Cabozantinib (a dual MET-VEGF inhibitor) in combination with erlotinib is being evaluated in patents with EGFR mutations.", 
    "disease": "Non-Small Cell Lung Cancer", 
    "favorable_prognosis": null, 
    "last_updated": "2017-11-03 14:39:01.238172", 
    "old_disease": "Non-Small Cell Lung Cancer", 
    "oncotree_code": "NSCLC", 
    "predictive_implication": "Level A", 
    "sources": [
      64
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "Cabozantinib+Erlotinib", 
    "therapy_sensitivity": true, 
    "therapy_type": "Targeted Drug", 
    "validated": true
  }, 
  {
    "alterations": [
      86
    ], 
    "assertion_id": 198, 
    "created_on": null, 
    "description": "Capmatinib (a cMET inhibitor) is being evaluated in combination with gefitinib in patients with EGFR mutations.", 
    "disease": "Non-Small Cell Lung Cancer", 
    "favorable_prognosis": null, 
    "last_updated": "2017-11-03 14:39:01.245804", 
    "old_disease": "Non-Small Cell Lung Cancer", 
    "oncotree_code": "NSCLC", 
    "predictive_implication": "Level A", 
    "sources": [
      64
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "Capmatinib+Gefitinib", 
    "therapy_sensitivity": true, 
    "therapy_type": "Targeted Drug", 
    "validated": true
  }, 
  {
    "alterations": [
      86
    ], 
    "assertion_id": 199, 
    "created_on": null, 
    "description": "Mutant EGFR may suggest sensitivity to Icotinib as a first or subsequent line of therapy.", 
    "disease": "Non-Small Cell Lung Cancer", 
    "favorable_prognosis": null, 
    "last_updated": "2017-11-03 14:39:01.253776", 
    "old_disease": "Non-Small Cell Lung Cancer", 
    "oncotree_code": "NSCLC", 
    "predictive_implication": "Level A", 
    "sources": [
      64
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "Icotinib", 
    "therapy_sensitivity": true, 
    "therapy_type": "Targeted Drug", 
    "validated": true
  }, 
  {
    "alterations": [
      85
    ], 
    "assertion_id": 200, 
    "created_on": null, 
    "description": "Second-site mutations within the EGFR kinase domain, such as T790M, are associated with acquired resistance to EGFR TKIs.", 
    "disease": "Non-Small Cell Lung Cancer", 
    "favorable_prognosis": null, 
    "last_updated": "2017-11-03 14:39:01.259965", 
    "old_disease": "Non-Small Cell Lung Cancer", 
    "oncotree_code": "NSCLC", 
    "predictive_implication": "FDA-Approved", 
    "sources": [
      2
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "Tyrosine-Kinase Inhibitor", 
    "therapy_sensitivity": false, 
    "therapy_type": "Drug Class", 
    "validated": true
  }, 
  {
    "alterations": [
      86
    ], 
    "assertion_id": 201, 
    "created_on": null, 
    "description": "Mutant EGFR may suggest sensitivity to Afatinib as a first or subsequent line of therapy. See NCCN guidelines for more details in the case of resistance to Afatinib in the presence of mutant EGFR.", 
    "disease": "Non-Small Cell Lung Cancer", 
    "favorable_prognosis": null, 
    "last_updated": "2017-11-03 14:39:01.266476", 
    "old_disease": "Non-Small Cell Lung Cancer", 
    "oncotree_code": "NSCLC", 
    "predictive_implication": "FDA-Approved", 
    "sources": [
      2
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "Afatinib", 
    "therapy_sensitivity": true, 
    "therapy_type": "Targeted Drug", 
    "validated": true
  }, 
  {
    "alterations": [
      86
    ], 
    "assertion_id": 202, 
    "created_on": null, 
    "description": "Mutant EGFR may suggest sensitivity to Erlotinib as a first or subsequent line of therapy. See NCCN guidelines for more details in the case of resistance to Erlotinib in the presence of mutant EGFR.", 
    "disease": "Non-Small Cell Lung Cancer", 
    "favorable_prognosis": null, 
    "last_updated": "2017-11-03 14:39:01.274355", 
    "old_disease": "Non-Small Cell Lung Cancer", 
    "oncotree_code": "NSCLC", 
    "predictive_implication": "FDA-Approved", 
    "sources": [
      2
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "Erlotinib", 
    "therapy_sensitivity": true, 
    "therapy_type": "Targeted Drug", 
    "validated": true
  }, 
  {
    "alterations": [
      86
    ], 
    "assertion_id": 203, 
    "created_on": null, 
    "description": "Mutant EGFR may suggest sensitivity to Gefitinib as a first or subsequent line of therapy. See NCCN guidelines for more details in the case of resistance to Gefitinib in the presence of mutant EGFR.", 
    "disease": "Non-Small Cell Lung Cancer", 
    "favorable_prognosis": null, 
    "last_updated": "2017-11-03 14:39:01.282889", 
    "old_disease": "Non-Small Cell Lung Cancer", 
    "oncotree_code": "NSCLC", 
    "predictive_implication": "FDA-Approved", 
    "sources": [
      2
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "Gefitinib", 
    "therapy_sensitivity": true, 
    "therapy_type": "Targeted Drug", 
    "validated": true
  }, 
  {
    "alterations": [
      86
    ], 
    "assertion_id": 204, 
    "created_on": null, 
    "description": "There is significant association between EGFR mutants and sensitivity to EGFR TKIs.", 
    "disease": "Non-Small Cell Lung Cancer", 
    "favorable_prognosis": null, 
    "last_updated": "2017-11-03 14:39:01.293115", 
    "old_disease": "Non-Small Cell Lung Cancer", 
    "oncotree_code": "NSCLC", 
    "predictive_implication": "Level A", 
    "sources": [
      2
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "Tyrosine-Kinase Inhibitor", 
    "therapy_sensitivity": true, 
    "therapy_type": "Drug Class", 
    "validated": true
  }, 
  {
    "alterations": [
      88
    ], 
    "assertion_id": 205, 
    "created_on": null, 
    "description": "EGFR exon 20 insertions may predict resistance to TKIs.", 
    "disease": "Non-Small Cell Lung Cancer", 
    "favorable_prognosis": null, 
    "last_updated": "2017-11-03 14:39:01.303179", 
    "old_disease": "Non-Small Cell Lung Cancer", 
    "oncotree_code": "NSCLC", 
    "predictive_implication": "Level A", 
    "sources": [
      2
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "Tyrosine-Kinase Inhibitor", 
    "therapy_sensitivity": false, 
    "therapy_type": "Drug Class", 
    "validated": true
  }, 
  {
    "alterations": [
      85
    ], 
    "assertion_id": 206, 
    "created_on": null, 
    "description": "Rociletinib was found to be effective in some patients in a 130-patient trial.", 
    "disease": "Non-Small Cell Lung Cancer", 
    "favorable_prognosis": null, 
    "last_updated": "2017-11-03 14:39:01.313071", 
    "old_disease": "Non-Small Cell Lung Cancer", 
    "oncotree_code": "NSCLC", 
    "predictive_implication": "Level A", 
    "sources": [
      65
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "Rociletinib", 
    "therapy_sensitivity": true, 
    "therapy_type": "Targeted Drug", 
    "validated": true
  }, 
  {
    "alterations": [
      89
    ], 
    "assertion_id": 207, 
    "created_on": null, 
    "description": "Amplification and mutation of EGFR was associated with better clinical outcomes in a trial of 66 non-small cell lung cancer patients who had experienced relapse after surgery.", 
    "disease": "Non-Small Cell Lung Cancer", 
    "favorable_prognosis": null, 
    "last_updated": "2017-11-03 14:39:01.321178", 
    "old_disease": "Non-Small Cell Lung Cancer", 
    "oncotree_code": "NSCLC", 
    "predictive_implication": "Level A", 
    "sources": [
      66
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "Gefitinib", 
    "therapy_sensitivity": true, 
    "therapy_type": "Targeted Drug", 
    "validated": true
  }, 
  {
    "alterations": [
      90
    ], 
    "assertion_id": 208, 
    "created_on": null, 
    "description": "Amplification and mutation of EGFR was associated with better clinical outcomes in a trial of 66 non-small cell lung cancer patients who had experienced relapse after surgery.", 
    "disease": "Non-Small Cell Lung Cancer", 
    "favorable_prognosis": null, 
    "last_updated": "2017-11-03 14:39:01.332889", 
    "old_disease": "Non-Small Cell Lung Cancer", 
    "oncotree_code": "NSCLC", 
    "predictive_implication": "Level A", 
    "sources": [
      66
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "Gefitinib", 
    "therapy_sensitivity": true, 
    "therapy_type": "Targeted Drug", 
    "validated": true
  }, 
  {
    "alterations": [
      87
    ], 
    "assertion_id": 209, 
    "created_on": null, 
    "description": "ASP8273 is being evaluated for clinical efficacy in patients with T790M or L858R mutations.", 
    "disease": "Non-Small Cell Lung Cancer", 
    "favorable_prognosis": null, 
    "last_updated": "2017-11-03 14:39:01.349530", 
    "old_disease": "Non-Small Cell Lung Cancer", 
    "oncotree_code": "NSCLC", 
    "predictive_implication": "Level A", 
    "sources": [
      67
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "ASP8273", 
    "therapy_sensitivity": true, 
    "therapy_type": "Targeted Drug", 
    "validated": true
  }, 
  {
    "alterations": [
      87
    ], 
    "assertion_id": 210, 
    "created_on": null, 
    "description": "EGF816 demonstrated clinical activity in a Phase 1 trial of patients with L858R and T790M mutations.", 
    "disease": "Non-Small Cell Lung Cancer", 
    "favorable_prognosis": null, 
    "last_updated": "2017-11-03 14:39:01.362842", 
    "old_disease": "Non-Small Cell Lung Cancer", 
    "oncotree_code": "NSCLC", 
    "predictive_implication": "Level A", 
    "sources": [
      67
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "EGF816", 
    "therapy_sensitivity": true, 
    "therapy_type": "Targeted Drug", 
    "validated": true
  }, 
  {
    "alterations": [
      87
    ], 
    "assertion_id": 211, 
    "created_on": null, 
    "description": "PF-06747775, a small molecule inhibitor of EGFR T790M, is being evaluated in advanced NSCLC patients with EGFR mutations (del 19 and L858R with or without T790M).", 
    "disease": "Non-Small Cell Lung Cancer", 
    "favorable_prognosis": null, 
    "last_updated": "2017-11-03 14:39:01.372140", 
    "old_disease": "Non-Small Cell Lung Cancer", 
    "oncotree_code": "NSCLC", 
    "predictive_implication": "Level A", 
    "sources": [
      67
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "PF-06747775", 
    "therapy_sensitivity": true, 
    "therapy_type": "Targeted Drug", 
    "validated": true
  }, 
  {
    "alterations": [
      85
    ], 
    "assertion_id": 212, 
    "created_on": null, 
    "description": "ASP8273 is being evaluated for clinical efficacy in patients with T790M or L858R mutations.", 
    "disease": "Non-Small Cell Lung Cancer", 
    "favorable_prognosis": null, 
    "last_updated": "2017-11-03 14:39:01.379875", 
    "old_disease": "Non-Small Cell Lung Cancer", 
    "oncotree_code": "NSCLC", 
    "predictive_implication": "Level A", 
    "sources": [
      67
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "ASP8273", 
    "therapy_sensitivity": true, 
    "therapy_type": "Targeted Drug", 
    "validated": true
  }, 
  {
    "alterations": [
      85
    ], 
    "assertion_id": 213, 
    "created_on": null, 
    "description": "EGF816 demonstrated clinical activity in a Phase 1 trial of patients with L858R and T790M mutations.", 
    "disease": "Non-Small Cell Lung Cancer", 
    "favorable_prognosis": null, 
    "last_updated": "2017-11-03 14:39:01.387566", 
    "old_disease": "Non-Small Cell Lung Cancer", 
    "oncotree_code": "NSCLC", 
    "predictive_implication": "Level A", 
    "sources": [
      67
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "EGF816", 
    "therapy_sensitivity": true, 
    "therapy_type": "Targeted Drug", 
    "validated": true
  }, 
  {
    "alterations": [
      85
    ], 
    "assertion_id": 214, 
    "created_on": null, 
    "description": "PF-06747775, a small molecule inhibitor of EGFR T790M, is being evaluated in advanced NSCLC patients with EGFR mutations (del 19 and L858R with or without T790M).", 
    "disease": "Non-Small Cell Lung Cancer", 
    "favorable_prognosis": null, 
    "last_updated": "2017-11-03 14:39:01.399846", 
    "old_disease": "Non-Small Cell Lung Cancer", 
    "oncotree_code": "NSCLC", 
    "predictive_implication": "Level A", 
    "sources": [
      67
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "PF-06747775", 
    "therapy_sensitivity": true, 
    "therapy_type": "Targeted Drug", 
    "validated": true
  }, 
  {
    "alterations": [
      86
    ], 
    "assertion_id": 215, 
    "created_on": null, 
    "description": "Osimertinib is FDA-Approved for metastatic non-small cell lung cancer patients with EGFR T790M mutations.", 
    "disease": "Non-Small Cell Lung Cancer", 
    "favorable_prognosis": null, 
    "last_updated": "2017-11-03 14:39:01.409235", 
    "old_disease": "Non-Small Cell Lung Cancer", 
    "oncotree_code": "NSCLC", 
    "predictive_implication": "FDA-Approved", 
    "sources": [
      67
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "Osimertinib", 
    "therapy_sensitivity": true, 
    "therapy_type": "Targeted Drug", 
    "validated": true
  }, 
  {
    "alterations": [
      91
    ], 
    "assertion_id": 216, 
    "created_on": null, 
    "description": "ALK rearrangement, notably with EML4, may suggest sensitivity to Crizotinib as a first or subsequent line of therapy. See NCCN guidelines for more details in the case of resistance to Crizotinib in the presence of ALK rearrangement.", 
    "disease": "Non-Small Cell Lung Cancer", 
    "favorable_prognosis": null, 
    "last_updated": "2017-11-03 14:39:01.418736", 
    "old_disease": "Non-Small Cell Lung Cancer", 
    "oncotree_code": "NSCLC", 
    "predictive_implication": "FDA-Approved", 
    "sources": [
      2
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "Crizotinib", 
    "therapy_sensitivity": true, 
    "therapy_type": "Targeted Drug", 
    "validated": true
  }, 
  {
    "alterations": [
      92
    ], 
    "assertion_id": 217, 
    "created_on": null, 
    "description": "Patients with defects in DNA mismatch repair genes often have a favorable prognosis and a decreased likelihood of metastasis. These patients do not benefit from, and may be resistant to, 5-fluorouracil therapy.", 
    "disease": "Colorectal Adenocarcinoma", 
    "favorable_prognosis": true, 
    "last_updated": "2017-11-03 14:39:01.430072", 
    "old_disease": "Colorectal Cancer", 
    "oncotree_code": "COADREAD", 
    "predictive_implication": "Level B", 
    "sources": [
      21
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "5-Fluorouracil", 
    "therapy_sensitivity": null, 
    "therapy_type": "Targeted Drug", 
    "validated": true
  }, 
  {
    "alterations": [
      93
    ], 
    "assertion_id": 218, 
    "created_on": null, 
    "description": "The combination of lapatinib with trastuzumab provided a statistically significant improvement in PFS compared with single-agent lapatinib when tested for erbb2 positive breast cancer patients, both primary and metastatic.", 
    "disease": "Invasive Breast Carcinoma", 
    "favorable_prognosis": null, 
    "last_updated": "2017-11-03 14:39:01.439925", 
    "old_disease": "Breast Cancer", 
    "oncotree_code": "BRCA", 
    "predictive_implication": "Level A", 
    "sources": [
      68
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "Trastuzumab+Lapatinib", 
    "therapy_sensitivity": true, 
    "therapy_type": "Targeted Drug", 
    "validated": true
  }, 
  {
    "alterations": [
      93
    ], 
    "assertion_id": 219, 
    "created_on": null, 
    "description": "Overexpression and gene amplification of ErbB2 (HER2/neu) is an adverse prognostic indicator associated with aggressive histopathologic parameters and correlated with decreased disease-free survival and overall survival (OS) in breast cancer (BC).", 
    "disease": "Invasive Breast Carcinoma", 
    "favorable_prognosis": false, 
    "last_updated": "2017-11-03 14:39:01.456649", 
    "old_disease": "Breast Cancer", 
    "oncotree_code": "BRCA", 
    "predictive_implication": "Level B", 
    "sources": [
      69
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "", 
    "therapy_sensitivity": null, 
    "therapy_type": "", 
    "validated": true
  }, 
  {
    "alterations": [
      93
    ], 
    "assertion_id": 220, 
    "created_on": null, 
    "description": "Patients with HER2 overexpression or amplification showed significant improvement in median overall survival with the addition of trastuzumab to chemotherapy compared to chemotherapy alone. This benefit is limited to patients with a tumor score of IHC 3 + or IHC 2 + and FISH positive.", 
    "disease": "Gastric Remnant Adenocarcinoma", 
    "favorable_prognosis": null, 
    "last_updated": "2017-11-03 14:39:01.470518", 
    "old_disease": "Gastric Cancer", 
    "oncotree_code": "GRC", 
    "predictive_implication": "Level A", 
    "sources": [
      70
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "Trastuzumab+Chemotherapy", 
    "therapy_sensitivity": true, 
    "therapy_type": "Targeted Drug", 
    "validated": true
  }, 
  {
    "alterations": [
      94
    ], 
    "assertion_id": 221, 
    "created_on": null, 
    "description": "Somatic mutations that occured in ERCC2 were enriched in responders relative to nonresponsers in a cohort of patients with muscle-invasive urothelial carcinoma who received neoadjuvant cisplatin-based chemotherapy followed by cystectomy.", 
    "disease": "Bladder Urothelial Carcinoma", 
    "favorable_prognosis": null, 
    "last_updated": "2017-11-03 14:39:01.481759", 
    "old_disease": "Bladder Cancer", 
    "oncotree_code": "BLCA", 
    "predictive_implication": "Level B", 
    "sources": [
      71, 
      72
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "Cisplatin", 
    "therapy_sensitivity": true, 
    "therapy_type": "Targeted Drug|Chemotherapy", 
    "validated": true
  }, 
  {
    "alterations": [
      95
    ], 
    "assertion_id": 222, 
    "created_on": null, 
    "description": "Rapid disease regression was notd in a patient with a ERFFI1 p.E384X nonsense variant when treated with erlotinib.", 
    "disease": "Cholangiocarcinoma", 
    "favorable_prognosis": null, 
    "last_updated": "2017-11-03 14:39:01.493853", 
    "old_disease": "Cholangiocarcinoma", 
    "oncotree_code": "CHOL", 
    "predictive_implication": "Level B", 
    "sources": [
      73
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "Erlotinib", 
    "therapy_sensitivity": true, 
    "therapy_type": "Targeted Drug", 
    "validated": true
  }, 
  {
    "alterations": [
      96
    ], 
    "assertion_id": 223, 
    "created_on": null, 
    "description": "Ampifications of ESR1 was significantly associated with poor disease-free survival and overall survival in a study of 99 patients with ER-positive breast cancer tumors.", 
    "disease": "Invasive Breast Carcinoma", 
    "favorable_prognosis": false, 
    "last_updated": "2017-11-03 14:39:01.507815", 
    "old_disease": "Breast Cancer", 
    "oncotree_code": "BRCA", 
    "predictive_implication": "Level B", 
    "sources": [
      74
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "", 
    "therapy_sensitivity": null, 
    "therapy_type": "", 
    "validated": true
  }, 
  {
    "alterations": [
      97
    ], 
    "assertion_id": 224, 
    "created_on": null, 
    "description": "Nonsynonymous mutations in ESR1 were found in metastatic breast cancer patients that developed resistance to endrocrin therapy. These patients were treated with anti-estrogens (taxmoxifen and/or fulvestrant) and aromataste inhibitors (letrozole, anastrozole, and/or exemestane).", 
    "disease": "Invasive Breast Carcinoma", 
    "favorable_prognosis": null, 
    "last_updated": "2017-11-03 14:39:01.521385", 
    "old_disease": "Breast Cancer", 
    "oncotree_code": "BRCA", 
    "predictive_implication": "Level B", 
    "sources": [
      75
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "anti-estogen+aromatase inhibitor", 
    "therapy_sensitivity": false, 
    "therapy_type": "Drug Class", 
    "validated": true
  }, 
  {
    "alterations": [
      98
    ], 
    "assertion_id": 225, 
    "created_on": null, 
    "description": "May be familial in rare cases.", 
    "disease": "Myelodysplasia ", 
    "favorable_prognosis": false, 
    "last_updated": "2017-11-03 14:39:01.532592", 
    "old_disease": "Myelodysplastic Syndromes", 
    "oncotree_code": "MDS", 
    "predictive_implication": "Level B", 
    "sources": [
      11
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "", 
    "therapy_sensitivity": null, 
    "therapy_type": "", 
    "validated": true
  }, 
  {
    "alterations": [
      99
    ], 
    "assertion_id": 226, 
    "created_on": null, 
    "description": "May be familial in rare cases.", 
    "disease": "Myelodysplasia ", 
    "favorable_prognosis": false, 
    "last_updated": "2017-11-03 14:39:01.543710", 
    "old_disease": "Myelodysplastic Syndromes", 
    "oncotree_code": "MDS", 
    "predictive_implication": "Level B", 
    "sources": [
      11
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "", 
    "therapy_sensitivity": null, 
    "therapy_type": "", 
    "validated": true
  }, 
  {
    "alterations": [
      100
    ], 
    "assertion_id": 227, 
    "created_on": null, 
    "description": "EWS-FLI1 translocations may be associated with improved prognosis in Ewing's Sarcoma; however, current treatments result in patient outcomes indistinguishable by EWS-FLI1 status.", 
    "disease": "Ewing Sarcoma", 
    "favorable_prognosis": true, 
    "last_updated": "2017-11-03 14:39:01.559475", 
    "old_disease": "Ewing's Sarcoma", 
    "oncotree_code": "ES", 
    "predictive_implication": "Level B", 
    "sources": [
      76
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "", 
    "therapy_sensitivity": null, 
    "therapy_type": "", 
    "validated": true
  }, 
  {
    "alterations": [
      101
    ], 
    "assertion_id": 228, 
    "created_on": null, 
    "description": "Most frequent in Chronic Myelomonocytic Leukemia.", 
    "disease": "Myelodysplasia ", 
    "favorable_prognosis": false, 
    "last_updated": "2017-11-03 14:39:01.570241", 
    "old_disease": "Myelodysplastic Syndromes", 
    "oncotree_code": "MDS", 
    "predictive_implication": "Level B", 
    "sources": [
      11
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "", 
    "therapy_sensitivity": null, 
    "therapy_type": "", 
    "validated": true
  }, 
  {
    "alterations": [
      102
    ], 
    "assertion_id": 229, 
    "created_on": null, 
    "description": "Most frequent in Chronic Myelomonocytic Leukemia.", 
    "disease": "Myelodysplasia ", 
    "favorable_prognosis": false, 
    "last_updated": "2017-11-03 14:39:01.579922", 
    "old_disease": "Myelodysplastic Syndromes", 
    "oncotree_code": "MDS", 
    "predictive_implication": "Level B", 
    "sources": [
      11
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "", 
    "therapy_sensitivity": null, 
    "therapy_type": "", 
    "validated": true
  }, 
  {
    "alterations": [
      103
    ], 
    "assertion_id": 230, 
    "created_on": null, 
    "description": "Breast cancer tumor cell lines harboring deletions or mutations in FBXW7 are particularly sensitive to rapamycin treatment, FBXW7 may be a biomarker for human cancers susceptible to treatment with inhibitors of the mTOR pathway.", 
    "disease": "Breast Invasive Ductal Carcinoma", 
    "favorable_prognosis": null, 
    "last_updated": "2017-11-03 14:39:01.589068", 
    "old_disease": "Breast Cancer", 
    "oncotree_code": "IDC", 
    "predictive_implication": "Level D", 
    "sources": [
      77
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "", 
    "therapy_sensitivity": true, 
    "therapy_type": "", 
    "validated": true
  }, 
  {
    "alterations": [
      104
    ], 
    "assertion_id": 231, 
    "created_on": null, 
    "description": "Breast cancer tumor cell lines harboring deletions or mutations in FBXW7 are particularly sensitive to rapamycin treatment, FBXW7 may be a biomarker for human cancers susceptible to treatment with inhibitors of the mTOR pathway.", 
    "disease": "Breast Invasive Ductal Carcinoma", 
    "favorable_prognosis": null, 
    "last_updated": "2017-11-03 14:39:01.601019", 
    "old_disease": "Breast Cancer", 
    "oncotree_code": "IDC", 
    "predictive_implication": "Level D", 
    "sources": [
      77
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "", 
    "therapy_sensitivity": true, 
    "therapy_type": "", 
    "validated": true
  }, 
  {
    "alterations": [
      105
    ], 
    "assertion_id": 232, 
    "created_on": null, 
    "description": "A study of 32 Cancer Cell Line Encyclopedia cell lines demonstrating FGFR1 and FGFR2 amplification demonstrated sensitivity to Infigratinib.", 
    "disease": "Colorectal Adenocarcinoma", 
    "favorable_prognosis": null, 
    "last_updated": "2017-11-03 14:39:01.617507", 
    "old_disease": "Colorectal Cancer", 
    "oncotree_code": "COADREAD", 
    "predictive_implication": "Level D", 
    "sources": [
      78
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "Infigratinib", 
    "therapy_sensitivity": true, 
    "therapy_type": "Targeted Drug", 
    "validated": true
  }, 
  {
    "alterations": [
      105
    ], 
    "assertion_id": 233, 
    "created_on": null, 
    "description": "A study of 32 Cancer Cell Line Encyclopedia cell lines demonstrating FGFR1 and FGFR2 amplification demonstrated sensitivity to Infigratinib.", 
    "disease": "Non-Small Cell Lung Cancer", 
    "favorable_prognosis": null, 
    "last_updated": "2017-11-03 14:39:01.629638", 
    "old_disease": "Non-Small Cell Lung Cancer", 
    "oncotree_code": "NSCLC", 
    "predictive_implication": "Level D", 
    "sources": [
      78
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "Infigratinib", 
    "therapy_sensitivity": true, 
    "therapy_type": "Targeted Drug", 
    "validated": true
  }, 
  {
    "alterations": [
      105
    ], 
    "assertion_id": 234, 
    "created_on": null, 
    "description": "A study of 32 Cancer Cell Line Encyclopedia cell lines demonstrating FGFR1 and FGFR2 amplification demonstrated sensitivity to Infigratinib.", 
    "disease": "Osteosarcoma", 
    "favorable_prognosis": null, 
    "last_updated": "2017-11-03 14:39:01.638169", 
    "old_disease": "Osteosarcoma", 
    "oncotree_code": "OS", 
    "predictive_implication": "Level D", 
    "sources": [
      78
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "Infigratinib", 
    "therapy_sensitivity": true, 
    "therapy_type": "Targeted Drug", 
    "validated": true
  }, 
  {
    "alterations": [
      105
    ], 
    "assertion_id": 235, 
    "created_on": null, 
    "description": "A study of 32 Cancer Cell Line Encyclopedia cell lines demonstrating FGFR1 and FGFR2 amplification demonstrated sensitivity to Infigratinib.", 
    "disease": "Invasive Breast Carcinoma", 
    "favorable_prognosis": null, 
    "last_updated": "2017-11-03 14:39:01.645927", 
    "old_disease": "Breast Cancer", 
    "oncotree_code": "BRCA", 
    "predictive_implication": "Level D", 
    "sources": [
      78
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "Infigratinib", 
    "therapy_sensitivity": true, 
    "therapy_type": "Targeted Drug", 
    "validated": true
  }, 
  {
    "alterations": [
      106
    ], 
    "assertion_id": 236, 
    "created_on": null, 
    "description": "A study of 32 Cancer Cell Line Encyclopedia cell lines demonstrating FGFR1 and FGFR2 amplification demonstrated sensitivity to Infigratinib.", 
    "disease": "Colorectal Adenocarcinoma", 
    "favorable_prognosis": null, 
    "last_updated": "2017-11-03 14:39:01.657757", 
    "old_disease": "Colorectal Cancer", 
    "oncotree_code": "COADREAD", 
    "predictive_implication": "Level D", 
    "sources": [
      78
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "Infigratinib", 
    "therapy_sensitivity": true, 
    "therapy_type": "Targeted Drug", 
    "validated": true
  }, 
  {
    "alterations": [
      106
    ], 
    "assertion_id": 237, 
    "created_on": null, 
    "description": "A study of 32 Cancer Cell Line Encyclopedia cell lines demonstrating FGFR1 and FGFR2 amplification demonstrated sensitivity to Infigratinib.", 
    "disease": "Non-Small Cell Lung Cancer", 
    "favorable_prognosis": null, 
    "last_updated": "2017-11-03 14:39:01.670187", 
    "old_disease": "Non-Small Cell Lung Cancer", 
    "oncotree_code": "NSCLC", 
    "predictive_implication": "Level D", 
    "sources": [
      78
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "Infigratinib", 
    "therapy_sensitivity": true, 
    "therapy_type": "Targeted Drug", 
    "validated": true
  }, 
  {
    "alterations": [
      106
    ], 
    "assertion_id": 238, 
    "created_on": null, 
    "description": "A study of 32 Cancer Cell Line Encyclopedia cell lines demonstrating FGFR1 and FGFR2 amplification demonstrated sensitivity to Infigratinib.", 
    "disease": "Osteosarcoma", 
    "favorable_prognosis": null, 
    "last_updated": "2017-11-03 14:39:01.679849", 
    "old_disease": "Osteosarcoma", 
    "oncotree_code": "OS", 
    "predictive_implication": "Level D", 
    "sources": [
      78
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "Infigratinib", 
    "therapy_sensitivity": true, 
    "therapy_type": "Targeted Drug", 
    "validated": true
  }, 
  {
    "alterations": [
      106
    ], 
    "assertion_id": 239, 
    "created_on": null, 
    "description": "A study of 32 Cancer Cell Line Encyclopedia cell lines demonstrating FGFR1 and FGFR2 amplification demonstrated sensitivity to Infigratinib.", 
    "disease": "Invasive Breast Carcinoma", 
    "favorable_prognosis": null, 
    "last_updated": "2017-11-03 14:39:01.689291", 
    "old_disease": "Breast Cancer", 
    "oncotree_code": "BRCA", 
    "predictive_implication": "Level D", 
    "sources": [
      78
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "Infigratinib", 
    "therapy_sensitivity": true, 
    "therapy_type": "Targeted Drug", 
    "validated": true
  }, 
  {
    "alterations": [
      107
    ], 
    "assertion_id": 240, 
    "created_on": null, 
    "description": "After progressing on previous treatments, a patient with a FGFR2-TACC3 fusion obtained stable disease after being treated with ponatinib.", 
    "disease": "Cholangiocarcinoma", 
    "favorable_prognosis": null, 
    "last_updated": "2017-11-03 14:39:01.698559", 
    "old_disease": "Cholangiocarcinoma", 
    "oncotree_code": "CHOL", 
    "predictive_implication": "Level B", 
    "sources": [
      73
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "Ponatinib", 
    "therapy_sensitivity": true, 
    "therapy_type": "Targeted Drug", 
    "validated": true
  }, 
  {
    "alterations": [
      108
    ], 
    "assertion_id": 241, 
    "created_on": null, 
    "description": "The combination of bortezomib with tandem transplant therapy was associated with increased event-free survival and complete remission duration in multiple myeloma patients.", 
    "disease": "Multiple Myeloma", 
    "favorable_prognosis": null, 
    "last_updated": "2017-11-03 14:39:01.710620", 
    "old_disease": "Multiple Myeloma", 
    "oncotree_code": "MM", 
    "predictive_implication": "Level B", 
    "sources": [
      79
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "Bortezomib", 
    "therapy_sensitivity": true, 
    "therapy_type": "Targeted Drug", 
    "validated": true
  }, 
  {
    "alterations": [
      109
    ], 
    "assertion_id": 242, 
    "created_on": null, 
    "description": "Loss of function mutations in TSC1, TSC2, or FLCN may predict sensitivity to mTOR inhibition", 
    "disease": "Anaplastic Thyroid Cancer", 
    "favorable_prognosis": null, 
    "last_updated": "2017-11-03 14:39:01.728162", 
    "old_disease": "Anaplastic Thyroid Cancer", 
    "oncotree_code": "THAP", 
    "predictive_implication": "Level B", 
    "sources": [
      80, 
      81
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "mTOR inhibitor", 
    "therapy_sensitivity": true, 
    "therapy_type": "Drug Class", 
    "validated": true
  }, 
  {
    "alterations": [
      110
    ], 
    "assertion_id": 243, 
    "created_on": null, 
    "description": "Loss of function mutations in TSC1, TSC2, or FLCN may predict sensitivity to mTOR inhibition", 
    "disease": "Anaplastic Thyroid Cancer", 
    "favorable_prognosis": null, 
    "last_updated": "2017-11-03 14:39:01.740997", 
    "old_disease": "Anaplastic Thyroid Cancer", 
    "oncotree_code": "THAP", 
    "predictive_implication": "Level B", 
    "sources": [
      80, 
      81
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "mTOR inhibitor", 
    "therapy_sensitivity": true, 
    "therapy_type": "Drug Class", 
    "validated": true
  }, 
  {
    "alterations": [
      109
    ], 
    "assertion_id": 244, 
    "created_on": null, 
    "description": "Loss of function mutations in TSC1, TSC2, or FLCN may predict sensitivity to mTOR inhibition", 
    "disease": "Bladder Urothelial Carcinoma", 
    "favorable_prognosis": null, 
    "last_updated": "2017-11-03 14:39:01.750335", 
    "old_disease": "Bladder Cancer", 
    "oncotree_code": "BLCA", 
    "predictive_implication": "Level B", 
    "sources": [
      80, 
      81
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "mTOR inhibitor", 
    "therapy_sensitivity": true, 
    "therapy_type": "Drug Class", 
    "validated": true
  }, 
  {
    "alterations": [
      110
    ], 
    "assertion_id": 245, 
    "created_on": null, 
    "description": "Loss of function mutations in TSC1, TSC2, or FLCN may predict sensitivity to mTOR inhibition", 
    "disease": "Bladder Urothelial Carcinoma", 
    "favorable_prognosis": null, 
    "last_updated": "2017-11-03 14:39:01.758541", 
    "old_disease": "Bladder Cancer", 
    "oncotree_code": "BLCA", 
    "predictive_implication": "Level B", 
    "sources": [
      80, 
      81
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "mTOR inhibitor", 
    "therapy_sensitivity": true, 
    "therapy_type": "Drug Class", 
    "validated": true
  }, 
  {
    "alterations": [
      111
    ], 
    "assertion_id": 246, 
    "created_on": null, 
    "description": "A second FTL3 internal tanden duplication mutation (FTL3 p.F691L) was detected in a patient with acute myeloid leukemia at the time of relapse followed Quizartinib (AC220) treatment. Normal karyotype of NPM1 and FLT3-ITD was observed before treatment.", 
    "disease": "Acute Myeloid Leukemia", 
    "favorable_prognosis": null, 
    "last_updated": "2017-11-03 14:39:01.771004", 
    "old_disease": "Acute Myeloid Leukemia", 
    "oncotree_code": "AML", 
    "predictive_implication": "Level B", 
    "sources": [
      82
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "Quizartinib", 
    "therapy_sensitivity": false, 
    "therapy_type": "Targeted Drug", 
    "validated": true
  }, 
  {
    "alterations": [
      112
    ], 
    "assertion_id": 247, 
    "created_on": null, 
    "description": "Sunitinib successfully inhibits cellular proliferation of cells Ba/F3 FLT3 K663Q cells in a dose-dependent manner.", 
    "disease": "Acute Myeloid Leukemia", 
    "favorable_prognosis": null, 
    "last_updated": "2017-11-03 14:39:01.787224", 
    "old_disease": "Acute Myeloid Leukemia", 
    "oncotree_code": "AML", 
    "predictive_implication": "Level D", 
    "sources": [
      83
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "Sunitinib", 
    "therapy_sensitivity": true, 
    "therapy_type": "Targeted Drug", 
    "validated": true
  }, 
  {
    "alterations": [
      113
    ], 
    "assertion_id": 248, 
    "created_on": null, 
    "description": "GATA3 mutation did not influence baseline Ki67 levels but was enriched in samples exhibiting greater percentage of Ki67 decline. While this requires further validation, it suggests that GATA3 mutation may be a positive marker for aromatase inhibitor response.", 
    "disease": "Invasive Breast Carcinoma", 
    "favorable_prognosis": null, 
    "last_updated": "2017-11-03 14:39:01.801846", 
    "old_disease": "Breast Cancer", 
    "oncotree_code": "BRCA", 
    "predictive_implication": "Level B", 
    "sources": [
      84
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "Aromatase Inhibitor", 
    "therapy_sensitivity": true, 
    "therapy_type": "Drug Class", 
    "validated": true
  }, 
  {
    "alterations": [
      114
    ], 
    "assertion_id": 249, 
    "created_on": null, 
    "description": "GATA3 mutation did not influence baseline Ki67 levels but was enriched in samples exhibiting greater percentage of Ki67 decline. While this requires further validation, it suggests that GATA3 mutation may be a positive marker for aromatase inhibitor response.", 
    "disease": "Invasive Breast Carcinoma", 
    "favorable_prognosis": null, 
    "last_updated": "2017-11-03 14:39:01.811788", 
    "old_disease": "Breast Cancer", 
    "oncotree_code": "BRCA", 
    "predictive_implication": "Level B", 
    "sources": [
      84
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "Aromatase Inhibitor", 
    "therapy_sensitivity": true, 
    "therapy_type": "Drug Class", 
    "validated": true
  }, 
  {
    "alterations": [
      115
    ], 
    "assertion_id": 250, 
    "created_on": null, 
    "description": "Mutation of IDH1 is associated with a survival benefit in patients treated with alkylating chemotherapy (but not untreated patients).", 
    "disease": "Glioma", 
    "favorable_prognosis": null, 
    "last_updated": "2017-11-03 14:39:01.822078", 
    "old_disease": "Glioma", 
    "oncotree_code": "GNOS", 
    "predictive_implication": "Level A", 
    "sources": [
      85
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "Alkylating Chemotherapy", 
    "therapy_sensitivity": true, 
    "therapy_type": "Drug Class", 
    "validated": true
  }, 
  {
    "alterations": [
      115
    ], 
    "assertion_id": 251, 
    "created_on": null, 
    "description": "Mutation of IDH1 is associated with a survival benefit in patients treated with alkylating chemotherapy (but not untreated patients).", 
    "disease": "Glioma", 
    "favorable_prognosis": true, 
    "last_updated": "2017-11-03 14:39:01.833617", 
    "old_disease": "Glioma", 
    "oncotree_code": "GNOS", 
    "predictive_implication": "Level A", 
    "sources": [
      85
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "", 
    "therapy_sensitivity": null, 
    "therapy_type": "", 
    "validated": true
  }, 
  {
    "alterations": [
      116
    ], 
    "assertion_id": 252, 
    "created_on": null, 
    "description": "More frequent in Acute Myeloid Leukemia.", 
    "disease": "Myelodysplasia ", 
    "favorable_prognosis": false, 
    "last_updated": "2017-11-03 14:39:01.846886", 
    "old_disease": "Myelodysplastic Syndromes", 
    "oncotree_code": "MDS", 
    "predictive_implication": "Level B", 
    "sources": [
      11
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "", 
    "therapy_sensitivity": null, 
    "therapy_type": "", 
    "validated": true
  }, 
  {
    "alterations": [
      117
    ], 
    "assertion_id": 253, 
    "created_on": null, 
    "description": "More frequent in Acute Myeloid Leukemia.", 
    "disease": "Myelodysplasia ", 
    "favorable_prognosis": false, 
    "last_updated": "2017-11-03 14:39:01.857441", 
    "old_disease": "Myelodysplastic Syndromes", 
    "oncotree_code": "MDS", 
    "predictive_implication": "Level B", 
    "sources": [
      11
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "", 
    "therapy_sensitivity": null, 
    "therapy_type": "", 
    "validated": true
  }, 
  {
    "alterations": [
      118
    ], 
    "assertion_id": 254, 
    "created_on": null, 
    "description": "Mutation of IDH2 is associated with a survival benefit in patients treated with alkylating chemotherapy (but not untreated patients).", 
    "disease": "Glioma", 
    "favorable_prognosis": null, 
    "last_updated": "2017-11-03 14:39:01.866188", 
    "old_disease": "Glioma", 
    "oncotree_code": "GNOS", 
    "predictive_implication": "Level A", 
    "sources": [
      85
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "Alkylating Chemotherapy", 
    "therapy_sensitivity": true, 
    "therapy_type": "Drug Class", 
    "validated": true
  }, 
  {
    "alterations": [
      118
    ], 
    "assertion_id": 255, 
    "created_on": null, 
    "description": "Mutation of IDH2 is associated with a survival benefit in patients treated with alkylating chemotherapy (but not untreated patients).", 
    "disease": "Glioma", 
    "favorable_prognosis": true, 
    "last_updated": "2017-11-03 14:39:01.875114", 
    "old_disease": "Glioma", 
    "oncotree_code": "GNOS", 
    "predictive_implication": "Level A", 
    "sources": [
      85
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "Alkylating Chemotherapy", 
    "therapy_sensitivity": null, 
    "therapy_type": "Drug Class", 
    "validated": true
  }, 
  {
    "alterations": [
      119
    ], 
    "assertion_id": 256, 
    "created_on": null, 
    "description": "A translocation between 11 and 14 [t(11;14)] has been reported to be associated with improved survival.", 
    "disease": "Multiple Myeloma", 
    "favorable_prognosis": true, 
    "last_updated": "2017-11-03 14:39:01.889928", 
    "old_disease": "Multiple Myeloma", 
    "oncotree_code": "MM", 
    "predictive_implication": "Level B", 
    "sources": [
      86
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "", 
    "therapy_sensitivity": null, 
    "therapy_type": "", 
    "validated": true
  }, 
  {
    "alterations": [
      120
    ], 
    "assertion_id": 257, 
    "created_on": null, 
    "description": "A translocation between 4 and 14 [t(4;14)] has been reported in several studies to be associated with poor prognosis.", 
    "disease": "Multiple Myeloma", 
    "favorable_prognosis": false, 
    "last_updated": "2017-11-03 14:39:01.902483", 
    "old_disease": "Multiple Myeloma", 
    "oncotree_code": "MM", 
    "predictive_implication": "Level B", 
    "sources": [
      86
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "", 
    "therapy_sensitivity": null, 
    "therapy_type": "", 
    "validated": true
  }, 
  {
    "alterations": [
      121
    ], 
    "assertion_id": 258, 
    "created_on": null, 
    "description": "Mutation may indicate increased susceptibility to early-onset colorectal cancer.", 
    "disease": "Colorectal Adenocarcinoma", 
    "favorable_prognosis": false, 
    "last_updated": "2017-11-03 14:39:01.914089", 
    "old_disease": "Colorectal Cancer", 
    "oncotree_code": "COADREAD", 
    "predictive_implication": "Level B", 
    "sources": [
      87
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "", 
    "therapy_sensitivity": null, 
    "therapy_type": "", 
    "validated": true
  }, 
  {
    "alterations": [
      122
    ], 
    "assertion_id": 259, 
    "created_on": null, 
    "description": "Mutation may indicate increased susceptibility to early-onset colorectal cancer.", 
    "disease": "Colorectal Adenocarcinoma", 
    "favorable_prognosis": false, 
    "last_updated": "2017-11-03 14:39:01.924379", 
    "old_disease": "Colorectal Cancer", 
    "oncotree_code": "COADREAD", 
    "predictive_implication": "Level B", 
    "sources": [
      87
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "", 
    "therapy_sensitivity": null, 
    "therapy_type": "", 
    "validated": true
  }, 
  {
    "alterations": [
      123
    ], 
    "assertion_id": 260, 
    "created_on": null, 
    "description": "MOHITO JAK1 V658F transplated mice were highly sensitive to growth inhibition by PU-H71.", 
    "disease": "Acute Lymphoid Leukemia", 
    "favorable_prognosis": null, 
    "last_updated": "2017-11-03 14:39:01.936817", 
    "old_disease": "Acute Lymphoblastic Leukemia", 
    "oncotree_code": "ALL", 
    "predictive_implication": "Level D", 
    "sources": [
      88
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "PU-H71", 
    "therapy_sensitivity": true, 
    "therapy_type": "Targeted Drug", 
    "validated": true
  }, 
  {
    "alterations": [
      124
    ], 
    "assertion_id": 261, 
    "created_on": null, 
    "description": "MOHITO JAK1 A634D transplated mice were highly sensitive to growth inhibition by PU-H71.", 
    "disease": "Acute Lymphoid Leukemia", 
    "favorable_prognosis": null, 
    "last_updated": "2017-11-03 14:39:01.951252", 
    "old_disease": "Acute Lymphoblastic Leukemia", 
    "oncotree_code": "ALL", 
    "predictive_implication": "Level D", 
    "sources": [
      88
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "PU-H71", 
    "therapy_sensitivity": true, 
    "therapy_type": "Targeted Drug", 
    "validated": true
  }, 
  {
    "alterations": [
      125
    ], 
    "assertion_id": 262, 
    "created_on": null, 
    "description": "A study of target-specific sequencing data taken from 112 ALL patients showed an association between JAK1 or JAK2 mutation and decreased survival.", 
    "disease": "B-Cell Acute Lymphoid Leukemia", 
    "favorable_prognosis": false, 
    "last_updated": "2017-11-03 14:39:01.961948", 
    "old_disease": "B-Cell Acute Lymphoblastic Leukemia", 
    "oncotree_code": "BALL", 
    "predictive_implication": "Level B", 
    "sources": [
      89
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "", 
    "therapy_sensitivity": null, 
    "therapy_type": "", 
    "validated": true
  }, 
  {
    "alterations": [
      126
    ], 
    "assertion_id": 263, 
    "created_on": null, 
    "description": "A study of target-specific sequencing data taken from 112 ALL patients showed an association between JAK1 or JAK2 mutation and decreased survival.", 
    "disease": "B-Cell Acute Lymphoid Leukemia", 
    "favorable_prognosis": false, 
    "last_updated": "2017-11-03 14:39:01.970704", 
    "old_disease": "B-Cell Acute Lymphoblastic Leukemia", 
    "oncotree_code": "BALL", 
    "predictive_implication": "Level B", 
    "sources": [
      89
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "", 
    "therapy_sensitivity": null, 
    "therapy_type": "", 
    "validated": true
  }, 
  {
    "alterations": [
      127
    ], 
    "assertion_id": 264, 
    "created_on": null, 
    "description": "In a retrospective study of 244 patients, significantly more patients with a JAK2 V617F variant than without had complications (secondary fibrosis, hemorrhage, and thrombosis) and had received cytoreductive treatment.", 
    "disease": "Myeloproliferative Neoplasm", 
    "favorable_prognosis": false, 
    "last_updated": "2017-11-03 14:39:01.981554", 
    "old_disease": "Myeloproliferative Disorders", 
    "oncotree_code": "MPN", 
    "predictive_implication": "Level B", 
    "sources": [
      90
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "", 
    "therapy_sensitivity": null, 
    "therapy_type": "", 
    "validated": true
  }, 
  {
    "alterations": [
      128
    ], 
    "assertion_id": 265, 
    "created_on": null, 
    "description": "Ba/F3 cell lines with mutant JAK3 were sensitive to Tofacitinib.", 
    "disease": "T-Cell Acute Lymphoid Leukemia", 
    "favorable_prognosis": null, 
    "last_updated": "2017-11-03 14:39:01.998354", 
    "old_disease": "T-Cell Acute Lymphoblastic Leukemia", 
    "oncotree_code": "TALL", 
    "predictive_implication": "Level D", 
    "sources": [
      91
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "Tofacitinib", 
    "therapy_sensitivity": true, 
    "therapy_type": "Targeted Drug", 
    "validated": true
  }, 
  {
    "alterations": [
      129
    ], 
    "assertion_id": 266, 
    "created_on": null, 
    "description": "Ba/F3 cell lines with mutant JAK3 were sensitive to Tofacitinib.", 
    "disease": "T-Cell Acute Lymphoid Leukemia", 
    "favorable_prognosis": null, 
    "last_updated": "2017-11-03 14:39:02.013429", 
    "old_disease": "T-Cell Acute Lymphoblastic Leukemia", 
    "oncotree_code": "TALL", 
    "predictive_implication": "Level D", 
    "sources": [
      91
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "Tofacitinib", 
    "therapy_sensitivity": true, 
    "therapy_type": "Targeted Drug", 
    "validated": true
  }, 
  {
    "alterations": [
      130
    ], 
    "assertion_id": 267, 
    "created_on": null, 
    "description": "Ba/F3 cell lines with mutant JAK3 were sensitive to Tofacitinib.", 
    "disease": "T-Cell Acute Lymphoid Leukemia", 
    "favorable_prognosis": null, 
    "last_updated": "2017-11-03 14:39:02.024738", 
    "old_disease": "T-Cell Acute Lymphoblastic Leukemia", 
    "oncotree_code": "TALL", 
    "predictive_implication": "Level D", 
    "sources": [
      91
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "Tofacitinib", 
    "therapy_sensitivity": true, 
    "therapy_type": "Targeted Drug", 
    "validated": true
  }, 
  {
    "alterations": [
      128
    ], 
    "assertion_id": 268, 
    "created_on": null, 
    "description": "Ba/F3 cell lines with mutant JAK3 were sensitive for low doses of ruxolitinib.", 
    "disease": "T-Cell Acute Lymphoid Leukemia", 
    "favorable_prognosis": null, 
    "last_updated": "2017-11-03 14:39:02.034595", 
    "old_disease": "T-Cell Acute Lymphoblastic Leukemia", 
    "oncotree_code": "TALL", 
    "predictive_implication": "Level D", 
    "sources": [
      91
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "Ruxolitinib", 
    "therapy_sensitivity": true, 
    "therapy_type": "Targeted Drug", 
    "validated": true
  }, 
  {
    "alterations": [
      129
    ], 
    "assertion_id": 269, 
    "created_on": null, 
    "description": "Ba/F3 cell lines with mutant JAK3 were sensitive for low doses of ruxolitinib.", 
    "disease": "T-Cell Acute Lymphoid Leukemia", 
    "favorable_prognosis": null, 
    "last_updated": "2017-11-03 14:39:02.044080", 
    "old_disease": "T-Cell Acute Lymphoblastic Leukemia", 
    "oncotree_code": "TALL", 
    "predictive_implication": "Level D", 
    "sources": [
      91
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "Ruxolitinib", 
    "therapy_sensitivity": true, 
    "therapy_type": "Targeted Drug", 
    "validated": true
  }, 
  {
    "alterations": [
      130
    ], 
    "assertion_id": 270, 
    "created_on": null, 
    "description": "Ba/F3 cell lines with mutant JAK3 were sensitive for low doses of ruxolitinib.", 
    "disease": "T-Cell Acute Lymphoid Leukemia", 
    "favorable_prognosis": null, 
    "last_updated": "2017-11-03 14:39:02.057160", 
    "old_disease": "T-Cell Acute Lymphoblastic Leukemia", 
    "oncotree_code": "TALL", 
    "predictive_implication": "Level D", 
    "sources": [
      91
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "Ruxolitinib", 
    "therapy_sensitivity": true, 
    "therapy_type": "Targeted Drug", 
    "validated": true
  }, 
  {
    "alterations": [
      131
    ], 
    "assertion_id": 271, 
    "created_on": null, 
    "description": "Mucosal Melanoma is a rare and highly aggressive neoplasm with poor prognosis. Patients with this disease and mutations with c-KIT mutations (KIT exon 11 or 13) may be sensitive to c-KIT inhibitors.", 
    "disease": "Head and Neck Squamous Cell Carcinoma", 
    "favorable_prognosis": null, 
    "last_updated": "2017-11-03 14:39:02.067292", 
    "old_disease": "Head and Neck Squamous Cell Carcinoma", 
    "oncotree_code": "HNSC", 
    "predictive_implication": "Level A", 
    "sources": [
      92
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "Imatinib", 
    "therapy_sensitivity": true, 
    "therapy_type": "Targeted Drug", 
    "validated": true
  }, 
  {
    "alterations": [
      131
    ], 
    "assertion_id": 272, 
    "created_on": null, 
    "description": "Mucosal Melanoma is a rare and highly aggressive neoplasm with poor prognosis. Patients with this disease and mutations with c-KIT mutations (KIT exon 11 or 13) may be sensitive to c-KIT inhibitors.", 
    "disease": "Head and Neck Squamous Cell Carcinoma", 
    "favorable_prognosis": false, 
    "last_updated": "2017-11-03 14:39:02.076678", 
    "old_disease": "Head and Neck Squamous Cell Carcinoma", 
    "oncotree_code": "HNSC", 
    "predictive_implication": "Level A", 
    "sources": [
      92
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "Imatinib", 
    "therapy_sensitivity": null, 
    "therapy_type": "Targeted Drug", 
    "validated": true
  }, 
  {
    "alterations": [
      131
    ], 
    "assertion_id": 273, 
    "created_on": null, 
    "description": "Activating KIT mutations are associated with an increased sensitvity to imatinib.", 
    "disease": "Melanoma", 
    "favorable_prognosis": null, 
    "last_updated": "2017-11-03 14:39:02.084885", 
    "old_disease": "Melanoma", 
    "oncotree_code": "MEL", 
    "predictive_implication": "Level A", 
    "sources": [
      30
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "Imatinib", 
    "therapy_sensitivity": true, 
    "therapy_type": "Targeted Drug", 
    "validated": true
  }, 
  {
    "alterations": [
      132
    ], 
    "assertion_id": 274, 
    "created_on": null, 
    "description": "", 
    "disease": "Myeloproliferative Neoplasm", 
    "favorable_prognosis": null, 
    "last_updated": "2017-11-03 14:39:02.096948", 
    "old_disease": "Myeloproliferative Disorders", 
    "oncotree_code": "MPN", 
    "predictive_implication": "Level B", 
    "sources": [
      93
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "Imatinib", 
    "therapy_sensitivity": true, 
    "therapy_type": "Targeted Drug", 
    "validated": true
  }, 
  {
    "alterations": [
      132
    ], 
    "assertion_id": 275, 
    "created_on": null, 
    "description": "", 
    "disease": "Myeloproliferative Neoplasm", 
    "favorable_prognosis": null, 
    "last_updated": "2017-11-03 14:39:02.109269", 
    "old_disease": "Myeloproliferative Disorders", 
    "oncotree_code": "MPN", 
    "predictive_implication": "Level B", 
    "sources": [
      93
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "Sunitinib", 
    "therapy_sensitivity": true, 
    "therapy_type": "Targeted Drug", 
    "validated": true
  }, 
  {
    "alterations": [
      133
    ], 
    "assertion_id": 276, 
    "created_on": null, 
    "description": "", 
    "disease": "Gastrointestinal Stromal Tumor", 
    "favorable_prognosis": null, 
    "last_updated": "2017-11-03 14:39:02.120562", 
    "old_disease": "GIST", 
    "oncotree_code": "GIST", 
    "predictive_implication": "Level A", 
    "sources": [
      94
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "Imatinib", 
    "therapy_sensitivity": true, 
    "therapy_type": "Targeted Drug", 
    "validated": true
  }, 
  {
    "alterations": [
      134
    ], 
    "assertion_id": 277, 
    "created_on": null, 
    "description": "Requires increased dose of TKI", 
    "disease": "Gastrointestinal Stromal Tumor", 
    "favorable_prognosis": null, 
    "last_updated": "2017-11-03 14:39:02.130647", 
    "old_disease": "GIST", 
    "oncotree_code": "GIST", 
    "predictive_implication": "Level D", 
    "sources": [
      95
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "Imatinib", 
    "therapy_sensitivity": false, 
    "therapy_type": "Targeted Drug", 
    "validated": true
  }, 
  {
    "alterations": [
      135
    ], 
    "assertion_id": 278, 
    "created_on": null, 
    "description": "exon 2 comment", 
    "disease": "Colorectal Adenocarcinoma", 
    "favorable_prognosis": null, 
    "last_updated": "2017-11-03 14:39:02.141414", 
    "old_disease": "Colorectal Cancer", 
    "oncotree_code": "COADREAD", 
    "predictive_implication": "Level B", 
    "sources": [
      21
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "Cetuximab", 
    "therapy_sensitivity": true, 
    "therapy_type": "Targeted Drug", 
    "validated": true
  }, 
  {
    "alterations": [
      136
    ], 
    "assertion_id": 279, 
    "created_on": null, 
    "description": "", 
    "disease": "Colorectal Adenocarcinoma", 
    "favorable_prognosis": null, 
    "last_updated": "2017-11-03 14:39:02.154384", 
    "old_disease": "Colorectal Cancer", 
    "oncotree_code": "COADREAD", 
    "predictive_implication": "Level B", 
    "sources": [
      21
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "Panitumumab", 
    "therapy_sensitivity": true, 
    "therapy_type": "Targeted Drug", 
    "validated": true
  }, 
  {
    "alterations": [
      137
    ], 
    "assertion_id": 280, 
    "created_on": null, 
    "description": "KRAS alterations predict resistance to treatment with cetuximab, both alone and in combination with alkylating chemotherapy; cetuximab may have a detrimental effect on these patients.", 
    "disease": "Colorectal Adenocarcinoma", 
    "favorable_prognosis": null, 
    "last_updated": "2017-11-03 14:39:02.171067", 
    "old_disease": "Colorectal Cancer", 
    "oncotree_code": "COADREAD", 
    "predictive_implication": "FDA-Approved", 
    "sources": [
      21
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "Cetuximab", 
    "therapy_sensitivity": false, 
    "therapy_type": "Targeted Drug", 
    "validated": true
  }, 
  {
    "alterations": [
      137
    ], 
    "assertion_id": 281, 
    "created_on": null, 
    "description": "KRAS alterations predict resistance to treatment with cetuximab, both alone and in combination with alkylating chemotherapy; cetuximab may have a detrimental effect on these patients.", 
    "disease": "Colorectal Adenocarcinoma", 
    "favorable_prognosis": null, 
    "last_updated": "2017-11-03 14:39:02.181662", 
    "old_disease": "Colorectal Cancer", 
    "oncotree_code": "COADREAD", 
    "predictive_implication": "FDA-Approved", 
    "sources": [
      21
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "Panitumumab", 
    "therapy_sensitivity": false, 
    "therapy_type": "Targeted Drug", 
    "validated": true
  }, 
  {
    "alterations": [
      137
    ], 
    "assertion_id": 282, 
    "created_on": null, 
    "description": "", 
    "disease": "Myelodysplasia ", 
    "favorable_prognosis": false, 
    "last_updated": "2017-11-03 14:39:02.190914", 
    "old_disease": "Myelodysplastic Syndromes", 
    "oncotree_code": "MDS", 
    "predictive_implication": "Level B", 
    "sources": [
      11
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "", 
    "therapy_sensitivity": null, 
    "therapy_type": "", 
    "validated": true
  }, 
  {
    "alterations": [
      137
    ], 
    "assertion_id": 283, 
    "created_on": null, 
    "description": "The presence of mutations in KRAS was found to be associated with resistance to treatment with zoledronic acid in several non-small cell lung cancer cell lines and in a SCID murine model.", 
    "disease": "Non-Small Cell Lung Cancer", 
    "favorable_prognosis": null, 
    "last_updated": "2017-11-03 14:39:02.200823", 
    "old_disease": "Non-Small Cell Lung Cancer", 
    "oncotree_code": "NSCLC", 
    "predictive_implication": "Level D", 
    "sources": [
      96
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "Zoledronic acid", 
    "therapy_sensitivity": false, 
    "therapy_type": "Drug", 
    "validated": true
  }, 
  {
    "alterations": [
      137
    ], 
    "assertion_id": 284, 
    "created_on": null, 
    "description": "The combination of trametinib (a MEK inhibitor) with inhibition of FGFR1 is shown to enhance lung cancer and pancreatic cancer tumor cell death in vitro and in vivo.", 
    "disease": "Non-Small Cell Lung Cancer", 
    "favorable_prognosis": null, 
    "last_updated": "2017-11-03 14:39:02.211660", 
    "old_disease": "Non-Small Cell Lung Cancer", 
    "oncotree_code": "NSCLC", 
    "predictive_implication": "Level D", 
    "sources": [
      97
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "Trametinib+FGFR1 Inhibitor", 
    "therapy_sensitivity": true, 
    "therapy_type": "Targeted Drug", 
    "validated": true
  }, 
  {
    "alterations": [
      137
    ], 
    "assertion_id": 285, 
    "created_on": null, 
    "description": "KRAS mutations are associated with intrinsic resistance to EGFR TKIs.", 
    "disease": "Non-Small Cell Lung Cancer", 
    "favorable_prognosis": null, 
    "last_updated": "2017-11-03 14:39:02.226439", 
    "old_disease": "Non-Small Cell Lung Cancer", 
    "oncotree_code": "NSCLC", 
    "predictive_implication": "Level A", 
    "sources": [
      2
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "Tyrosine-Kinase Inhibitor", 
    "therapy_sensitivity": false, 
    "therapy_type": "Drug Class", 
    "validated": true
  }, 
  {
    "alterations": [
      137
    ], 
    "assertion_id": 286, 
    "created_on": null, 
    "description": "In a cohort of 34 non-small cell lung cancer patients treated with pembrolizumab, the presence of a KRAS mutation was associated with an increased chance of DCB.", 
    "disease": "Non-Small Cell Lung Cancer", 
    "favorable_prognosis": null, 
    "last_updated": "2017-11-03 14:39:02.237185", 
    "old_disease": "Non-Small Cell Lung Cancer", 
    "oncotree_code": "NSCLC", 
    "predictive_implication": "Level B", 
    "sources": [
      98
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "Pembrolizumab", 
    "therapy_sensitivity": true, 
    "therapy_type": "Targeted Drug", 
    "validated": true
  }, 
  {
    "alterations": [
      137
    ], 
    "assertion_id": 287, 
    "created_on": null, 
    "description": "A phase 1b trial including 21 ovarian cancer patients demonstrated increased survival and an average PFS of 7 months when treated with a combination of buparlisib and trametinib (RP2D of buparlisib 60mg and trametinib 1.5mg daily).", 
    "disease": "Ovarian Cancer, Other", 
    "favorable_prognosis": null, 
    "last_updated": "2017-11-03 14:39:02.246990", 
    "old_disease": "Ovarian Cancer", 
    "oncotree_code": "OOVC", 
    "predictive_implication": "Level A", 
    "sources": [
      99
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "Buparlisib+Trametinib", 
    "therapy_sensitivity": true, 
    "therapy_type": "Targeted Drug", 
    "validated": true
  }, 
  {
    "alterations": [
      138
    ], 
    "assertion_id": 288, 
    "created_on": null, 
    "description": "KRAS mutation G12D is associated with an increased risk of developing advanced pancreatic ductal carcinoma.", 
    "disease": "Pancreatic Adenocarcinoma", 
    "favorable_prognosis": false, 
    "last_updated": "2017-11-03 14:39:02.260395", 
    "old_disease": "Pancreatic Cancer", 
    "oncotree_code": "PAAD", 
    "predictive_implication": "Level A", 
    "sources": [
      100
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "", 
    "therapy_sensitivity": null, 
    "therapy_type": "", 
    "validated": true
  }, 
  {
    "alterations": [
      137
    ], 
    "assertion_id": 289, 
    "created_on": null, 
    "description": "The combination of trametinib (a MEK inhibitor) with inhibition of FGFR1 is shown to enhance lung cancer and pancreatic cancer tumor cell death in vitro and in vivo.", 
    "disease": "Pancreatic Adenocarcinoma", 
    "favorable_prognosis": null, 
    "last_updated": "2017-11-03 14:39:02.274033", 
    "old_disease": "Pancreatic Cancer", 
    "oncotree_code": "PAAD", 
    "predictive_implication": "Level D", 
    "sources": [
      97
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "Trametinib+FGFR1 Inhibitor", 
    "therapy_sensitivity": true, 
    "therapy_type": "Targeted Drug", 
    "validated": true
  }, 
  {
    "alterations": [
      137
    ], 
    "assertion_id": 290, 
    "created_on": null, 
    "description": "KRAS mutations were associated with resistance to the BRAF inhibitor PLX-4032 in a study of 109 microdissected pancreatic ductal adenocarcinoma patients.", 
    "disease": "Pancreatic Adenocarcinoma", 
    "favorable_prognosis": null, 
    "last_updated": "2017-11-03 14:39:02.283607", 
    "old_disease": "Pancreatic Cancer", 
    "oncotree_code": "PAAD", 
    "predictive_implication": "Level B", 
    "sources": [
      10
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "Vemurafenib", 
    "therapy_sensitivity": false, 
    "therapy_type": "Targeted Drug", 
    "validated": true
  }, 
  {
    "alterations": [
      137
    ], 
    "assertion_id": 291, 
    "created_on": null, 
    "description": "Preclinical study suggests that TBK1/IKK\u00ce\u00b5 promote tumor survival by activating CCL5 and IL-6 and identify concurrent inhibition of TBK1/IKK\u00ce\u00b5, Janus-activated kinase (JAK), and MEK signaling as an effective approach to inhibit the actions of oncogenic KRAS", 
    "disease": "Leukemia", 
    "favorable_prognosis": null, 
    "last_updated": "2017-11-03 14:39:02.293124", 
    "old_disease": "Leukemia", 
    "oncotree_code": "LEUK", 
    "predictive_implication": "Level D", 
    "sources": [
      101
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "Ruxolitinib", 
    "therapy_sensitivity": true, 
    "therapy_type": "Targeted Drug", 
    "validated": true
  }, 
  {
    "alterations": [
      137
    ], 
    "assertion_id": 292, 
    "created_on": null, 
    "description": "Preclinical study suggests that TBK1/IKK\u00ce\u00b5 promote tumor survival by activating CCL5 and IL-6 and identify concurrent inhibition of TBK1/IKK\u00ce\u00b5, Janus-activated kinase (JAK), and MEK signaling as an effective approach to inhibit the actions of oncogenic KRAS", 
    "disease": "Leukemia", 
    "favorable_prognosis": null, 
    "last_updated": "2017-11-03 14:39:02.301500", 
    "old_disease": "Leukemia", 
    "oncotree_code": "LEUK", 
    "predictive_implication": "Level D", 
    "sources": [
      101
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "Momelotinib", 
    "therapy_sensitivity": true, 
    "therapy_type": "Targeted Drug", 
    "validated": true
  }, 
  {
    "alterations": [
      137
    ], 
    "assertion_id": 293, 
    "created_on": null, 
    "description": "The combination of palbociclib and trametinib has shown antitumor and radiosensitizing activity in preclinical models of non-small cell lung cancer, and is currently in a phase III clinical trial for non-small cell lung cancer.", 
    "disease": "Non-Small Cell Lung Cancer", 
    "favorable_prognosis": null, 
    "last_updated": "2017-11-03 14:39:02.314106", 
    "old_disease": "Lung Cancer", 
    "oncotree_code": "NSCLC", 
    "predictive_implication": "Level A", 
    "sources": [
      102, 
      103
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "Palbociclib+Trametinib", 
    "therapy_sensitivity": true, 
    "therapy_type": "Targeted Drug", 
    "validated": true
  }, 
  {
    "alterations": [
      139
    ], 
    "assertion_id": 294, 
    "created_on": null, 
    "description": "Mutation may indicate increased susceptibility to early-onset colorectal cancer.", 
    "disease": "Colorectal Adenocarcinoma", 
    "favorable_prognosis": false, 
    "last_updated": "2017-11-03 14:39:02.330580", 
    "old_disease": "Colorectal Cancer", 
    "oncotree_code": "COADREAD", 
    "predictive_implication": "Level B", 
    "sources": [
      87
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "", 
    "therapy_sensitivity": null, 
    "therapy_type": "", 
    "validated": true
  }, 
  {
    "alterations": [
      140
    ], 
    "assertion_id": 295, 
    "created_on": null, 
    "description": "Mutation may indicate increased susceptibility to early-onset colorectal cancer.", 
    "disease": "Colorectal Adenocarcinoma", 
    "favorable_prognosis": false, 
    "last_updated": "2017-11-03 14:39:02.343992", 
    "old_disease": "Colorectal Cancer", 
    "oncotree_code": "COADREAD", 
    "predictive_implication": "Level B", 
    "sources": [
      87
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "", 
    "therapy_sensitivity": null, 
    "therapy_type": "", 
    "validated": true
  }, 
  {
    "alterations": [
      141
    ], 
    "assertion_id": 296, 
    "created_on": null, 
    "description": "Mutation may indicate increased susceptibility to early-onset colorectal cancer.", 
    "disease": "Colorectal Adenocarcinoma", 
    "favorable_prognosis": false, 
    "last_updated": "2017-11-03 14:39:02.355074", 
    "old_disease": "Colorectal Cancer", 
    "oncotree_code": "COADREAD", 
    "predictive_implication": "Level B", 
    "sources": [
      87
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "", 
    "therapy_sensitivity": null, 
    "therapy_type": "", 
    "validated": true
  }, 
  {
    "alterations": [
      142
    ], 
    "assertion_id": 297, 
    "created_on": null, 
    "description": "Presence of this variant may suggest resistance to Selumetinib.", 
    "disease": "Melanoma", 
    "favorable_prognosis": null, 
    "last_updated": "2017-11-03 14:39:02.367288", 
    "old_disease": "Melanoma", 
    "oncotree_code": "MEL", 
    "predictive_implication": "Level B", 
    "sources": [
      26
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "Selumetinib", 
    "therapy_sensitivity": false, 
    "therapy_type": "Targeted Drug", 
    "validated": true
  }, 
  {
    "alterations": [
      142
    ], 
    "assertion_id": 298, 
    "created_on": null, 
    "description": "Presence of this variant in vitro suggests resistance to PLX4720, a precursor to Vemurafenib, in metastatic melanoma.", 
    "disease": "Melanoma", 
    "favorable_prognosis": null, 
    "last_updated": "2017-11-03 14:39:02.374666", 
    "old_disease": "Melanoma", 
    "oncotree_code": "MEL", 
    "predictive_implication": "Level D", 
    "sources": [
      26
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "Vemurafenib", 
    "therapy_sensitivity": false, 
    "therapy_type": "Targeted Drug", 
    "validated": true
  }, 
  {
    "alterations": [
      143
    ], 
    "assertion_id": 299, 
    "created_on": null, 
    "description": "Presence of this variant in vitro suggests resistance to PLX4720, a precursor to Vemurafenib, in metastatic melanoma.", 
    "disease": "Melanoma", 
    "favorable_prognosis": null, 
    "last_updated": "2017-11-03 14:39:02.395471", 
    "old_disease": "Melanoma", 
    "oncotree_code": "MEL", 
    "predictive_implication": "Level D", 
    "sources": [
      26
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "Vemurafenib", 
    "therapy_sensitivity": false, 
    "therapy_type": "Targeted Drug", 
    "validated": true
  }, 
  {
    "alterations": [
      144
    ], 
    "assertion_id": 300, 
    "created_on": null, 
    "description": "MEK1 Q56P confers resistance to monotherapy with RAF or MEK inhibitors in vitro.", 
    "disease": "Melanoma", 
    "favorable_prognosis": null, 
    "last_updated": "2017-11-03 14:39:02.406677", 
    "old_disease": "Melanoma", 
    "oncotree_code": "MEL", 
    "predictive_implication": "Level D", 
    "sources": [
      104
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "RAF inhibitors", 
    "therapy_sensitivity": false, 
    "therapy_type": "Drug Class", 
    "validated": true
  }, 
  {
    "alterations": [
      144
    ], 
    "assertion_id": 301, 
    "created_on": null, 
    "description": "MEK1 Q56P confers resistance to monotherapy with RAF or MEK inhibitors in vitro.", 
    "disease": "Melanoma", 
    "favorable_prognosis": null, 
    "last_updated": "2017-11-03 14:39:02.415635", 
    "old_disease": "Melanoma", 
    "oncotree_code": "MEL", 
    "predictive_implication": "Level D", 
    "sources": [
      104
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "MEK inhibitors", 
    "therapy_sensitivity": false, 
    "therapy_type": "Drug Class", 
    "validated": true
  }, 
  {
    "alterations": [
      145
    ], 
    "assertion_id": 302, 
    "created_on": null, 
    "description": "", 
    "disease": "Melanoma", 
    "favorable_prognosis": null, 
    "last_updated": "2017-11-03 14:39:02.427077", 
    "old_disease": "Melanoma", 
    "oncotree_code": "MEL", 
    "predictive_implication": "Level D", 
    "sources": [
      105
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "Selumetinib", 
    "therapy_sensitivity": false, 
    "therapy_type": "Targeted Drug", 
    "validated": true
  }, 
  {
    "alterations": [
      145
    ], 
    "assertion_id": 303, 
    "created_on": null, 
    "description": "", 
    "disease": "Melanoma", 
    "favorable_prognosis": null, 
    "last_updated": "2017-11-03 14:39:02.442631", 
    "old_disease": "Melanoma", 
    "oncotree_code": "MEL", 
    "predictive_implication": "Level D", 
    "sources": [
      105
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "Vemurafenib", 
    "therapy_sensitivity": false, 
    "therapy_type": "Targeted Drug", 
    "validated": true
  }, 
  {
    "alterations": [
      146
    ], 
    "assertion_id": 304, 
    "created_on": null, 
    "description": "", 
    "disease": "Non-Small Cell Lung Cancer", 
    "favorable_prognosis": null, 
    "last_updated": "2017-11-03 14:39:02.452905", 
    "old_disease": "Non-Small Cell Lung Cancer", 
    "oncotree_code": "NSCLC", 
    "predictive_implication": "Level D", 
    "sources": [
      106
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "Erlotinib", 
    "therapy_sensitivity": false, 
    "therapy_type": "Targeted Drug", 
    "validated": true
  }, 
  {
    "alterations": [
      147
    ], 
    "assertion_id": 305, 
    "created_on": null, 
    "description": "", 
    "disease": "Non-Small Cell Lung Cancer", 
    "favorable_prognosis": null, 
    "last_updated": "2017-11-03 14:39:02.461646", 
    "old_disease": "Non-Small Cell Lung Cancer", 
    "oncotree_code": "NSCLC", 
    "predictive_implication": "Level D", 
    "sources": [
      106
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "Erlotinib", 
    "therapy_sensitivity": false, 
    "therapy_type": "Targeted Drug", 
    "validated": true
  }, 
  {
    "alterations": [
      147
    ], 
    "assertion_id": 306, 
    "created_on": null, 
    "description": "", 
    "disease": "Non-Small Cell Lung Cancer", 
    "favorable_prognosis": null, 
    "last_updated": "2017-11-03 14:39:02.470319", 
    "old_disease": "Non-Small Cell Lung Cancer", 
    "oncotree_code": "NSCLC", 
    "predictive_implication": "Level D", 
    "sources": [
      106
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "Erlotinib", 
    "therapy_sensitivity": false, 
    "therapy_type": "Targeted Drug", 
    "validated": true
  }, 
  {
    "alterations": [
      147
    ], 
    "assertion_id": 307, 
    "created_on": null, 
    "description": "", 
    "disease": "Non-Small Cell Lung Cancer", 
    "favorable_prognosis": null, 
    "last_updated": "2017-11-03 14:39:02.480029", 
    "old_disease": "Non-Small Cell Lung Cancer", 
    "oncotree_code": "NSCLC", 
    "predictive_implication": "Level D", 
    "sources": [
      106
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "Gefitinib", 
    "therapy_sensitivity": false, 
    "therapy_type": "Targeted Drug", 
    "validated": true
  }, 
  {
    "alterations": [
      147
    ], 
    "assertion_id": 308, 
    "created_on": null, 
    "description": "", 
    "disease": "Non-Small Cell Lung Cancer", 
    "favorable_prognosis": null, 
    "last_updated": "2017-11-03 14:39:02.492423", 
    "old_disease": "Non-Small Cell Lung Cancer", 
    "oncotree_code": "NSCLC", 
    "predictive_implication": "Level D", 
    "sources": [
      106
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "Gefitinib", 
    "therapy_sensitivity": false, 
    "therapy_type": "Targeted Drug", 
    "validated": true
  }, 
  {
    "alterations": [
      143
    ], 
    "assertion_id": 309, 
    "created_on": null, 
    "description": "", 
    "disease": "Non-Small Cell Lung Cancer", 
    "favorable_prognosis": null, 
    "last_updated": "2017-11-03 14:39:02.502195", 
    "old_disease": "Non-Small Cell Lung Cancer", 
    "oncotree_code": "NSCLC", 
    "predictive_implication": "Level D", 
    "sources": [
      106
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "Gefitinib", 
    "therapy_sensitivity": false, 
    "therapy_type": "Targeted Drug", 
    "validated": true
  }, 
  {
    "alterations": [
      143
    ], 
    "assertion_id": 310, 
    "created_on": null, 
    "description": "Cell line NCI-H1437 harbors MAP2K1 p.Q56P, a known transformation-component allele of MEK1 originally identified in rat fibroblasts, and is sensitive to treatment with Selumetinib (AZD6244).", 
    "disease": "Non-Small Cell Lung Cancer", 
    "favorable_prognosis": null, 
    "last_updated": "2017-11-03 14:39:02.510072", 
    "old_disease": "Non-Small Cell Lung Cancer", 
    "oncotree_code": "NSCLC", 
    "predictive_implication": "Level D", 
    "sources": [
      106
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "Selumetinib", 
    "therapy_sensitivity": true, 
    "therapy_type": "Targeted Drug", 
    "validated": true
  }, 
  {
    "alterations": [
      148
    ], 
    "assertion_id": 311, 
    "created_on": null, 
    "description": "MEK2 Q60P was observed in a patient's trametinib resistant tumor but not pretreatment tumor.", 
    "disease": "Melanoma", 
    "favorable_prognosis": null, 
    "last_updated": "2017-11-03 14:39:02.518631", 
    "old_disease": "Melanoma", 
    "oncotree_code": "MEL", 
    "predictive_implication": "Level B", 
    "sources": [
      33
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "Trametinib", 
    "therapy_sensitivity": false, 
    "therapy_type": "Targeted Drug", 
    "validated": true
  }, 
  {
    "alterations": [
      149
    ], 
    "assertion_id": 312, 
    "created_on": null, 
    "description": "In an exceptional responder, erlotinib resulted in complete and rapid response in MAPK1 mutant HNSCC", 
    "disease": "Head and Neck Squamous Cell Carcinoma", 
    "favorable_prognosis": null, 
    "last_updated": "2017-11-03 14:39:02.533201", 
    "old_disease": "Head and Neck Squamous Cell Carcinoma", 
    "oncotree_code": "HNSC", 
    "predictive_implication": "Level D", 
    "sources": [
      107
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "Erlotinib", 
    "therapy_sensitivity": true, 
    "therapy_type": "Targeted Drug", 
    "validated": true
  }, 
  {
    "alterations": [
      150
    ], 
    "assertion_id": 313, 
    "created_on": null, 
    "description": "The presence of MC1R polymorphisms in a cohort of 53 metastatic melanoma patients treated with BRAF inhibitors was associated with a poorer prognosis (ORR: 59% vs. 95%; PFS shorter than 6 months: 72% vs. 33%).", 
    "disease": "Melanoma", 
    "favorable_prognosis": false, 
    "last_updated": "2017-11-03 14:39:02.551320", 
    "old_disease": "Melanoma", 
    "oncotree_code": "MEL", 
    "predictive_implication": "Level B", 
    "sources": [
      108
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "", 
    "therapy_sensitivity": null, 
    "therapy_type": "", 
    "validated": true
  }, 
  {
    "alterations": [
      151
    ], 
    "assertion_id": 314, 
    "created_on": null, 
    "description": "Presence of amplified MDM2 may suggest sensitivity to nutlin-3 in the absense of mutant TP53.", 
    "disease": "Gastric Remnant Adenocarcinoma", 
    "favorable_prognosis": null, 
    "last_updated": "2017-11-03 14:39:02.563907", 
    "old_disease": "Gastric Cancer", 
    "oncotree_code": "GRC", 
    "predictive_implication": "Level D", 
    "sources": [
      109
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "nutlin-3", 
    "therapy_sensitivity": true, 
    "therapy_type": "Targeted Drug", 
    "validated": true
  }, 
  {
    "alterations": [
      152
    ], 
    "assertion_id": 315, 
    "created_on": null, 
    "description": "Presence of this variant may suggest sensitivity to SU11274.", 
    "disease": "Head and Neck Squamous Cell Carcinoma", 
    "favorable_prognosis": null, 
    "last_updated": "2017-11-03 14:39:02.574351", 
    "old_disease": "Head and Neck Squamous Cell Carcinoma", 
    "oncotree_code": "HNSC", 
    "predictive_implication": "Level D", 
    "sources": [
      110
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "SU11274", 
    "therapy_sensitivity": true, 
    "therapy_type": "Targeted Drug", 
    "validated": true
  }, 
  {
    "alterations": [
      153
    ], 
    "assertion_id": 316, 
    "created_on": null, 
    "description": "Amplification of alternative kinases, such as MET, may suggest resistance to EGFR TKIs.", 
    "disease": "Non-Small Cell Lung Cancer", 
    "favorable_prognosis": null, 
    "last_updated": "2017-11-03 14:39:02.585057", 
    "old_disease": "Non-Small Cell Lung Cancer", 
    "oncotree_code": "NSCLC", 
    "predictive_implication": "Level A", 
    "sources": [
      2
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "Tyrosine-Kinase Inhibitor", 
    "therapy_sensitivity": false, 
    "therapy_type": "Drug Class", 
    "validated": true
  }, 
  {
    "alterations": [
      154
    ], 
    "assertion_id": 317, 
    "created_on": null, 
    "description": "Amplification of the 13q31-34 region, which contains MIR17HG, was associated with increased sensitivity to neoadjuvant chemotherapy and surgery in 41% of participants in a 120-patient study.", 
    "disease": "Rectal Adenocarcinoma", 
    "favorable_prognosis": null, 
    "last_updated": "2017-11-03 14:39:02.598200", 
    "old_disease": "Rectal Cancer", 
    "oncotree_code": "READ", 
    "predictive_implication": "Level D", 
    "sources": [
      111
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "Neoadjuvant Chemotherapy+Surgery", 
    "therapy_sensitivity": true, 
    "therapy_type": "Procedure", 
    "validated": true
  }, 
  {
    "alterations": [
      155
    ], 
    "assertion_id": 318, 
    "created_on": null, 
    "description": "Deletion of the 13q31-34 region, which contains MIR17HG, was associated with resistance to neoadjuvant chemotherapy and surgery in 41% of participants in a 120-patient study.", 
    "disease": "Rectal Adenocarcinoma", 
    "favorable_prognosis": null, 
    "last_updated": "2017-11-03 14:39:02.612216", 
    "old_disease": "Rectal Cancer", 
    "oncotree_code": "READ", 
    "predictive_implication": "Level D", 
    "sources": [
      111
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "Neoadjuvant Chemotherapy+Surgery", 
    "therapy_sensitivity": false, 
    "therapy_type": "Procedure", 
    "validated": true
  }, 
  {
    "alterations": [
      156
    ], 
    "assertion_id": 319, 
    "created_on": null, 
    "description": "Patients with defects in DNA mismatch repair genes often have a favorable prognosis and a decreased likelihood of metastasis. These patients do not benefit from, and may be resistant to, 5-fluorouracil therapy.", 
    "disease": "Colorectal Adenocarcinoma", 
    "favorable_prognosis": true, 
    "last_updated": "2017-11-03 14:39:02.622900", 
    "old_disease": "Colorectal Cancer", 
    "oncotree_code": "COADREAD", 
    "predictive_implication": "Level B", 
    "sources": [
      21
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "5-Fluorouracil", 
    "therapy_sensitivity": null, 
    "therapy_type": "Targeted Drug", 
    "validated": true
  }, 
  {
    "alterations": [
      157
    ], 
    "assertion_id": 320, 
    "created_on": null, 
    "description": "Patients with defects in DNA mismatch repair genes may have enhanced sensitivity to immune checkpoint blockade.", 
    "disease": "Colorectal Adenocarcinoma", 
    "favorable_prognosis": null, 
    "last_updated": "2017-11-03 14:39:02.635682", 
    "old_disease": "Colorectal Cancer", 
    "oncotree_code": "COADREAD", 
    "predictive_implication": "Level B", 
    "sources": [
      112
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "PD-1 Inhibitors", 
    "therapy_sensitivity": true, 
    "therapy_type": "Immunotherapy", 
    "validated": true
  }, 
  {
    "alterations": [
      158
    ], 
    "assertion_id": 321, 
    "created_on": null, 
    "description": "Patients with defects in DNA mismatch repair genes may have enhanced sensitivity to immune checkpoint blockade.", 
    "disease": "Colorectal Adenocarcinoma", 
    "favorable_prognosis": null, 
    "last_updated": "2017-11-03 14:39:02.650663", 
    "old_disease": "Colorectal Cancer", 
    "oncotree_code": "COADREAD", 
    "predictive_implication": "Level B", 
    "sources": [
      112
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "PD-1 Inhibitors", 
    "therapy_sensitivity": true, 
    "therapy_type": "Immunotherapy", 
    "validated": true
  }, 
  {
    "alterations": [
      159
    ], 
    "assertion_id": 322, 
    "created_on": null, 
    "description": "Presence of this variant may suggest sensitivity to JAK2 inhibition. This variant was observed to suggest sensitivity to EXEL-8232 in vivo.", 
    "disease": "Myeloproliferative Neoplasm", 
    "favorable_prognosis": null, 
    "last_updated": "2017-11-03 14:39:02.664704", 
    "old_disease": "Myeloproliferative Disorders", 
    "oncotree_code": "MPN", 
    "predictive_implication": "Level D", 
    "sources": [
      113
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "EXEL-8232", 
    "therapy_sensitivity": true, 
    "therapy_type": "Targeted Drug", 
    "validated": true
  }, 
  {
    "alterations": [
      160
    ], 
    "assertion_id": 323, 
    "created_on": null, 
    "description": "Mutation may indicate increased susceptibility to early-onset colorectal cancer.", 
    "disease": "Colorectal Adenocarcinoma", 
    "favorable_prognosis": false, 
    "last_updated": "2017-11-03 14:39:02.675696", 
    "old_disease": "Colorectal Cancer", 
    "oncotree_code": "COADREAD", 
    "predictive_implication": "Level B", 
    "sources": [
      87
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "", 
    "therapy_sensitivity": null, 
    "therapy_type": "", 
    "validated": true
  }, 
  {
    "alterations": [
      161
    ], 
    "assertion_id": 324, 
    "created_on": null, 
    "description": "Mutation may indicate increased susceptibility to early-onset colorectal cancer.", 
    "disease": "Colorectal Adenocarcinoma", 
    "favorable_prognosis": false, 
    "last_updated": "2017-11-03 14:39:02.684515", 
    "old_disease": "Colorectal Cancer", 
    "oncotree_code": "COADREAD", 
    "predictive_implication": "Level B", 
    "sources": [
      87
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "", 
    "therapy_sensitivity": null, 
    "therapy_type": "", 
    "validated": true
  }, 
  {
    "alterations": [
      162
    ], 
    "assertion_id": 325, 
    "created_on": null, 
    "description": "Mutation may indicate increased susceptibility to early-onset colorectal cancer.", 
    "disease": "Colorectal Adenocarcinoma", 
    "favorable_prognosis": false, 
    "last_updated": "2017-11-03 14:39:02.693568", 
    "old_disease": "Colorectal Cancer", 
    "oncotree_code": "COADREAD", 
    "predictive_implication": "Level B", 
    "sources": [
      87
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "", 
    "therapy_sensitivity": null, 
    "therapy_type": "", 
    "validated": true
  }, 
  {
    "alterations": [
      163
    ], 
    "assertion_id": 326, 
    "created_on": null, 
    "description": "Patients with defects in DNA mismatch repair genes may have enhanced sensitivity to immune checkpoint blockade.", 
    "disease": "Colorectal Adenocarcinoma", 
    "favorable_prognosis": null, 
    "last_updated": "2017-11-03 14:39:02.707824", 
    "old_disease": "Colorectal Cancer", 
    "oncotree_code": "COADREAD", 
    "predictive_implication": "Level B", 
    "sources": [
      112
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "PD-1 Inhibitors", 
    "therapy_sensitivity": true, 
    "therapy_type": "Immunotherapy", 
    "validated": true
  }, 
  {
    "alterations": [
      164
    ], 
    "assertion_id": 327, 
    "created_on": null, 
    "description": "Patients with defects in DNA mismatch repair genes may have enhanced sensitivity to immune checkpoint blockade.", 
    "disease": "Colorectal Adenocarcinoma", 
    "favorable_prognosis": null, 
    "last_updated": "2017-11-03 14:39:02.718353", 
    "old_disease": "Colorectal Cancer", 
    "oncotree_code": "COADREAD", 
    "predictive_implication": "Level B", 
    "sources": [
      112
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "PD-1 Inhibitors", 
    "therapy_sensitivity": true, 
    "therapy_type": "Immunotherapy", 
    "validated": true
  }, 
  {
    "alterations": [
      164
    ], 
    "assertion_id": 328, 
    "created_on": null, 
    "description": "Patients with defects in DNA mismatch repair genes often have a favorable prognosis and a decreased likelihood of metastasis. These patients do not benefit from, and may be resistant to, 5-fluorouracil therapy.", 
    "disease": "Colorectal Adenocarcinoma", 
    "favorable_prognosis": true, 
    "last_updated": "2017-11-03 14:39:02.725561", 
    "old_disease": "Colorectal Cancer", 
    "oncotree_code": "COADREAD", 
    "predictive_implication": "Level B", 
    "sources": [
      21
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "5-Fluorouracil", 
    "therapy_sensitivity": null, 
    "therapy_type": "Targeted Drug", 
    "validated": true
  }, 
  {
    "alterations": [
      165
    ], 
    "assertion_id": 329, 
    "created_on": null, 
    "description": "Patients with defects in DNA mismatch repair genes may have enhanced sensitivity to immune checkpoint blockade.", 
    "disease": "Colorectal Adenocarcinoma", 
    "favorable_prognosis": null, 
    "last_updated": "2017-11-03 14:39:02.733409", 
    "old_disease": "Colorectal Cancer", 
    "oncotree_code": "COADREAD", 
    "predictive_implication": "Level B", 
    "sources": [
      112
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "PD-1 Inhibitors", 
    "therapy_sensitivity": true, 
    "therapy_type": "Immunotherapy", 
    "validated": true
  }, 
  {
    "alterations": [
      166
    ], 
    "assertion_id": 330, 
    "created_on": null, 
    "description": "Patients with defects in DNA mismatch repair genes may have enhanced sensitivity to immune checkpoint blockade.", 
    "disease": "Colorectal Adenocarcinoma", 
    "favorable_prognosis": null, 
    "last_updated": "2017-11-03 14:39:02.747249", 
    "old_disease": "Colorectal Cancer", 
    "oncotree_code": "COADREAD", 
    "predictive_implication": "Level B", 
    "sources": [
      112
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "PD-1 Inhibitors", 
    "therapy_sensitivity": true, 
    "therapy_type": "Immunotherapy", 
    "validated": true
  }, 
  {
    "alterations": [
      166
    ], 
    "assertion_id": 331, 
    "created_on": null, 
    "description": "Patients with defects in DNA mismatch repair genes often have a favorable prognosis and a decreased likelihood of metastasis. These patients do not benefit from, and may be resistant to, 5-fluorouracil therapy.", 
    "disease": "Colorectal Adenocarcinoma", 
    "favorable_prognosis": true, 
    "last_updated": "2017-11-03 14:39:02.761535", 
    "old_disease": "Colorectal Cancer", 
    "oncotree_code": "COADREAD", 
    "predictive_implication": "Level B", 
    "sources": [
      21
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "5-Fluorouracil", 
    "therapy_sensitivity": null, 
    "therapy_type": "Targeted Drug", 
    "validated": true
  }, 
  {
    "alterations": [
      167
    ], 
    "assertion_id": 332, 
    "created_on": null, 
    "description": "Amplification of 8q24 (which includes the MYC oncogene) was associated with poor outcomes in a study of 109 microdissected pancreatic adenocarcinoma tumors.", 
    "disease": "Pancreatic Adenocarcinoma", 
    "favorable_prognosis": false, 
    "last_updated": "2017-11-03 14:39:02.772266", 
    "old_disease": "Pancreatic Cancer", 
    "oncotree_code": "PAAD", 
    "predictive_implication": "Level B", 
    "sources": [
      10
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "", 
    "therapy_sensitivity": null, 
    "therapy_type": "", 
    "validated": true
  }, 
  {
    "alterations": [
      168
    ], 
    "assertion_id": 333, 
    "created_on": null, 
    "description": "Poor prognosis (< 15%) was observed for patients with amplified MYC with Medulloblastoma.", 
    "disease": "Medulloblastoma", 
    "favorable_prognosis": false, 
    "last_updated": "2017-11-03 14:39:02.782399", 
    "old_disease": "Medulloblastoma", 
    "oncotree_code": "MBL", 
    "predictive_implication": "Level A", 
    "sources": [
      114
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "", 
    "therapy_sensitivity": null, 
    "therapy_type": "", 
    "validated": true
  }, 
  {
    "alterations": [
      169
    ], 
    "assertion_id": 334, 
    "created_on": null, 
    "description": "Patients whose tumors contain DNA repair deficiencies may benefit from anti-PD-1 therapy. MMR deficient colorectal and noncolorectal cancer were enriched for partial response to Pembrolizumab in a cohort of 41 patients.", 
    "disease": "Colorectal Adenocarcinoma", 
    "favorable_prognosis": null, 
    "last_updated": "2017-11-03 14:39:02.792682", 
    "old_disease": "Colorectal Cancer", 
    "oncotree_code": "COADREAD", 
    "predictive_implication": "Level E", 
    "sources": [
      112
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "Pembrolizumab", 
    "therapy_sensitivity": true, 
    "therapy_type": "Immunotherapy", 
    "validated": true
  }, 
  {
    "alterations": [
      170
    ], 
    "assertion_id": 335, 
    "created_on": null, 
    "description": "NRAS alterations predict resistance to treatment with Cetuximab, both alone and in combination with alkylating chemotherapy.", 
    "disease": "Colorectal Adenocarcinoma", 
    "favorable_prognosis": null, 
    "last_updated": "2017-11-03 14:39:02.804095", 
    "old_disease": "Colorectal Cancer", 
    "oncotree_code": "COADREAD", 
    "predictive_implication": "FDA-Approved", 
    "sources": [
      21
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "Cetuximab", 
    "therapy_sensitivity": false, 
    "therapy_type": "Targeted Drug", 
    "validated": true
  }, 
  {
    "alterations": [
      170
    ], 
    "assertion_id": 336, 
    "created_on": null, 
    "description": "NRAS alterations predict resistance to treatment with Panitumumab, both alone and in combination with alkylating chemotherapy.chemotherapy.", 
    "disease": "Colorectal Adenocarcinoma", 
    "favorable_prognosis": null, 
    "last_updated": "2017-11-03 14:39:02.816977", 
    "old_disease": "Colorectal Cancer", 
    "oncotree_code": "COADREAD", 
    "predictive_implication": "FDA-Approved", 
    "sources": [
      21
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "Panitumumab", 
    "therapy_sensitivity": false, 
    "therapy_type": "Targeted Drug", 
    "validated": true
  }, 
  {
    "alterations": [
      171
    ], 
    "assertion_id": 337, 
    "created_on": null, 
    "description": "Presence of this variant may suggest sensitivity to Selumetinib.", 
    "disease": "Melanoma", 
    "favorable_prognosis": null, 
    "last_updated": "2017-11-03 14:39:02.828544", 
    "old_disease": "Melanoma", 
    "oncotree_code": "MEL", 
    "predictive_implication": "Level B", 
    "sources": [
      115
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "Selumetinib", 
    "therapy_sensitivity": true, 
    "therapy_type": "Targeted Drug", 
    "validated": true
  }, 
  {
    "alterations": [
      172
    ], 
    "assertion_id": 338, 
    "created_on": null, 
    "description": "Presence of this variant may suggest sensitivity to Selumetinib.", 
    "disease": "Melanoma", 
    "favorable_prognosis": null, 
    "last_updated": "2017-11-03 14:39:02.839419", 
    "old_disease": "Melanoma", 
    "oncotree_code": "MEL", 
    "predictive_implication": "Level B", 
    "sources": [
      115
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "Selumetinib", 
    "therapy_sensitivity": true, 
    "therapy_type": "Targeted Drug", 
    "validated": true
  }, 
  {
    "alterations": [
      173
    ], 
    "assertion_id": 339, 
    "created_on": null, 
    "description": "Presence of this variant may suggest sensitivity to Selumetinib.", 
    "disease": "Melanoma", 
    "favorable_prognosis": null, 
    "last_updated": "2017-11-03 14:39:02.850437", 
    "old_disease": "Melanoma", 
    "oncotree_code": "MEL", 
    "predictive_implication": "Level B", 
    "sources": [
      115
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "Selumetinib", 
    "therapy_sensitivity": true, 
    "therapy_type": "Targeted Drug", 
    "validated": true
  }, 
  {
    "alterations": [
      174
    ], 
    "assertion_id": 340, 
    "created_on": null, 
    "description": "Presence of this variant may suggest sensitivity to Selumetinib.", 
    "disease": "Melanoma", 
    "favorable_prognosis": null, 
    "last_updated": "2017-11-03 14:39:02.862518", 
    "old_disease": "Melanoma", 
    "oncotree_code": "MEL", 
    "predictive_implication": "Level B", 
    "sources": [
      115
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "Selumetinib", 
    "therapy_sensitivity": true, 
    "therapy_type": "Targeted Drug", 
    "validated": true
  }, 
  {
    "alterations": [
      175
    ], 
    "assertion_id": 341, 
    "created_on": null, 
    "description": "Presence of this variant may suggest sensitivity to Selumetinib.", 
    "disease": "Melanoma", 
    "favorable_prognosis": null, 
    "last_updated": "2017-11-03 14:39:02.876657", 
    "old_disease": "Melanoma", 
    "oncotree_code": "MEL", 
    "predictive_implication": "Level B", 
    "sources": [
      115
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "Selumetinib", 
    "therapy_sensitivity": true, 
    "therapy_type": "Targeted Drug", 
    "validated": true
  }, 
  {
    "alterations": [
      176
    ], 
    "assertion_id": 342, 
    "created_on": null, 
    "description": "Presence of this variant may suggest sensitivity to Selumetinib.", 
    "disease": "Melanoma", 
    "favorable_prognosis": null, 
    "last_updated": "2017-11-03 14:39:02.888073", 
    "old_disease": "Melanoma", 
    "oncotree_code": "MEL", 
    "predictive_implication": "Level B", 
    "sources": [
      115
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "Selumetinib", 
    "therapy_sensitivity": true, 
    "therapy_type": "Targeted Drug", 
    "validated": true
  }, 
  {
    "alterations": [
      177
    ], 
    "assertion_id": 343, 
    "created_on": null, 
    "description": "Presence of this variant may suggest sensitivity to Selumetinib.", 
    "disease": "Melanoma", 
    "favorable_prognosis": null, 
    "last_updated": "2017-11-03 14:39:02.900270", 
    "old_disease": "Melanoma", 
    "oncotree_code": "MEL", 
    "predictive_implication": "Level B", 
    "sources": [
      115
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "Selumetinib", 
    "therapy_sensitivity": true, 
    "therapy_type": "Targeted Drug", 
    "validated": true
  }, 
  {
    "alterations": [
      178
    ], 
    "assertion_id": 344, 
    "created_on": null, 
    "description": "Presence of this variant may suggest sensitivity to Selumetinib.", 
    "disease": "Melanoma", 
    "favorable_prognosis": null, 
    "last_updated": "2017-11-03 14:39:02.910079", 
    "old_disease": "Melanoma", 
    "oncotree_code": "MEL", 
    "predictive_implication": "Level B", 
    "sources": [
      115
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "Selumetinib", 
    "therapy_sensitivity": true, 
    "therapy_type": "Targeted Drug", 
    "validated": true
  }, 
  {
    "alterations": [
      179
    ], 
    "assertion_id": 345, 
    "created_on": null, 
    "description": "Presence of this variant may suggest sensitivity to Selumetinib.", 
    "disease": "Melanoma", 
    "favorable_prognosis": null, 
    "last_updated": "2017-11-03 14:39:02.926958", 
    "old_disease": "Melanoma", 
    "oncotree_code": "MEL", 
    "predictive_implication": "Level B", 
    "sources": [
      115
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "Selumetinib", 
    "therapy_sensitivity": true, 
    "therapy_type": "Targeted Drug", 
    "validated": true
  }, 
  {
    "alterations": [
      180
    ], 
    "assertion_id": 346, 
    "created_on": null, 
    "description": "Presence of this variant may suggest sensitivity to Selumetinib.", 
    "disease": "Melanoma", 
    "favorable_prognosis": null, 
    "last_updated": "2017-11-03 14:39:02.937913", 
    "old_disease": "Melanoma", 
    "oncotree_code": "MEL", 
    "predictive_implication": "Level B", 
    "sources": [
      115
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "Selumetinib", 
    "therapy_sensitivity": true, 
    "therapy_type": "Targeted Drug", 
    "validated": true
  }, 
  {
    "alterations": [
      181
    ], 
    "assertion_id": 347, 
    "created_on": null, 
    "description": "Presence of this variant may suggest sensitivity to Selumetinib.", 
    "disease": "Melanoma", 
    "favorable_prognosis": null, 
    "last_updated": "2017-11-03 14:39:02.949006", 
    "old_disease": "Melanoma", 
    "oncotree_code": "MEL", 
    "predictive_implication": "Level B", 
    "sources": [
      115
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "Selumetinib", 
    "therapy_sensitivity": true, 
    "therapy_type": "Targeted Drug", 
    "validated": true
  }, 
  {
    "alterations": [
      182
    ], 
    "assertion_id": 348, 
    "created_on": null, 
    "description": "Presence of this variant may suggest sensitivity to Selumetinib.", 
    "disease": "Melanoma", 
    "favorable_prognosis": null, 
    "last_updated": "2017-11-03 14:39:02.959306", 
    "old_disease": "Melanoma", 
    "oncotree_code": "MEL", 
    "predictive_implication": "Level B", 
    "sources": [
      115
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "Selumetinib", 
    "therapy_sensitivity": true, 
    "therapy_type": "Targeted Drug", 
    "validated": true
  }, 
  {
    "alterations": [
      183
    ], 
    "assertion_id": 349, 
    "created_on": null, 
    "description": "Presence of this variant may suggest sensitivity to Selumetinib.", 
    "disease": "Melanoma", 
    "favorable_prognosis": null, 
    "last_updated": "2017-11-03 14:39:02.973974", 
    "old_disease": "Melanoma", 
    "oncotree_code": "MEL", 
    "predictive_implication": "Level B", 
    "sources": [
      115
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "Selumetinib", 
    "therapy_sensitivity": true, 
    "therapy_type": "Targeted Drug", 
    "validated": true
  }, 
  {
    "alterations": [
      183
    ], 
    "assertion_id": 350, 
    "created_on": null, 
    "description": "Presence of this variant may suggest sensitivity to Selumetinib.", 
    "disease": "Melanoma", 
    "favorable_prognosis": null, 
    "last_updated": "2017-11-03 14:39:02.983317", 
    "old_disease": "Melanoma", 
    "oncotree_code": "MEL", 
    "predictive_implication": "Level B", 
    "sources": [
      115
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "Selumetinib", 
    "therapy_sensitivity": true, 
    "therapy_type": "Targeted Drug", 
    "validated": true
  }, 
  {
    "alterations": [
      184
    ], 
    "assertion_id": 351, 
    "created_on": null, 
    "description": "Presence of this variant may suggest sensitivity to Selumetinib.", 
    "disease": "Melanoma", 
    "favorable_prognosis": null, 
    "last_updated": "2017-11-03 14:39:02.994446", 
    "old_disease": "Melanoma", 
    "oncotree_code": "MEL", 
    "predictive_implication": "Level B", 
    "sources": [
      115
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "Selumetinib", 
    "therapy_sensitivity": true, 
    "therapy_type": "Targeted Drug", 
    "validated": true
  }, 
  {
    "alterations": [
      185
    ], 
    "assertion_id": 352, 
    "created_on": null, 
    "description": "Presence of this variant may suggest sensitivity to Selumetinib.", 
    "disease": "Melanoma", 
    "favorable_prognosis": null, 
    "last_updated": "2017-11-03 14:39:03.002629", 
    "old_disease": "Melanoma", 
    "oncotree_code": "MEL", 
    "predictive_implication": "Level B", 
    "sources": [
      115
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "Selumetinib", 
    "therapy_sensitivity": true, 
    "therapy_type": "Targeted Drug", 
    "validated": true
  }, 
  {
    "alterations": [
      170
    ], 
    "assertion_id": 353, 
    "created_on": null, 
    "description": "A retrospective study of 677 metastatic melanoma patients found that patients with BRAF and NRAS mutations had a higher risk of CNS involvement at diagnosis of stage IV disease (24% of BRAF and 23% of NRAS compared to 12% WT). Non-uveal melanoma patients tested for mutations within a median 6 months of diagnosis (n=313) showed an association between BRAF and NRAS mutation and a shorter survival (median 8.2 months vs. 15.1 months).", 
    "disease": "Melanoma", 
    "favorable_prognosis": false, 
    "last_updated": "2017-11-03 14:39:03.013473", 
    "old_disease": "Melanoma", 
    "oncotree_code": "MEL", 
    "predictive_implication": "Level B", 
    "sources": [
      116
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "", 
    "therapy_sensitivity": null, 
    "therapy_type": "", 
    "validated": true
  }, 
  {
    "alterations": [
      186
    ], 
    "assertion_id": 354, 
    "created_on": null, 
    "description": "More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.", 
    "disease": "Myelodysplasia ", 
    "favorable_prognosis": false, 
    "last_updated": "2017-11-03 14:39:03.028923", 
    "old_disease": "Myelodysplastic Syndromes", 
    "oncotree_code": "MDS", 
    "predictive_implication": "Level B", 
    "sources": [
      11
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "", 
    "therapy_sensitivity": null, 
    "therapy_type": "", 
    "validated": true
  }, 
  {
    "alterations": [
      187
    ], 
    "assertion_id": 355, 
    "created_on": null, 
    "description": "More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.", 
    "disease": "Myelodysplasia ", 
    "favorable_prognosis": false, 
    "last_updated": "2017-11-03 14:39:03.044235", 
    "old_disease": "Myelodysplastic Syndromes", 
    "oncotree_code": "MDS", 
    "predictive_implication": "Level B", 
    "sources": [
      11
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "", 
    "therapy_sensitivity": null, 
    "therapy_type": "", 
    "validated": true
  }, 
  {
    "alterations": [
      188
    ], 
    "assertion_id": 356, 
    "created_on": null, 
    "description": "More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.", 
    "disease": "Myelodysplasia ", 
    "favorable_prognosis": false, 
    "last_updated": "2017-11-03 14:39:03.055816", 
    "old_disease": "Myelodysplastic Syndromes", 
    "oncotree_code": "MDS", 
    "predictive_implication": "Level B", 
    "sources": [
      11
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "", 
    "therapy_sensitivity": null, 
    "therapy_type": "", 
    "validated": true
  }, 
  {
    "alterations": [
      189
    ], 
    "assertion_id": 357, 
    "created_on": null, 
    "description": "NTRK fusions may respond to NTRK inhibitors", 
    "disease": "", 
    "favorable_prognosis": null, 
    "last_updated": "2017-11-03 14:39:03.070253", 
    "old_disease": "", 
    "oncotree_code": "", 
    "predictive_implication": "Level B", 
    "sources": [
      117
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "Entrectinib", 
    "therapy_sensitivity": true, 
    "therapy_type": "Targeted Drug", 
    "validated": true
  }, 
  {
    "alterations": [
      190
    ], 
    "assertion_id": 358, 
    "created_on": null, 
    "description": "NTRK fusions may respond to NTRK inhibitors", 
    "disease": "", 
    "favorable_prognosis": null, 
    "last_updated": "2017-11-03 14:39:03.086505", 
    "old_disease": "", 
    "oncotree_code": "", 
    "predictive_implication": "Level B", 
    "sources": [
      117
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "Entrectinib", 
    "therapy_sensitivity": true, 
    "therapy_type": "Targeted Drug", 
    "validated": true
  }, 
  {
    "alterations": [
      191
    ], 
    "assertion_id": 359, 
    "created_on": null, 
    "description": "NTRK fusions may respond to NTRK inhibitors", 
    "disease": "", 
    "favorable_prognosis": null, 
    "last_updated": "2017-11-03 14:39:03.100763", 
    "old_disease": "", 
    "oncotree_code": "", 
    "predictive_implication": "Level B", 
    "sources": [
      117
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "Entrectinib", 
    "therapy_sensitivity": true, 
    "therapy_type": "Targeted Drug", 
    "validated": true
  }, 
  {
    "alterations": [
      192
    ], 
    "assertion_id": 360, 
    "created_on": null, 
    "description": "PAK1 amplification showed reduced recurrence-free survival and decreased benefit from Tamoxifen in a randomized control trial of postmenopausal breast cancer patients.", 
    "disease": "Invasive Breast Carcinoma", 
    "favorable_prognosis": false, 
    "last_updated": "2017-11-03 14:39:03.111164", 
    "old_disease": "Breast Cancer", 
    "oncotree_code": "BRCA", 
    "predictive_implication": "Level A", 
    "sources": [
      50
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "Tamoxifen", 
    "therapy_sensitivity": false, 
    "therapy_type": "Targeted Drug", 
    "validated": true
  }, 
  {
    "alterations": [
      193
    ], 
    "assertion_id": 361, 
    "created_on": null, 
    "description": "Somatic homologous recombination mutations werepredictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.", 
    "disease": "Ovarian Cancer, Other", 
    "favorable_prognosis": null, 
    "last_updated": "2017-11-03 14:39:03.122900", 
    "old_disease": "Ovarian Cancer", 
    "oncotree_code": "OOVC", 
    "predictive_implication": "Level E", 
    "sources": [
      15
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "Platinum", 
    "therapy_sensitivity": true, 
    "therapy_type": "Chemotherapy", 
    "validated": true
  }, 
  {
    "alterations": [
      194
    ], 
    "assertion_id": 362, 
    "created_on": null, 
    "description": "Germline homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas. Mutant cases also had better overall survival than wild type.", 
    "disease": "Ovarian Cancer, Other", 
    "favorable_prognosis": true, 
    "last_updated": "2017-11-03 14:39:03.135260", 
    "old_disease": "Ovarian Cancer", 
    "oncotree_code": "OOVC", 
    "predictive_implication": "Level E", 
    "sources": [
      15
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "Platinum", 
    "therapy_sensitivity": null, 
    "therapy_type": "Chemotherapy", 
    "validated": true
  }, 
  {
    "alterations": [
      193
    ], 
    "assertion_id": 363, 
    "created_on": null, 
    "description": "Somatic homologous recombination mutations werepredictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.", 
    "disease": "Ovarian Cancer, Other", 
    "favorable_prognosis": true, 
    "last_updated": "2017-11-03 14:39:03.146594", 
    "old_disease": "Ovarian Cancer", 
    "oncotree_code": "OOVC", 
    "predictive_implication": "Level E", 
    "sources": [
      15
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "Platinum", 
    "therapy_sensitivity": null, 
    "therapy_type": "Chemotherapy", 
    "validated": true
  }, 
  {
    "alterations": [
      194
    ], 
    "assertion_id": 364, 
    "created_on": null, 
    "description": "Germline homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas. Mutant cases also had better overall survival than wild type.", 
    "disease": "Ovarian Cancer, Other", 
    "favorable_prognosis": true, 
    "last_updated": "2017-11-03 14:39:03.154367", 
    "old_disease": "Ovarian Cancer", 
    "oncotree_code": "OOVC", 
    "predictive_implication": "Level E", 
    "sources": [
      15
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "Platinum", 
    "therapy_sensitivity": null, 
    "therapy_type": "Chemotherapy", 
    "validated": true
  }, 
  {
    "alterations": [
      193
    ], 
    "assertion_id": 365, 
    "created_on": null, 
    "description": "When present alongside genomic instability, the inactivation of DNA maintenance genes (BRCA1, BRCA2, or PALB2) was associated with increased sensitivity to platinum therapy in pancreatic cancer patients.", 
    "disease": "Pancreatic Adenocarcinoma", 
    "favorable_prognosis": null, 
    "last_updated": "2017-11-03 14:39:03.162003", 
    "old_disease": "Pancreatic Cancer", 
    "oncotree_code": "PAAD", 
    "predictive_implication": "Level A", 
    "sources": [
      43
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "Platins", 
    "therapy_sensitivity": true, 
    "therapy_type": "Drug Class", 
    "validated": true
  }, 
  {
    "alterations": [
      193
    ], 
    "assertion_id": 366, 
    "created_on": null, 
    "description": "Somatic homologous recombination mutations werepredictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.", 
    "disease": "Peritoneal Mesothelioma", 
    "favorable_prognosis": null, 
    "last_updated": "2017-11-03 14:39:03.169054", 
    "old_disease": "Peritoneal Carcinoma", 
    "oncotree_code": "PEMESO", 
    "predictive_implication": "Level E", 
    "sources": [
      15
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "Platinum", 
    "therapy_sensitivity": true, 
    "therapy_type": "Chemotherapy", 
    "validated": true
  }, 
  {
    "alterations": [
      194
    ], 
    "assertion_id": 367, 
    "created_on": null, 
    "description": "Germline homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas. Mutant cases also had better overall survival than wild type.", 
    "disease": "Peritoneal Mesothelioma", 
    "favorable_prognosis": true, 
    "last_updated": "2017-11-03 14:39:03.177179", 
    "old_disease": "Peritoneal Carcinoma", 
    "oncotree_code": "PEMESO", 
    "predictive_implication": "Level E", 
    "sources": [
      15
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "Platinum", 
    "therapy_sensitivity": null, 
    "therapy_type": "Chemotherapy", 
    "validated": true
  }, 
  {
    "alterations": [
      193
    ], 
    "assertion_id": 368, 
    "created_on": null, 
    "description": "Somatic homologous recombination mutations werepredictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.", 
    "disease": "Peritoneal Mesothelioma", 
    "favorable_prognosis": true, 
    "last_updated": "2017-11-03 14:39:03.186197", 
    "old_disease": "Peritoneal Carcinoma", 
    "oncotree_code": "PEMESO", 
    "predictive_implication": "Level E", 
    "sources": [
      15
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "Platinum", 
    "therapy_sensitivity": null, 
    "therapy_type": "Chemotherapy", 
    "validated": true
  }, 
  {
    "alterations": [
      194
    ], 
    "assertion_id": 369, 
    "created_on": null, 
    "description": "Germline homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas. Mutant cases also had better overall survival than wild type.", 
    "disease": "Peritoneal Mesothelioma", 
    "favorable_prognosis": true, 
    "last_updated": "2017-11-03 14:39:03.199842", 
    "old_disease": "Peritoneal Carcinoma", 
    "oncotree_code": "PEMESO", 
    "predictive_implication": "Level E", 
    "sources": [
      15
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "Platinum", 
    "therapy_sensitivity": null, 
    "therapy_type": "Chemotherapy", 
    "validated": true
  }, 
  {
    "alterations": [
      193
    ], 
    "assertion_id": 370, 
    "created_on": null, 
    "description": "Somatic homologous recombination mutations werepredictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.", 
    "disease": "Serous Ovarian Cancer", 
    "favorable_prognosis": null, 
    "last_updated": "2017-11-03 14:39:03.209650", 
    "old_disease": "Fallopian Tube Carcinoma", 
    "oncotree_code": "SOC", 
    "predictive_implication": "Level E", 
    "sources": [
      15
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "Platinum", 
    "therapy_sensitivity": true, 
    "therapy_type": "Chemotherapy", 
    "validated": true
  }, 
  {
    "alterations": [
      194
    ], 
    "assertion_id": 371, 
    "created_on": null, 
    "description": "Germline homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas. Mutant cases also had better overall survival than wild type.", 
    "disease": "Serous Ovarian Cancer", 
    "favorable_prognosis": true, 
    "last_updated": "2017-11-03 14:39:03.217032", 
    "old_disease": "Fallopian Tube Carcinoma", 
    "oncotree_code": "SOC", 
    "predictive_implication": "Level E", 
    "sources": [
      15
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "Platinum", 
    "therapy_sensitivity": null, 
    "therapy_type": "Chemotherapy", 
    "validated": true
  }, 
  {
    "alterations": [
      193
    ], 
    "assertion_id": 372, 
    "created_on": null, 
    "description": "Somatic homologous recombination mutations werepredictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.", 
    "disease": "Serous Ovarian Cancer", 
    "favorable_prognosis": true, 
    "last_updated": "2017-11-03 14:39:03.224545", 
    "old_disease": "Fallopian Tube Carcinoma", 
    "oncotree_code": "SOC", 
    "predictive_implication": "Level E", 
    "sources": [
      15
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "Platinum", 
    "therapy_sensitivity": null, 
    "therapy_type": "Chemotherapy", 
    "validated": true
  }, 
  {
    "alterations": [
      194
    ], 
    "assertion_id": 373, 
    "created_on": null, 
    "description": "Germline homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas. Mutant cases also had better overall survival than wild type.", 
    "disease": "Serous Ovarian Cancer", 
    "favorable_prognosis": true, 
    "last_updated": "2017-11-03 14:39:03.232710", 
    "old_disease": "Fallopian Tube Carcinoma", 
    "oncotree_code": "SOC", 
    "predictive_implication": "Level E", 
    "sources": [
      15
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "Platinum", 
    "therapy_sensitivity": null, 
    "therapy_type": "Chemotherapy", 
    "validated": true
  }, 
  {
    "alterations": [
      195
    ], 
    "assertion_id": 374, 
    "created_on": null, 
    "description": "Loss of function PBRM1 mutations may predict sensitivity to VEGF inhibitors in advanced clear cell renal cell carcinoma", 
    "disease": "Renal Cell Carcinoma", 
    "favorable_prognosis": null, 
    "last_updated": "2017-11-03 14:39:03.243233", 
    "old_disease": "Renal cell carcinoma", 
    "oncotree_code": "RCC", 
    "predictive_implication": "Level D", 
    "sources": [
      118
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "VEGF inhibitors", 
    "therapy_sensitivity": true, 
    "therapy_type": "Drug Class", 
    "validated": true
  }, 
  {
    "alterations": [
      196
    ], 
    "assertion_id": 375, 
    "created_on": null, 
    "description": "Loss of function PBRM1 mutations may predict sensitivity to VEGF inhibitors in advanced clear cell renal cell carcinoma", 
    "disease": "Renal Cell Carcinoma", 
    "favorable_prognosis": null, 
    "last_updated": "2017-11-03 14:39:03.259626", 
    "old_disease": "Renal cell carcinoma", 
    "oncotree_code": "RCC", 
    "predictive_implication": "Level D", 
    "sources": [
      118
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "VEGF inhibitors", 
    "therapy_sensitivity": true, 
    "therapy_type": "Drug Class", 
    "validated": true
  }, 
  {
    "alterations": [
      197
    ], 
    "assertion_id": 376, 
    "created_on": null, 
    "description": "PDGFRB translocations are associated with sensitivity to imatinib in Chronic Myelomonocytic Leuekmia.", 
    "disease": "Myelodysplasia ", 
    "favorable_prognosis": null, 
    "last_updated": "2017-11-03 14:39:03.271332", 
    "old_disease": "Myelodysplastic Syndromes", 
    "oncotree_code": "MDS", 
    "predictive_implication": "FDA-Approved", 
    "sources": [
      11
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "Imatinib", 
    "therapy_sensitivity": true, 
    "therapy_type": "Targeted Drug", 
    "validated": true
  }, 
  {
    "alterations": [
      198
    ], 
    "assertion_id": 377, 
    "created_on": null, 
    "description": "PGC1A silencing causes poorly metastatic melanoma cells to become invasive, while PGC1A rescue suppresses metastasis in human melanoma tumor samples.", 
    "disease": "Melanoma", 
    "favorable_prognosis": false, 
    "last_updated": "2017-11-03 14:39:03.283186", 
    "old_disease": "Melanoma", 
    "oncotree_code": "MEL", 
    "predictive_implication": "Level D", 
    "sources": [
      119
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "", 
    "therapy_sensitivity": null, 
    "therapy_type": "", 
    "validated": true
  }, 
  {
    "alterations": [
      199
    ], 
    "assertion_id": 378, 
    "created_on": null, 
    "description": "A heavily-pretreated, platinum-refractory ovarian cancer patient with PIK3CA amplification achieved radiologically stable disease for four months in a phase 1 clinical trial of pictisilib in solid tumors (RP2D of 330mg daily).", 
    "disease": "Ovarian Cancer, Other", 
    "favorable_prognosis": null, 
    "last_updated": "2017-11-03 14:39:03.294022", 
    "old_disease": "Ovarian Cancer", 
    "oncotree_code": "OOVC", 
    "predictive_implication": "Level A", 
    "sources": [
      120
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "Pictilisib", 
    "therapy_sensitivity": true, 
    "therapy_type": "Targeted Drug", 
    "validated": true
  }, 
  {
    "alterations": [
      200
    ], 
    "assertion_id": 379, 
    "created_on": null, 
    "description": "PIK3CA, but not AKT1 mutation, increased sensitivity to the PI3K inhibitor GDC-0941 and the allosteric AKT inhibitor MK-2206", 
    "disease": "Breast Invasive Ductal Carcinoma", 
    "favorable_prognosis": null, 
    "last_updated": "2017-11-03 14:39:03.311711", 
    "old_disease": "Breast Cancer", 
    "oncotree_code": "IDC", 
    "predictive_implication": "Level D", 
    "sources": [
      121
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "GDC-0941", 
    "therapy_sensitivity": true, 
    "therapy_type": "Targeted Drug", 
    "validated": true
  }, 
  {
    "alterations": [
      201
    ], 
    "assertion_id": 380, 
    "created_on": null, 
    "description": "In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.", 
    "disease": "Invasive Breast Carcinoma", 
    "favorable_prognosis": null, 
    "last_updated": "2017-11-03 14:39:03.323734", 
    "old_disease": "Breast Cancer", 
    "oncotree_code": "BRCA", 
    "predictive_implication": "Level D", 
    "sources": [
      122
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "Pictilisib", 
    "therapy_sensitivity": true, 
    "therapy_type": "Targeted Drug", 
    "validated": true
  }, 
  {
    "alterations": [
      202
    ], 
    "assertion_id": 381, 
    "created_on": null, 
    "description": "In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.", 
    "disease": "Invasive Breast Carcinoma", 
    "favorable_prognosis": null, 
    "last_updated": "2017-11-03 14:39:03.332854", 
    "old_disease": "Breast Cancer", 
    "oncotree_code": "BRCA", 
    "predictive_implication": "Level D", 
    "sources": [
      122
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "Pictilisib", 
    "therapy_sensitivity": true, 
    "therapy_type": "Targeted Drug", 
    "validated": true
  }, 
  {
    "alterations": [
      203
    ], 
    "assertion_id": 382, 
    "created_on": null, 
    "description": "In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.", 
    "disease": "Invasive Breast Carcinoma", 
    "favorable_prognosis": null, 
    "last_updated": "2017-11-03 14:39:03.342883", 
    "old_disease": "Breast Cancer", 
    "oncotree_code": "BRCA", 
    "predictive_implication": "Level D", 
    "sources": [
      122
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "Pictilisib", 
    "therapy_sensitivity": true, 
    "therapy_type": "Targeted Drug", 
    "validated": true
  }, 
  {
    "alterations": [
      204
    ], 
    "assertion_id": 383, 
    "created_on": null, 
    "description": "In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.", 
    "disease": "Invasive Breast Carcinoma", 
    "favorable_prognosis": null, 
    "last_updated": "2017-11-03 14:39:03.359084", 
    "old_disease": "Breast Cancer", 
    "oncotree_code": "BRCA", 
    "predictive_implication": "Level D", 
    "sources": [
      122
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "Pictilisib", 
    "therapy_sensitivity": true, 
    "therapy_type": "Targeted Drug", 
    "validated": true
  }, 
  {
    "alterations": [
      205
    ], 
    "assertion_id": 384, 
    "created_on": null, 
    "description": "In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.", 
    "disease": "Invasive Breast Carcinoma", 
    "favorable_prognosis": null, 
    "last_updated": "2017-11-03 14:39:03.370497", 
    "old_disease": "Breast Cancer", 
    "oncotree_code": "BRCA", 
    "predictive_implication": "Level D", 
    "sources": [
      122
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "Pictilisib", 
    "therapy_sensitivity": true, 
    "therapy_type": "Targeted Drug", 
    "validated": true
  }, 
  {
    "alterations": [
      205
    ], 
    "assertion_id": 385, 
    "created_on": null, 
    "description": "In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.", 
    "disease": "Invasive Breast Carcinoma", 
    "favorable_prognosis": null, 
    "last_updated": "2017-11-03 14:39:03.378836", 
    "old_disease": "Breast Cancer", 
    "oncotree_code": "BRCA", 
    "predictive_implication": "Level D", 
    "sources": [
      122
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "Pictilisib", 
    "therapy_sensitivity": true, 
    "therapy_type": "Targeted Drug", 
    "validated": true
  }, 
  {
    "alterations": [
      206
    ], 
    "assertion_id": 386, 
    "created_on": null, 
    "description": "In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.", 
    "disease": "Invasive Breast Carcinoma", 
    "favorable_prognosis": null, 
    "last_updated": "2017-11-03 14:39:03.387122", 
    "old_disease": "Breast Cancer", 
    "oncotree_code": "BRCA", 
    "predictive_implication": "Level D", 
    "sources": [
      122
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "Pictilisib", 
    "therapy_sensitivity": true, 
    "therapy_type": "Targeted Drug", 
    "validated": true
  }, 
  {
    "alterations": [
      207
    ], 
    "assertion_id": 387, 
    "created_on": null, 
    "description": "In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.", 
    "disease": "Invasive Breast Carcinoma", 
    "favorable_prognosis": null, 
    "last_updated": "2017-11-03 14:39:03.397260", 
    "old_disease": "Breast Cancer", 
    "oncotree_code": "BRCA", 
    "predictive_implication": "Level D", 
    "sources": [
      122
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "Pictilisib", 
    "therapy_sensitivity": true, 
    "therapy_type": "Targeted Drug", 
    "validated": true
  }, 
  {
    "alterations": [
      208
    ], 
    "assertion_id": 388, 
    "created_on": null, 
    "description": "In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.", 
    "disease": "Invasive Breast Carcinoma", 
    "favorable_prognosis": null, 
    "last_updated": "2017-11-03 14:39:03.411412", 
    "old_disease": "Breast Cancer", 
    "oncotree_code": "BRCA", 
    "predictive_implication": "Level D", 
    "sources": [
      122
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "Pictilisib", 
    "therapy_sensitivity": true, 
    "therapy_type": "Targeted Drug", 
    "validated": true
  }, 
  {
    "alterations": [
      209
    ], 
    "assertion_id": 389, 
    "created_on": null, 
    "description": "In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.", 
    "disease": "Invasive Breast Carcinoma", 
    "favorable_prognosis": null, 
    "last_updated": "2017-11-03 14:39:03.424810", 
    "old_disease": "Breast Cancer", 
    "oncotree_code": "BRCA", 
    "predictive_implication": "Level D", 
    "sources": [
      122
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "Pictilisib", 
    "therapy_sensitivity": true, 
    "therapy_type": "Targeted Drug", 
    "validated": true
  }, 
  {
    "alterations": [
      210
    ], 
    "assertion_id": 390, 
    "created_on": null, 
    "description": "In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.", 
    "disease": "Invasive Breast Carcinoma", 
    "favorable_prognosis": null, 
    "last_updated": "2017-11-03 14:39:03.434223", 
    "old_disease": "Breast Cancer", 
    "oncotree_code": "BRCA", 
    "predictive_implication": "Level D", 
    "sources": [
      122
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "Pictilisib", 
    "therapy_sensitivity": true, 
    "therapy_type": "Targeted Drug", 
    "validated": true
  }, 
  {
    "alterations": [
      211
    ], 
    "assertion_id": 391, 
    "created_on": null, 
    "description": "In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.", 
    "disease": "Invasive Breast Carcinoma", 
    "favorable_prognosis": null, 
    "last_updated": "2017-11-03 14:39:03.443660", 
    "old_disease": "Breast Cancer", 
    "oncotree_code": "BRCA", 
    "predictive_implication": "Level D", 
    "sources": [
      122
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "Pictilisib", 
    "therapy_sensitivity": true, 
    "therapy_type": "Targeted Drug", 
    "validated": true
  }, 
  {
    "alterations": [
      212
    ], 
    "assertion_id": 392, 
    "created_on": null, 
    "description": "In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.", 
    "disease": "Invasive Breast Carcinoma", 
    "favorable_prognosis": null, 
    "last_updated": "2017-11-03 14:39:03.454818", 
    "old_disease": "Breast Cancer", 
    "oncotree_code": "BRCA", 
    "predictive_implication": "Level D", 
    "sources": [
      122
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "Pictilisib", 
    "therapy_sensitivity": true, 
    "therapy_type": "Targeted Drug", 
    "validated": true
  }, 
  {
    "alterations": [
      213
    ], 
    "assertion_id": 393, 
    "created_on": null, 
    "description": "In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.", 
    "disease": "Invasive Breast Carcinoma", 
    "favorable_prognosis": null, 
    "last_updated": "2017-11-03 14:39:03.470301", 
    "old_disease": "Breast Cancer", 
    "oncotree_code": "BRCA", 
    "predictive_implication": "Level D", 
    "sources": [
      122
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "Pictilisib", 
    "therapy_sensitivity": true, 
    "therapy_type": "Targeted Drug", 
    "validated": true
  }, 
  {
    "alterations": [
      214
    ], 
    "assertion_id": 394, 
    "created_on": null, 
    "description": "In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.", 
    "disease": "Invasive Breast Carcinoma", 
    "favorable_prognosis": null, 
    "last_updated": "2017-11-03 14:39:03.484801", 
    "old_disease": "Breast Cancer", 
    "oncotree_code": "BRCA", 
    "predictive_implication": "Level D", 
    "sources": [
      122
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "Pictilisib", 
    "therapy_sensitivity": true, 
    "therapy_type": "Targeted Drug", 
    "validated": true
  }, 
  {
    "alterations": [
      215
    ], 
    "assertion_id": 395, 
    "created_on": null, 
    "description": "In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.", 
    "disease": "Invasive Breast Carcinoma", 
    "favorable_prognosis": null, 
    "last_updated": "2017-11-03 14:39:03.494948", 
    "old_disease": "Breast Cancer", 
    "oncotree_code": "BRCA", 
    "predictive_implication": "Level D", 
    "sources": [
      122
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "Pictilisib", 
    "therapy_sensitivity": true, 
    "therapy_type": "Targeted Drug", 
    "validated": true
  }, 
  {
    "alterations": [
      216
    ], 
    "assertion_id": 396, 
    "created_on": null, 
    "description": "In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.", 
    "disease": "Invasive Breast Carcinoma", 
    "favorable_prognosis": null, 
    "last_updated": "2017-11-03 14:39:03.505225", 
    "old_disease": "Breast Cancer", 
    "oncotree_code": "BRCA", 
    "predictive_implication": "Level D", 
    "sources": [
      122
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "Pictilisib", 
    "therapy_sensitivity": true, 
    "therapy_type": "Targeted Drug", 
    "validated": true
  }, 
  {
    "alterations": [
      217
    ], 
    "assertion_id": 397, 
    "created_on": null, 
    "description": "In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.", 
    "disease": "Invasive Breast Carcinoma", 
    "favorable_prognosis": null, 
    "last_updated": "2017-11-03 14:39:03.515383", 
    "old_disease": "Breast Cancer", 
    "oncotree_code": "BRCA", 
    "predictive_implication": "Level D", 
    "sources": [
      122
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "Pictilisib", 
    "therapy_sensitivity": true, 
    "therapy_type": "Targeted Drug", 
    "validated": true
  }, 
  {
    "alterations": [
      217
    ], 
    "assertion_id": 398, 
    "created_on": null, 
    "description": "In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.", 
    "disease": "Invasive Breast Carcinoma", 
    "favorable_prognosis": null, 
    "last_updated": "2017-11-03 14:39:03.529887", 
    "old_disease": "Breast Cancer", 
    "oncotree_code": "BRCA", 
    "predictive_implication": "Level D", 
    "sources": [
      122
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "Pictilisib", 
    "therapy_sensitivity": true, 
    "therapy_type": "Targeted Drug", 
    "validated": true
  }, 
  {
    "alterations": [
      218
    ], 
    "assertion_id": 399, 
    "created_on": null, 
    "description": "In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.", 
    "disease": "Invasive Breast Carcinoma", 
    "favorable_prognosis": null, 
    "last_updated": "2017-11-03 14:39:03.542303", 
    "old_disease": "Breast Cancer", 
    "oncotree_code": "BRCA", 
    "predictive_implication": "Level D", 
    "sources": [
      122
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "Pictilisib", 
    "therapy_sensitivity": true, 
    "therapy_type": "Targeted Drug", 
    "validated": true
  }, 
  {
    "alterations": [
      219
    ], 
    "assertion_id": 400, 
    "created_on": null, 
    "description": "In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.", 
    "disease": "Invasive Breast Carcinoma", 
    "favorable_prognosis": null, 
    "last_updated": "2017-11-03 14:39:03.551179", 
    "old_disease": "Breast Cancer", 
    "oncotree_code": "BRCA", 
    "predictive_implication": "Level D", 
    "sources": [
      122
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "Pictilisib", 
    "therapy_sensitivity": true, 
    "therapy_type": "Targeted Drug", 
    "validated": true
  }, 
  {
    "alterations": [
      220
    ], 
    "assertion_id": 401, 
    "created_on": null, 
    "description": "In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.", 
    "disease": "Invasive Breast Carcinoma", 
    "favorable_prognosis": null, 
    "last_updated": "2017-11-03 14:39:03.560654", 
    "old_disease": "Breast Cancer", 
    "oncotree_code": "BRCA", 
    "predictive_implication": "Level D", 
    "sources": [
      122
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "Pictilisib", 
    "therapy_sensitivity": true, 
    "therapy_type": "Targeted Drug", 
    "validated": true
  }, 
  {
    "alterations": [
      221
    ], 
    "assertion_id": 402, 
    "created_on": null, 
    "description": "In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.", 
    "disease": "Invasive Breast Carcinoma", 
    "favorable_prognosis": null, 
    "last_updated": "2017-11-03 14:39:03.575211", 
    "old_disease": "Breast Cancer", 
    "oncotree_code": "BRCA", 
    "predictive_implication": "Level D", 
    "sources": [
      122
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "Pictilisib", 
    "therapy_sensitivity": true, 
    "therapy_type": "Targeted Drug", 
    "validated": true
  }, 
  {
    "alterations": [
      222
    ], 
    "assertion_id": 403, 
    "created_on": null, 
    "description": "PIK3CB mutations may confer sensitivity to selective PI3K inhibition", 
    "disease": "", 
    "favorable_prognosis": null, 
    "last_updated": "2017-11-03 14:39:03.590116", 
    "old_disease": "", 
    "oncotree_code": "", 
    "predictive_implication": "Level D", 
    "sources": [
      123
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "AZD8186", 
    "therapy_sensitivity": true, 
    "therapy_type": "Targeted Drug", 
    "validated": true
  }, 
  {
    "alterations": [
      223
    ], 
    "assertion_id": 404, 
    "created_on": null, 
    "description": "Patients with defects in DNA mismatch repair genes often have a favorable prognosis and a decreased likelihood of metastasis. These patients do not benefit from, and may be resistant to, 5-fluorouracil therapy.", 
    "disease": "Colorectal Adenocarcinoma", 
    "favorable_prognosis": true, 
    "last_updated": "2017-11-03 14:39:03.600990", 
    "old_disease": "Colorectal Cancer", 
    "oncotree_code": "COADREAD", 
    "predictive_implication": "Level B", 
    "sources": [
      21
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "5-Fluorouracil", 
    "therapy_sensitivity": null, 
    "therapy_type": "Targeted Drug", 
    "validated": true
  }, 
  {
    "alterations": [
      224
    ], 
    "assertion_id": 405, 
    "created_on": null, 
    "description": "Patients whose tumors contain DNA repair deficiencies may benefit from anti-PD-1 therapy. MMR deficient colorectal and noncolorectal cancer were enriched for partial response to Pembrolizumab in a cohort of 41 patients.", 
    "disease": "Colorectal Adenocarcinoma", 
    "favorable_prognosis": null, 
    "last_updated": "2017-11-03 14:39:03.610799", 
    "old_disease": "Colorectal Cancer", 
    "oncotree_code": "COADREAD", 
    "predictive_implication": "Level E", 
    "sources": [
      112
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "Pembrolizumab", 
    "therapy_sensitivity": true, 
    "therapy_type": "Immunotherapy", 
    "validated": true
  }, 
  {
    "alterations": [
      225
    ], 
    "assertion_id": 406, 
    "created_on": null, 
    "description": "A study of 529 patients with hereditary CRC were found to have an increased susceptibility to brain tumors.", 
    "disease": "Colorectal Adenocarcinoma", 
    "favorable_prognosis": false, 
    "last_updated": "2017-11-03 14:39:03.623725", 
    "old_disease": "Colorectal Cancer", 
    "oncotree_code": "COADREAD", 
    "predictive_implication": "Level B", 
    "sources": [
      124
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "", 
    "therapy_sensitivity": null, 
    "therapy_type": "", 
    "validated": true
  }, 
  {
    "alterations": [
      226
    ], 
    "assertion_id": 407, 
    "created_on": null, 
    "description": "A study of 529 patients with hereditary CRC were found to have an increased susceptibility to brain tumors.", 
    "disease": "Colorectal Adenocarcinoma", 
    "favorable_prognosis": false, 
    "last_updated": "2017-11-03 14:39:03.638804", 
    "old_disease": "Colorectal Cancer", 
    "oncotree_code": "COADREAD", 
    "predictive_implication": "Level B", 
    "sources": [
      124
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "", 
    "therapy_sensitivity": null, 
    "therapy_type": "", 
    "validated": true
  }, 
  {
    "alterations": [
      227
    ], 
    "assertion_id": 408, 
    "created_on": null, 
    "description": "A study of 529 patients with hereditary CRC were found to have an increased susceptibility to brain tumors.", 
    "disease": "Colorectal Adenocarcinoma", 
    "favorable_prognosis": false, 
    "last_updated": "2017-11-03 14:39:03.651497", 
    "old_disease": "Colorectal Cancer", 
    "oncotree_code": "COADREAD", 
    "predictive_implication": "Level B", 
    "sources": [
      124
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "", 
    "therapy_sensitivity": null, 
    "therapy_type": "", 
    "validated": true
  }, 
  {
    "alterations": [
      228
    ], 
    "assertion_id": 409, 
    "created_on": null, 
    "description": "A study of 529 patients with hereditary CRC were found to have an increased susceptibility to brain tumors.", 
    "disease": "Colorectal Adenocarcinoma", 
    "favorable_prognosis": false, 
    "last_updated": "2017-11-03 14:39:03.660806", 
    "old_disease": "Colorectal Cancer", 
    "oncotree_code": "COADREAD", 
    "predictive_implication": "Level B", 
    "sources": [
      124
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "", 
    "therapy_sensitivity": null, 
    "therapy_type": "", 
    "validated": true
  }, 
  {
    "alterations": [
      229
    ], 
    "assertion_id": 410, 
    "created_on": null, 
    "description": "A study of 529 patients with hereditary CRC were found to have an increased susceptibility to brain tumors.", 
    "disease": "Colorectal Adenocarcinoma", 
    "favorable_prognosis": false, 
    "last_updated": "2017-11-03 14:39:03.673963", 
    "old_disease": "Colorectal Cancer", 
    "oncotree_code": "COADREAD", 
    "predictive_implication": "Level B", 
    "sources": [
      124
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "", 
    "therapy_sensitivity": null, 
    "therapy_type": "", 
    "validated": true
  }, 
  {
    "alterations": [
      230
    ], 
    "assertion_id": 411, 
    "created_on": null, 
    "description": "Patients whose tumors contain DNA repair deficiencies may benefit from anti-PD-1 therapy. MMR deficient colorectal and noncolorectal cancer were enriched for partial response to Pembrolizumab in a cohort of 41 patients.", 
    "disease": "Colorectal Adenocarcinoma", 
    "favorable_prognosis": null, 
    "last_updated": "2017-11-03 14:39:03.689297", 
    "old_disease": "Colorectal Cancer", 
    "oncotree_code": "COADREAD", 
    "predictive_implication": "Level E", 
    "sources": [
      112
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "Pembrolizumab", 
    "therapy_sensitivity": true, 
    "therapy_type": "Immunotherapy", 
    "validated": true
  }, 
  {
    "alterations": [
      231
    ], 
    "assertion_id": 412, 
    "created_on": null, 
    "description": "Mutation may indicate increased susceptibility to early-onset colorectal cancer.", 
    "disease": "Colorectal Adenocarcinoma", 
    "favorable_prognosis": false, 
    "last_updated": "2017-11-03 14:39:03.703011", 
    "old_disease": "Colorectal Cancer", 
    "oncotree_code": "COADREAD", 
    "predictive_implication": "Level B", 
    "sources": [
      87
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "", 
    "therapy_sensitivity": null, 
    "therapy_type": "", 
    "validated": true
  }, 
  {
    "alterations": [
      232
    ], 
    "assertion_id": 413, 
    "created_on": null, 
    "description": "Mutation may indicate increased susceptibility to early-onset colorectal cancer.", 
    "disease": "Colorectal Adenocarcinoma", 
    "favorable_prognosis": false, 
    "last_updated": "2017-11-03 14:39:03.714012", 
    "old_disease": "Colorectal Cancer", 
    "oncotree_code": "COADREAD", 
    "predictive_implication": "Level B", 
    "sources": [
      87
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "", 
    "therapy_sensitivity": null, 
    "therapy_type": "", 
    "validated": true
  }, 
  {
    "alterations": [
      233
    ], 
    "assertion_id": 414, 
    "created_on": null, 
    "description": "Mutation may indicate increased susceptibility to early-onset colorectal cancer.", 
    "disease": "Colorectal Adenocarcinoma", 
    "favorable_prognosis": false, 
    "last_updated": "2017-11-03 14:39:03.725298", 
    "old_disease": "Colorectal Cancer", 
    "oncotree_code": "COADREAD", 
    "predictive_implication": "Level B", 
    "sources": [
      87
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "", 
    "therapy_sensitivity": null, 
    "therapy_type": "", 
    "validated": true
  }, 
  {
    "alterations": [
      234
    ], 
    "assertion_id": 415, 
    "created_on": null, 
    "description": "Mutation may indicate increased susceptibility to early-onset colorectal cancer.", 
    "disease": "Colorectal Adenocarcinoma", 
    "favorable_prognosis": false, 
    "last_updated": "2017-11-03 14:39:03.741146", 
    "old_disease": "Colorectal Cancer", 
    "oncotree_code": "COADREAD", 
    "predictive_implication": "Level B", 
    "sources": [
      87
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "", 
    "therapy_sensitivity": null, 
    "therapy_type": "", 
    "validated": true
  }, 
  {
    "alterations": [
      235
    ], 
    "assertion_id": 416, 
    "created_on": null, 
    "description": "", 
    "disease": "Myelodysplasia ", 
    "favorable_prognosis": false, 
    "last_updated": "2017-11-03 14:39:03.755747", 
    "old_disease": "Myelodysplastic Syndromes", 
    "oncotree_code": "MDS", 
    "predictive_implication": "Level B", 
    "sources": [
      11
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "", 
    "therapy_sensitivity": null, 
    "therapy_type": "", 
    "validated": true
  }, 
  {
    "alterations": [
      236
    ], 
    "assertion_id": 417, 
    "created_on": null, 
    "description": "PTEN loss in the setting of KRAS G12D mutation was associated with an increased sensitivity to mTOR inhibition in a mouse model.", 
    "disease": "Pancreatic Adenocarcinoma", 
    "favorable_prognosis": null, 
    "last_updated": "2017-11-03 14:39:03.768699", 
    "old_disease": "Pancreatic Cancer", 
    "oncotree_code": "PAAD", 
    "predictive_implication": "Level D", 
    "sources": [
      125
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "mTOR inhibitor", 
    "therapy_sensitivity": true, 
    "therapy_type": "Drug Class", 
    "validated": true
  }, 
  {
    "alterations": [
      236
    ], 
    "assertion_id": 418, 
    "created_on": null, 
    "description": "PTEN loss of function may confer sensitivity to selective PI3K inhibition", 
    "disease": "", 
    "favorable_prognosis": null, 
    "last_updated": "2017-11-03 14:39:03.778152", 
    "old_disease": "", 
    "oncotree_code": "", 
    "predictive_implication": "Level D", 
    "sources": [
      123
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "AZD8186", 
    "therapy_sensitivity": true, 
    "therapy_type": "Targeted Drug", 
    "validated": true
  }, 
  {
    "alterations": [
      237
    ], 
    "assertion_id": 419, 
    "created_on": null, 
    "description": "PTEN loss of function may confer sensitivity to selective PI3K inhibition", 
    "disease": "", 
    "favorable_prognosis": null, 
    "last_updated": "2017-11-03 14:39:03.787540", 
    "old_disease": "", 
    "oncotree_code": "", 
    "predictive_implication": "Level D", 
    "sources": [
      123
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "AZD8186", 
    "therapy_sensitivity": true, 
    "therapy_type": "Targeted Drug", 
    "validated": true
  }, 
  {
    "alterations": [
      238
    ], 
    "assertion_id": 420, 
    "created_on": null, 
    "description": "PTEN loss of function may confer sensitivity to selective PI3K inhibition", 
    "disease": "", 
    "favorable_prognosis": null, 
    "last_updated": "2017-11-03 14:39:03.805487", 
    "old_disease": "", 
    "oncotree_code": "", 
    "predictive_implication": "Level D", 
    "sources": [
      123
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "AZD8186", 
    "therapy_sensitivity": true, 
    "therapy_type": "Targeted Drug", 
    "validated": true
  }, 
  {
    "alterations": [
      239
    ], 
    "assertion_id": 421, 
    "created_on": null, 
    "description": "PTEN loss of function may confer sensitivity to selective PI3K inhibition", 
    "disease": "", 
    "favorable_prognosis": null, 
    "last_updated": "2017-11-03 14:39:03.820573", 
    "old_disease": "", 
    "oncotree_code": "", 
    "predictive_implication": "Level D", 
    "sources": [
      123
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "AZD8186", 
    "therapy_sensitivity": true, 
    "therapy_type": "Targeted Drug", 
    "validated": true
  }, 
  {
    "alterations": [
      236
    ], 
    "assertion_id": 422, 
    "created_on": null, 
    "description": "PTEN loss may predict resistance to immune checkpoint blockade", 
    "disease": "Uterine Leiomyoma", 
    "favorable_prognosis": null, 
    "last_updated": "2017-11-03 14:39:03.834952", 
    "old_disease": "Uterine Leiomyoma", 
    "oncotree_code": "ULM", 
    "predictive_implication": "Level B", 
    "sources": [
      126, 
      127
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "PD-1 Inhibitors", 
    "therapy_sensitivity": false, 
    "therapy_type": "Drug Class", 
    "validated": true
  }, 
  {
    "alterations": [
      237
    ], 
    "assertion_id": 423, 
    "created_on": null, 
    "description": "PTEN loss may predict resistance to immune checkpoint blockade", 
    "disease": "Uterine Leiomyoma", 
    "favorable_prognosis": null, 
    "last_updated": "2017-11-03 14:39:03.847820", 
    "old_disease": "Uterine Leiomyoma", 
    "oncotree_code": "ULM", 
    "predictive_implication": "Level B", 
    "sources": [
      126, 
      127
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "PD-1 Inhibitors", 
    "therapy_sensitivity": false, 
    "therapy_type": "Drug Class", 
    "validated": true
  }, 
  {
    "alterations": [
      238
    ], 
    "assertion_id": 424, 
    "created_on": null, 
    "description": "PTEN loss may predict resistance to immune checkpoint blockade", 
    "disease": "Uterine Leiomyoma", 
    "favorable_prognosis": null, 
    "last_updated": "2017-11-03 14:39:03.862081", 
    "old_disease": "Uterine Leiomyoma", 
    "oncotree_code": "ULM", 
    "predictive_implication": "Level B", 
    "sources": [
      126, 
      127
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "PD-1 Inhibitors", 
    "therapy_sensitivity": false, 
    "therapy_type": "Drug Class", 
    "validated": true
  }, 
  {
    "alterations": [
      239
    ], 
    "assertion_id": 425, 
    "created_on": null, 
    "description": "PTEN loss may predict resistance to immune checkpoint blockade", 
    "disease": "Uterine Leiomyoma", 
    "favorable_prognosis": null, 
    "last_updated": "2017-11-03 14:39:03.873421", 
    "old_disease": "Uterine Leiomyoma", 
    "oncotree_code": "ULM", 
    "predictive_implication": "Level B", 
    "sources": [
      126, 
      127
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "PD-1 Inhibitors", 
    "therapy_sensitivity": false, 
    "therapy_type": "Drug Class", 
    "validated": true
  }, 
  {
    "alterations": [
      240
    ], 
    "assertion_id": 426, 
    "created_on": null, 
    "description": "", 
    "disease": "Myelodysplasia ", 
    "favorable_prognosis": false, 
    "last_updated": "2017-11-03 14:39:03.883496", 
    "old_disease": "Myelodysplastic Syndromes", 
    "oncotree_code": "MDS", 
    "predictive_implication": "Level B", 
    "sources": [
      11
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "", 
    "therapy_sensitivity": null, 
    "therapy_type": "", 
    "validated": true
  }, 
  {
    "alterations": [
      241
    ], 
    "assertion_id": 427, 
    "created_on": null, 
    "description": "RNAi knockdown of RAD17 in the HME-CC breast cancer cell line resulted in increased sensitivity to ABT-888, Veliparib (PARP inhibitor). If RAD50 is also knocked out, a further increase in sensitivity is observed.", 
    "disease": "Invasive Breast Carcinoma", 
    "favorable_prognosis": null, 
    "last_updated": "2017-11-03 14:39:03.894048", 
    "old_disease": "Breast Cancer", 
    "oncotree_code": "BRCA", 
    "predictive_implication": "Level D", 
    "sources": [
      128
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "Veliparib", 
    "therapy_sensitivity": true, 
    "therapy_type": "Targeted Drug", 
    "validated": true
  }, 
  {
    "alterations": [
      241
    ], 
    "assertion_id": 428, 
    "created_on": null, 
    "description": "RNAi knockdown of RAD17 in the HME-CC breast cancer cell line resulted in increased sensitivity to carboplatin. A further increase in sensitivity occurred when knocked down with RAD50.", 
    "disease": "Invasive Breast Carcinoma", 
    "favorable_prognosis": null, 
    "last_updated": "2017-11-03 14:39:03.903569", 
    "old_disease": "Breast Cancer", 
    "oncotree_code": "BRCA", 
    "predictive_implication": "Level D", 
    "sources": [
      128
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "Carboplatin", 
    "therapy_sensitivity": true, 
    "therapy_type": "Targeted Drug", 
    "validated": true
  }, 
  {
    "alterations": [
      242
    ], 
    "assertion_id": 429, 
    "created_on": null, 
    "description": "RNAi knockdown of RAD50 in the HME-CC breast cancer cell line resulted in increased resistance to carboplatin.", 
    "disease": "Invasive Breast Carcinoma", 
    "favorable_prognosis": null, 
    "last_updated": "2017-11-03 14:39:03.916479", 
    "old_disease": "Breast Cancer", 
    "oncotree_code": "BRCA", 
    "predictive_implication": "Level D", 
    "sources": [
      128
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "Carboplatin", 
    "therapy_sensitivity": false, 
    "therapy_type": "Targeted Drug", 
    "validated": true
  }, 
  {
    "alterations": [
      243
    ], 
    "assertion_id": 430, 
    "created_on": null, 
    "description": "Somatic homologous recombination mutations werepredictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.", 
    "disease": "Ovarian Cancer, Other", 
    "favorable_prognosis": null, 
    "last_updated": "2017-11-03 14:39:03.927870", 
    "old_disease": "Ovarian Cancer", 
    "oncotree_code": "OOVC", 
    "predictive_implication": "Level E", 
    "sources": [
      15
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "Platinum", 
    "therapy_sensitivity": true, 
    "therapy_type": "Chemotherapy", 
    "validated": true
  }, 
  {
    "alterations": [
      244
    ], 
    "assertion_id": 431, 
    "created_on": null, 
    "description": "Germline homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas. Mutant cases also had better overall survival than wild type.", 
    "disease": "Ovarian Cancer, Other", 
    "favorable_prognosis": true, 
    "last_updated": "2017-11-03 14:39:03.938687", 
    "old_disease": "Ovarian Cancer", 
    "oncotree_code": "OOVC", 
    "predictive_implication": "Level E", 
    "sources": [
      15
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "Platinum", 
    "therapy_sensitivity": null, 
    "therapy_type": "Chemotherapy", 
    "validated": true
  }, 
  {
    "alterations": [
      243
    ], 
    "assertion_id": 432, 
    "created_on": null, 
    "description": "Somatic homologous recombination mutations werepredictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.", 
    "disease": "Ovarian Cancer, Other", 
    "favorable_prognosis": true, 
    "last_updated": "2017-11-03 14:39:03.949503", 
    "old_disease": "Ovarian Cancer", 
    "oncotree_code": "OOVC", 
    "predictive_implication": "Level E", 
    "sources": [
      15
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "Platinum", 
    "therapy_sensitivity": null, 
    "therapy_type": "Chemotherapy", 
    "validated": true
  }, 
  {
    "alterations": [
      244
    ], 
    "assertion_id": 433, 
    "created_on": null, 
    "description": "Germline homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas. Mutant cases also had better overall survival than wild type.", 
    "disease": "Ovarian Cancer, Other", 
    "favorable_prognosis": true, 
    "last_updated": "2017-11-03 14:39:03.958015", 
    "old_disease": "Ovarian Cancer", 
    "oncotree_code": "OOVC", 
    "predictive_implication": "Level E", 
    "sources": [
      15
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "Platinum", 
    "therapy_sensitivity": null, 
    "therapy_type": "Chemotherapy", 
    "validated": true
  }, 
  {
    "alterations": [
      243
    ], 
    "assertion_id": 434, 
    "created_on": null, 
    "description": "Somatic homologous recombination mutations werepredictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.", 
    "disease": "Peritoneal Mesothelioma", 
    "favorable_prognosis": null, 
    "last_updated": "2017-11-03 14:39:03.971547", 
    "old_disease": "Peritoneal Carcinoma", 
    "oncotree_code": "PEMESO", 
    "predictive_implication": "Level E", 
    "sources": [
      15
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "Platinum", 
    "therapy_sensitivity": true, 
    "therapy_type": "Chemotherapy", 
    "validated": true
  }, 
  {
    "alterations": [
      244
    ], 
    "assertion_id": 435, 
    "created_on": null, 
    "description": "Germline homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas. Mutant cases also had better overall survival than wild type.", 
    "disease": "Peritoneal Mesothelioma", 
    "favorable_prognosis": true, 
    "last_updated": "2017-11-03 14:39:03.986725", 
    "old_disease": "Peritoneal Carcinoma", 
    "oncotree_code": "PEMESO", 
    "predictive_implication": "Level E", 
    "sources": [
      15
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "Platinum", 
    "therapy_sensitivity": null, 
    "therapy_type": "Chemotherapy", 
    "validated": true
  }, 
  {
    "alterations": [
      243
    ], 
    "assertion_id": 436, 
    "created_on": null, 
    "description": "Somatic homologous recombination mutations werepredictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.", 
    "disease": "Peritoneal Mesothelioma", 
    "favorable_prognosis": true, 
    "last_updated": "2017-11-03 14:39:03.995370", 
    "old_disease": "Peritoneal Carcinoma", 
    "oncotree_code": "PEMESO", 
    "predictive_implication": "Level E", 
    "sources": [
      15
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "Platinum", 
    "therapy_sensitivity": null, 
    "therapy_type": "Chemotherapy", 
    "validated": true
  }, 
  {
    "alterations": [
      244
    ], 
    "assertion_id": 437, 
    "created_on": null, 
    "description": "Germline homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas. Mutant cases also had better overall survival than wild type.", 
    "disease": "Peritoneal Mesothelioma", 
    "favorable_prognosis": true, 
    "last_updated": "2017-11-03 14:39:04.005893", 
    "old_disease": "Peritoneal Carcinoma", 
    "oncotree_code": "PEMESO", 
    "predictive_implication": "Level E", 
    "sources": [
      15
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "Platinum", 
    "therapy_sensitivity": null, 
    "therapy_type": "Chemotherapy", 
    "validated": true
  }, 
  {
    "alterations": [
      243
    ], 
    "assertion_id": 438, 
    "created_on": null, 
    "description": "Somatic homologous recombination mutations werepredictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.", 
    "disease": "Serous Ovarian Cancer", 
    "favorable_prognosis": null, 
    "last_updated": "2017-11-03 14:39:04.013106", 
    "old_disease": "Fallopian Tube Carcinoma", 
    "oncotree_code": "SOC", 
    "predictive_implication": "Level E", 
    "sources": [
      15
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "Platinum", 
    "therapy_sensitivity": true, 
    "therapy_type": "Chemotherapy", 
    "validated": true
  }, 
  {
    "alterations": [
      244
    ], 
    "assertion_id": 439, 
    "created_on": null, 
    "description": "Germline homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas. Mutant cases also had better overall survival than wild type.", 
    "disease": "Serous Ovarian Cancer", 
    "favorable_prognosis": true, 
    "last_updated": "2017-11-03 14:39:04.025930", 
    "old_disease": "Fallopian Tube Carcinoma", 
    "oncotree_code": "SOC", 
    "predictive_implication": "Level E", 
    "sources": [
      15
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "Platinum", 
    "therapy_sensitivity": null, 
    "therapy_type": "Chemotherapy", 
    "validated": true
  }, 
  {
    "alterations": [
      243
    ], 
    "assertion_id": 440, 
    "created_on": null, 
    "description": "Somatic homologous recombination mutations werepredictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.", 
    "disease": "Serous Ovarian Cancer", 
    "favorable_prognosis": true, 
    "last_updated": "2017-11-03 14:39:04.034046", 
    "old_disease": "Fallopian Tube Carcinoma", 
    "oncotree_code": "SOC", 
    "predictive_implication": "Level E", 
    "sources": [
      15
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "Platinum", 
    "therapy_sensitivity": null, 
    "therapy_type": "Chemotherapy", 
    "validated": true
  }, 
  {
    "alterations": [
      244
    ], 
    "assertion_id": 441, 
    "created_on": null, 
    "description": "Germline homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas. Mutant cases also had better overall survival than wild type.", 
    "disease": "Serous Ovarian Cancer", 
    "favorable_prognosis": true, 
    "last_updated": "2017-11-03 14:39:04.041542", 
    "old_disease": "Fallopian Tube Carcinoma", 
    "oncotree_code": "SOC", 
    "predictive_implication": "Level E", 
    "sources": [
      15
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "Platinum", 
    "therapy_sensitivity": null, 
    "therapy_type": "Chemotherapy", 
    "validated": true
  }, 
  {
    "alterations": [
      245
    ], 
    "assertion_id": 442, 
    "created_on": null, 
    "description": "Somatic homologous recombination mutations werepredictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.", 
    "disease": "Ovarian Cancer, Other", 
    "favorable_prognosis": null, 
    "last_updated": "2017-11-03 14:39:04.050138", 
    "old_disease": "Ovarian Cancer", 
    "oncotree_code": "OOVC", 
    "predictive_implication": "Level E", 
    "sources": [
      15
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "Platinum", 
    "therapy_sensitivity": true, 
    "therapy_type": "Chemotherapy", 
    "validated": true
  }, 
  {
    "alterations": [
      246
    ], 
    "assertion_id": 443, 
    "created_on": null, 
    "description": "Germline homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas. Mutant cases also had better overall survival than wild type.", 
    "disease": "Ovarian Cancer, Other", 
    "favorable_prognosis": true, 
    "last_updated": "2017-11-03 14:39:04.062124", 
    "old_disease": "Ovarian Cancer", 
    "oncotree_code": "OOVC", 
    "predictive_implication": "Level E", 
    "sources": [
      15
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "Platinum", 
    "therapy_sensitivity": null, 
    "therapy_type": "Chemotherapy", 
    "validated": true
  }, 
  {
    "alterations": [
      245
    ], 
    "assertion_id": 444, 
    "created_on": null, 
    "description": "Somatic homologous recombination mutations werepredictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.", 
    "disease": "Ovarian Cancer, Other", 
    "favorable_prognosis": true, 
    "last_updated": "2017-11-03 14:39:04.075512", 
    "old_disease": "Ovarian Cancer", 
    "oncotree_code": "OOVC", 
    "predictive_implication": "Level E", 
    "sources": [
      15
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "Platinum", 
    "therapy_sensitivity": null, 
    "therapy_type": "Chemotherapy", 
    "validated": true
  }, 
  {
    "alterations": [
      246
    ], 
    "assertion_id": 445, 
    "created_on": null, 
    "description": "Germline homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas. Mutant cases also had better overall survival than wild type.", 
    "disease": "Ovarian Cancer, Other", 
    "favorable_prognosis": true, 
    "last_updated": "2017-11-03 14:39:04.085348", 
    "old_disease": "Ovarian Cancer", 
    "oncotree_code": "OOVC", 
    "predictive_implication": "Level E", 
    "sources": [
      15
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "Platinum", 
    "therapy_sensitivity": null, 
    "therapy_type": "Chemotherapy", 
    "validated": true
  }, 
  {
    "alterations": [
      245
    ], 
    "assertion_id": 446, 
    "created_on": null, 
    "description": "Somatic homologous recombination mutations werepredictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.", 
    "disease": "Peritoneal Mesothelioma", 
    "favorable_prognosis": null, 
    "last_updated": "2017-11-03 14:39:04.093312", 
    "old_disease": "Peritoneal Carcinoma", 
    "oncotree_code": "PEMESO", 
    "predictive_implication": "Level E", 
    "sources": [
      15
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "Platinum", 
    "therapy_sensitivity": true, 
    "therapy_type": "Chemotherapy", 
    "validated": true
  }, 
  {
    "alterations": [
      246
    ], 
    "assertion_id": 447, 
    "created_on": null, 
    "description": "Germline homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas. Mutant cases also had better overall survival than wild type.", 
    "disease": "Peritoneal Mesothelioma", 
    "favorable_prognosis": true, 
    "last_updated": "2017-11-03 14:39:04.100575", 
    "old_disease": "Peritoneal Carcinoma", 
    "oncotree_code": "PEMESO", 
    "predictive_implication": "Level E", 
    "sources": [
      15
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "Platinum", 
    "therapy_sensitivity": null, 
    "therapy_type": "Chemotherapy", 
    "validated": true
  }, 
  {
    "alterations": [
      245
    ], 
    "assertion_id": 448, 
    "created_on": null, 
    "description": "Somatic homologous recombination mutations werepredictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.", 
    "disease": "Peritoneal Mesothelioma", 
    "favorable_prognosis": true, 
    "last_updated": "2017-11-03 14:39:04.108214", 
    "old_disease": "Peritoneal Carcinoma", 
    "oncotree_code": "PEMESO", 
    "predictive_implication": "Level E", 
    "sources": [
      15
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "Platinum", 
    "therapy_sensitivity": null, 
    "therapy_type": "Chemotherapy", 
    "validated": true
  }, 
  {
    "alterations": [
      246
    ], 
    "assertion_id": 449, 
    "created_on": null, 
    "description": "Germline homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas. Mutant cases also had better overall survival than wild type.", 
    "disease": "Peritoneal Mesothelioma", 
    "favorable_prognosis": true, 
    "last_updated": "2017-11-03 14:39:04.117638", 
    "old_disease": "Peritoneal Carcinoma", 
    "oncotree_code": "PEMESO", 
    "predictive_implication": "Level E", 
    "sources": [
      15
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "Platinum", 
    "therapy_sensitivity": null, 
    "therapy_type": "Chemotherapy", 
    "validated": true
  }, 
  {
    "alterations": [
      245
    ], 
    "assertion_id": 450, 
    "created_on": null, 
    "description": "Somatic homologous recombination mutations werepredictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.", 
    "disease": "Serous Ovarian Cancer", 
    "favorable_prognosis": null, 
    "last_updated": "2017-11-03 14:39:04.130478", 
    "old_disease": "Fallopian Tube Carcinoma", 
    "oncotree_code": "SOC", 
    "predictive_implication": "Level E", 
    "sources": [
      15
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "Platinum", 
    "therapy_sensitivity": true, 
    "therapy_type": "Chemotherapy", 
    "validated": true
  }, 
  {
    "alterations": [
      246
    ], 
    "assertion_id": 451, 
    "created_on": null, 
    "description": "Germline homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas. Mutant cases also had better overall survival than wild type.", 
    "disease": "Serous Ovarian Cancer", 
    "favorable_prognosis": true, 
    "last_updated": "2017-11-03 14:39:04.140223", 
    "old_disease": "Fallopian Tube Carcinoma", 
    "oncotree_code": "SOC", 
    "predictive_implication": "Level E", 
    "sources": [
      15
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "Platinum", 
    "therapy_sensitivity": null, 
    "therapy_type": "Chemotherapy", 
    "validated": true
  }, 
  {
    "alterations": [
      245
    ], 
    "assertion_id": 452, 
    "created_on": null, 
    "description": "Somatic homologous recombination mutations werepredictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.", 
    "disease": "Serous Ovarian Cancer", 
    "favorable_prognosis": true, 
    "last_updated": "2017-11-03 14:39:04.148020", 
    "old_disease": "Fallopian Tube Carcinoma", 
    "oncotree_code": "SOC", 
    "predictive_implication": "Level E", 
    "sources": [
      15
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "Platinum", 
    "therapy_sensitivity": null, 
    "therapy_type": "Chemotherapy", 
    "validated": true
  }, 
  {
    "alterations": [
      246
    ], 
    "assertion_id": 453, 
    "created_on": null, 
    "description": "Germline homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas. Mutant cases also had better overall survival than wild type.", 
    "disease": "Serous Ovarian Cancer", 
    "favorable_prognosis": true, 
    "last_updated": "2017-11-03 14:39:04.155737", 
    "old_disease": "Fallopian Tube Carcinoma", 
    "oncotree_code": "SOC", 
    "predictive_implication": "Level E", 
    "sources": [
      15
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "Platinum", 
    "therapy_sensitivity": null, 
    "therapy_type": "Chemotherapy", 
    "validated": true
  }, 
  {
    "alterations": [
      247
    ], 
    "assertion_id": 454, 
    "created_on": null, 
    "description": "Deletion of chromosome 13 seems to have an amplifying effect on cell cycle gene expression and is reported to be associated with short event-free survival (EFS) and overall survival (OS). This copy loss event results in haploinsufficiency of RB1 and other genes mapped to chromosome 13.", 
    "disease": "Multiple Myeloma", 
    "favorable_prognosis": false, 
    "last_updated": "2017-11-03 14:39:04.165918", 
    "old_disease": "Multiple Myeloma", 
    "oncotree_code": "MM", 
    "predictive_implication": "Level B", 
    "sources": [
      86
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "", 
    "therapy_sensitivity": null, 
    "therapy_type": "", 
    "validated": true
  }, 
  {
    "alterations": [
      248
    ], 
    "assertion_id": 455, 
    "created_on": null, 
    "description": "RBM10 mutations were associated with better prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors. Note that all RBM10-mutant patients were found to have high-grade pT3 stage tumors.", 
    "disease": "Pancreatic Adenocarcinoma", 
    "favorable_prognosis": true, 
    "last_updated": "2017-11-03 14:39:04.174470", 
    "old_disease": "Pancreatic Cancer", 
    "oncotree_code": "PAAD", 
    "predictive_implication": "Level B", 
    "sources": [
      10
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "", 
    "therapy_sensitivity": null, 
    "therapy_type": "", 
    "validated": true
  }, 
  {
    "alterations": [
      249
    ], 
    "assertion_id": 456, 
    "created_on": null, 
    "description": "Cabozantinib (a dual MET-VEGF inhibitor) is being evaluated for efficacy in patients with RET fusion-positive tumors.", 
    "disease": "Non-Small Cell Lung Cancer", 
    "favorable_prognosis": null, 
    "last_updated": "2017-11-03 14:39:04.192351", 
    "old_disease": "Non-Small Cell Lung Cancer", 
    "oncotree_code": "NSCLC", 
    "predictive_implication": "Level A", 
    "sources": [
      129
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "Cabozantinib", 
    "therapy_sensitivity": true, 
    "therapy_type": "Targeted Drug", 
    "validated": true
  }, 
  {
    "alterations": [
      250
    ], 
    "assertion_id": 457, 
    "created_on": null, 
    "description": "May be familial in rare cases.", 
    "disease": "Myelodysplasia ", 
    "favorable_prognosis": false, 
    "last_updated": "2017-11-03 14:39:04.204155", 
    "old_disease": "Myelodysplastic Syndromes", 
    "oncotree_code": "MDS", 
    "predictive_implication": "Level B", 
    "sources": [
      11
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "", 
    "therapy_sensitivity": null, 
    "therapy_type": "", 
    "validated": true
  }, 
  {
    "alterations": [
      251
    ], 
    "assertion_id": 458, 
    "created_on": null, 
    "description": "May be familial in rare cases.", 
    "disease": "Myelodysplasia ", 
    "favorable_prognosis": false, 
    "last_updated": "2017-11-03 14:39:04.216853", 
    "old_disease": "Myelodysplastic Syndromes", 
    "oncotree_code": "MDS", 
    "predictive_implication": "Level B", 
    "sources": [
      11
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "", 
    "therapy_sensitivity": null, 
    "therapy_type": "", 
    "validated": true
  }, 
  {
    "alterations": [
      252
    ], 
    "assertion_id": 459, 
    "created_on": null, 
    "description": "t(8;21)(q22;q22) results in the expression of fusion protein RUNX1-MTG8, which recruits histone deacetylases (HDAC) to silence RUNX1 target genes (such as IL-3). Combined use of HDAC inhibitors and DNMT inhibitors may rescue RUNX1 target genes.", 
    "disease": "Myelodysplasia ", 
    "favorable_prognosis": null, 
    "last_updated": "2017-11-03 14:39:04.227738", 
    "old_disease": "Myelodysplastic Syndromes", 
    "oncotree_code": "MDS", 
    "predictive_implication": "Level D", 
    "sources": [
      11
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "HDAC inhibitors+DNMT inhibitors", 
    "therapy_sensitivity": true, 
    "therapy_type": "Targeted Drug", 
    "validated": true
  }, 
  {
    "alterations": [
      253
    ], 
    "assertion_id": 460, 
    "created_on": null, 
    "description": "Associated with disease progression. More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.", 
    "disease": "Myelodysplasia ", 
    "favorable_prognosis": false, 
    "last_updated": "2017-11-03 14:39:04.242090", 
    "old_disease": "Myelodysplastic Syndromes", 
    "oncotree_code": "MDS", 
    "predictive_implication": "Level B", 
    "sources": [
      11
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "", 
    "therapy_sensitivity": null, 
    "therapy_type": "", 
    "validated": true
  }, 
  {
    "alterations": [
      254
    ], 
    "assertion_id": 461, 
    "created_on": null, 
    "description": "Associated with disease progression. More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.", 
    "disease": "Myelodysplasia ", 
    "favorable_prognosis": false, 
    "last_updated": "2017-11-03 14:39:04.253689", 
    "old_disease": "Myelodysplastic Syndromes", 
    "oncotree_code": "MDS", 
    "predictive_implication": "Level B", 
    "sources": [
      11
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "", 
    "therapy_sensitivity": null, 
    "therapy_type": "", 
    "validated": true
  }, 
  {
    "alterations": [
      255
    ], 
    "assertion_id": 462, 
    "created_on": null, 
    "description": "Associated with disease progression. More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.", 
    "disease": "Myelodysplasia ", 
    "favorable_prognosis": false, 
    "last_updated": "2017-11-03 14:39:04.265084", 
    "old_disease": "Myelodysplastic Syndromes", 
    "oncotree_code": "MDS", 
    "predictive_implication": "Level B", 
    "sources": [
      11
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "", 
    "therapy_sensitivity": null, 
    "therapy_type": "", 
    "validated": true
  }, 
  {
    "alterations": [
      256
    ], 
    "assertion_id": 463, 
    "created_on": null, 
    "description": "Associated with disease progression. More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.", 
    "disease": "Myelodysplasia ", 
    "favorable_prognosis": false, 
    "last_updated": "2017-11-03 14:39:04.276034", 
    "old_disease": "Myelodysplastic Syndromes", 
    "oncotree_code": "MDS", 
    "predictive_implication": "Level B", 
    "sources": [
      11
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "", 
    "therapy_sensitivity": null, 
    "therapy_type": "", 
    "validated": true
  }, 
  {
    "alterations": [
      257
    ], 
    "assertion_id": 464, 
    "created_on": null, 
    "description": "Associated with disease progression. More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.", 
    "disease": "Myelodysplasia ", 
    "favorable_prognosis": false, 
    "last_updated": "2017-11-03 14:39:04.287698", 
    "old_disease": "Myelodysplastic Syndromes", 
    "oncotree_code": "MDS", 
    "predictive_implication": "Level B", 
    "sources": [
      11
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "", 
    "therapy_sensitivity": null, 
    "therapy_type": "", 
    "validated": true
  }, 
  {
    "alterations": [
      258
    ], 
    "assertion_id": 465, 
    "created_on": null, 
    "description": "Associated with disease progression. More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.", 
    "disease": "Myelodysplasia ", 
    "favorable_prognosis": false, 
    "last_updated": "2017-11-03 14:39:04.304601", 
    "old_disease": "Myelodysplastic Syndromes", 
    "oncotree_code": "MDS", 
    "predictive_implication": "Level B", 
    "sources": [
      11
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "", 
    "therapy_sensitivity": null, 
    "therapy_type": "", 
    "validated": true
  }, 
  {
    "alterations": [
      259
    ], 
    "assertion_id": 466, 
    "created_on": null, 
    "description": "", 
    "disease": "Myelodysplasia ", 
    "favorable_prognosis": false, 
    "last_updated": "2017-11-03 14:39:04.316049", 
    "old_disease": "Myelodysplastic Syndromes", 
    "oncotree_code": "MDS", 
    "predictive_implication": "Level B", 
    "sources": [
      11
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "", 
    "therapy_sensitivity": null, 
    "therapy_type": "", 
    "validated": true
  }, 
  {
    "alterations": [
      260
    ], 
    "assertion_id": 467, 
    "created_on": null, 
    "description": "", 
    "disease": "Myelodysplasia ", 
    "favorable_prognosis": true, 
    "last_updated": "2017-11-03 14:39:04.325974", 
    "old_disease": "Myelodysplastic Syndromes", 
    "oncotree_code": "MDS", 
    "predictive_implication": "Level B", 
    "sources": [
      11
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "", 
    "therapy_sensitivity": null, 
    "therapy_type": "", 
    "validated": true
  }, 
  {
    "alterations": [
      261
    ], 
    "assertion_id": 468, 
    "created_on": null, 
    "description": "", 
    "disease": "Myelodysplasia ", 
    "favorable_prognosis": true, 
    "last_updated": "2017-11-03 14:39:04.335660", 
    "old_disease": "Myelodysplastic Syndromes", 
    "oncotree_code": "MDS", 
    "predictive_implication": "Level B", 
    "sources": [
      11
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "", 
    "therapy_sensitivity": null, 
    "therapy_type": "", 
    "validated": true
  }, 
  {
    "alterations": [
      262
    ], 
    "assertion_id": 469, 
    "created_on": null, 
    "description": "", 
    "disease": "Myelodysplasia ", 
    "favorable_prognosis": true, 
    "last_updated": "2017-11-03 14:39:04.351024", 
    "old_disease": "Myelodysplastic Syndromes", 
    "oncotree_code": "MDS", 
    "predictive_implication": "Level B", 
    "sources": [
      11
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "", 
    "therapy_sensitivity": null, 
    "therapy_type": "", 
    "validated": true
  }, 
  {
    "alterations": [
      263
    ], 
    "assertion_id": 470, 
    "created_on": null, 
    "description": "", 
    "disease": "Myelodysplasia ", 
    "favorable_prognosis": true, 
    "last_updated": "2017-11-03 14:39:04.363559", 
    "old_disease": "Myelodysplastic Syndromes", 
    "oncotree_code": "MDS", 
    "predictive_implication": "Level B", 
    "sources": [
      11
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "", 
    "therapy_sensitivity": null, 
    "therapy_type": "", 
    "validated": true
  }, 
  {
    "alterations": [
      264
    ], 
    "assertion_id": 471, 
    "created_on": null, 
    "description": "", 
    "disease": "Myelodysplasia ", 
    "favorable_prognosis": true, 
    "last_updated": "2017-11-03 14:39:04.373819", 
    "old_disease": "Myelodysplastic Syndromes", 
    "oncotree_code": "MDS", 
    "predictive_implication": "Level B", 
    "sources": [
      11
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "", 
    "therapy_sensitivity": null, 
    "therapy_type": "", 
    "validated": true
  }, 
  {
    "alterations": [
      265
    ], 
    "assertion_id": 472, 
    "created_on": null, 
    "description": "", 
    "disease": "Myelodysplasia ", 
    "favorable_prognosis": true, 
    "last_updated": "2017-11-03 14:39:04.383918", 
    "old_disease": "Myelodysplastic Syndromes", 
    "oncotree_code": "MDS", 
    "predictive_implication": "Level B", 
    "sources": [
      11
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "", 
    "therapy_sensitivity": null, 
    "therapy_type": "", 
    "validated": true
  }, 
  {
    "alterations": [
      266
    ], 
    "assertion_id": 473, 
    "created_on": null, 
    "description": "", 
    "disease": "Myelodysplasia ", 
    "favorable_prognosis": true, 
    "last_updated": "2017-11-03 14:39:04.396211", 
    "old_disease": "Myelodysplastic Syndromes", 
    "oncotree_code": "MDS", 
    "predictive_implication": "Level B", 
    "sources": [
      11
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "", 
    "therapy_sensitivity": null, 
    "therapy_type": "", 
    "validated": true
  }, 
  {
    "alterations": [
      267
    ], 
    "assertion_id": 474, 
    "created_on": null, 
    "description": "", 
    "disease": "Myelodysplasia ", 
    "favorable_prognosis": true, 
    "last_updated": "2017-11-03 14:39:04.413518", 
    "old_disease": "Myelodysplastic Syndromes", 
    "oncotree_code": "MDS", 
    "predictive_implication": "Level B", 
    "sources": [
      11
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "", 
    "therapy_sensitivity": null, 
    "therapy_type": "", 
    "validated": true
  }, 
  {
    "alterations": [
      268
    ], 
    "assertion_id": 475, 
    "created_on": null, 
    "description": "", 
    "disease": "Myelodysplasia ", 
    "favorable_prognosis": true, 
    "last_updated": "2017-11-03 14:39:04.424543", 
    "old_disease": "Myelodysplastic Syndromes", 
    "oncotree_code": "MDS", 
    "predictive_implication": "Level B", 
    "sources": [
      11
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "", 
    "therapy_sensitivity": null, 
    "therapy_type": "", 
    "validated": true
  }, 
  {
    "alterations": [
      269
    ], 
    "assertion_id": 476, 
    "created_on": null, 
    "description": "", 
    "disease": "Myelodysplasia ", 
    "favorable_prognosis": true, 
    "last_updated": "2017-11-03 14:39:04.436060", 
    "old_disease": "Myelodysplastic Syndromes", 
    "oncotree_code": "MDS", 
    "predictive_implication": "Level B", 
    "sources": [
      11
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "", 
    "therapy_sensitivity": null, 
    "therapy_type": "", 
    "validated": true
  }, 
  {
    "alterations": [
      270
    ], 
    "assertion_id": 477, 
    "created_on": null, 
    "description": "", 
    "disease": "Myelodysplasia ", 
    "favorable_prognosis": true, 
    "last_updated": "2017-11-03 14:39:04.448998", 
    "old_disease": "Myelodysplastic Syndromes", 
    "oncotree_code": "MDS", 
    "predictive_implication": "Level B", 
    "sources": [
      11
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "", 
    "therapy_sensitivity": null, 
    "therapy_type": "", 
    "validated": true
  }, 
  {
    "alterations": [
      271
    ], 
    "assertion_id": 478, 
    "created_on": null, 
    "description": "", 
    "disease": "Myelodysplasia ", 
    "favorable_prognosis": true, 
    "last_updated": "2017-11-03 14:39:04.465410", 
    "old_disease": "Myelodysplastic Syndromes", 
    "oncotree_code": "MDS", 
    "predictive_implication": "Level B", 
    "sources": [
      11
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "", 
    "therapy_sensitivity": null, 
    "therapy_type": "", 
    "validated": true
  }, 
  {
    "alterations": [
      272
    ], 
    "assertion_id": 479, 
    "created_on": null, 
    "description": "SMARCA4 inactivating mutations and sensitivity to AURKA inhibitor in preclinical models of non small cell lung adenocarcinoma", 
    "disease": "Non-Small Cell Lung Cancer", 
    "favorable_prognosis": null, 
    "last_updated": "2017-11-03 14:39:04.480207", 
    "old_disease": "Non-Small Cell Lung Cancer", 
    "oncotree_code": "NSCLC", 
    "predictive_implication": "Level D", 
    "sources": [
      130
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "VX-680", 
    "therapy_sensitivity": true, 
    "therapy_type": "", 
    "validated": true
  }, 
  {
    "alterations": [
      273
    ], 
    "assertion_id": 480, 
    "created_on": null, 
    "description": "SMARCA4 inactivating mutations and sensitivity to AURKA inhibitor in preclinical models of non small cell lung adenocarcinoma", 
    "disease": "Non-Small Cell Lung Cancer", 
    "favorable_prognosis": null, 
    "last_updated": "2017-11-03 14:39:04.488951", 
    "old_disease": "Non-Small Cell Lung Cancer", 
    "oncotree_code": "NSCLC", 
    "predictive_implication": "Level D", 
    "sources": [
      130
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "VX-680", 
    "therapy_sensitivity": true, 
    "therapy_type": "", 
    "validated": true
  }, 
  {
    "alterations": [
      274
    ], 
    "assertion_id": 481, 
    "created_on": null, 
    "description": "SMARCA4 inactivating mutations and sensitivity to AURKA inhibitor in preclinical models of non small cell lung adenocarcinoma", 
    "disease": "Non-Small Cell Lung Cancer", 
    "favorable_prognosis": null, 
    "last_updated": "2017-11-03 14:39:04.498729", 
    "old_disease": "Non-Small Cell Lung Cancer", 
    "oncotree_code": "NSCLC", 
    "predictive_implication": "Level D", 
    "sources": [
      130
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "VX-680", 
    "therapy_sensitivity": true, 
    "therapy_type": "", 
    "validated": true
  }, 
  {
    "alterations": [
      275
    ], 
    "assertion_id": 482, 
    "created_on": null, 
    "description": "Most frequent in Chronic Myelomonocytic Leukemia.", 
    "disease": "Myelodysplasia ", 
    "favorable_prognosis": false, 
    "last_updated": "2017-11-03 14:39:04.509906", 
    "old_disease": "Myelodysplastic Syndromes", 
    "oncotree_code": "MDS", 
    "predictive_implication": "Level B", 
    "sources": [
      11
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "", 
    "therapy_sensitivity": null, 
    "therapy_type": "", 
    "validated": true
  }, 
  {
    "alterations": [
      276
    ], 
    "assertion_id": 483, 
    "created_on": null, 
    "description": "", 
    "disease": "Myelodysplasia ", 
    "favorable_prognosis": false, 
    "last_updated": "2017-11-03 14:39:04.528449", 
    "old_disease": "Myelodysplastic Syndromes", 
    "oncotree_code": "MDS", 
    "predictive_implication": "Level B", 
    "sources": [
      11
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "", 
    "therapy_sensitivity": null, 
    "therapy_type": "", 
    "validated": true
  }, 
  {
    "alterations": [
      277
    ], 
    "assertion_id": 484, 
    "created_on": null, 
    "description": "", 
    "disease": "Myelodysplasia ", 
    "favorable_prognosis": false, 
    "last_updated": "2017-11-03 14:39:04.538951", 
    "old_disease": "Myelodysplastic Syndromes", 
    "oncotree_code": "MDS", 
    "predictive_implication": "Level B", 
    "sources": [
      11
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "", 
    "therapy_sensitivity": null, 
    "therapy_type": "", 
    "validated": true
  }, 
  {
    "alterations": [
      278
    ], 
    "assertion_id": 485, 
    "created_on": null, 
    "description": "", 
    "disease": "Myelodysplasia ", 
    "favorable_prognosis": false, 
    "last_updated": "2017-11-03 14:39:04.548812", 
    "old_disease": "Myelodysplastic Syndromes", 
    "oncotree_code": "MDS", 
    "predictive_implication": "Level B", 
    "sources": [
      11
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "", 
    "therapy_sensitivity": null, 
    "therapy_type": "", 
    "validated": true
  }, 
  {
    "alterations": [
      279
    ], 
    "assertion_id": 486, 
    "created_on": null, 
    "description": "TET2 mutations are associated with an increased sensitivity to hypomethylating agents (such as AzaC). This increased sensitivity may be partially abrogated in the presence of ASXL1 mutations.", 
    "disease": "Myelodysplasia ", 
    "favorable_prognosis": null, 
    "last_updated": "2017-11-03 14:39:04.559798", 
    "old_disease": "Myelodysplastic Syndromes", 
    "oncotree_code": "MDS", 
    "predictive_implication": "FDA-Approved", 
    "sources": [
      11
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "AzaC", 
    "therapy_sensitivity": true, 
    "therapy_type": "Drug Class", 
    "validated": true
  }, 
  {
    "alterations": [
      279
    ], 
    "assertion_id": 487, 
    "created_on": null, 
    "description": "TET2 mutations are associated with an increased sensitivity to hypomethylating agents (such as AzaC). This increased sensitivity may be partially abrogated in the presence of ASXL1 mutations.", 
    "disease": "Myelodysplasia ", 
    "favorable_prognosis": null, 
    "last_updated": "2017-11-03 14:39:04.574267", 
    "old_disease": "Myelodysplastic Syndromes", 
    "oncotree_code": "MDS", 
    "predictive_implication": "FDA-Approved", 
    "sources": [
      11
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "Hypomethylating agents", 
    "therapy_sensitivity": true, 
    "therapy_type": "Drug Class", 
    "validated": true
  }, 
  {
    "alterations": [
      280
    ], 
    "assertion_id": 488, 
    "created_on": null, 
    "description": "Cells which harbored the TMPRSS2-ERG fusion became radiosensitive following radiation and PARP inhibitor, specifically Rucaparib.", 
    "disease": "Prostate Adenocarcinoma", 
    "favorable_prognosis": null, 
    "last_updated": "2017-11-03 14:39:04.588519", 
    "old_disease": "Prostate Cancer", 
    "oncotree_code": "PRAD", 
    "predictive_implication": "Level D", 
    "sources": [
      131
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "Rucaparib", 
    "therapy_sensitivity": true, 
    "therapy_type": "Targeted Drug", 
    "validated": true
  }, 
  {
    "alterations": [
      280
    ], 
    "assertion_id": 489, 
    "created_on": null, 
    "description": "A cohort of men with localized prostate cancer was followed and a statistically significant association between the presense of the TMPRSS2-ERG fusion and prostate cancer specific death was observed. Prostate cancer with this fusion may be of a more aggressive phenotype.", 
    "disease": "Prostate Adenocarcinoma", 
    "favorable_prognosis": false, 
    "last_updated": "2017-11-03 14:39:04.597987", 
    "old_disease": "Prostate Cancer", 
    "oncotree_code": "PRAD", 
    "predictive_implication": "Level B", 
    "sources": [
      132
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "", 
    "therapy_sensitivity": null, 
    "therapy_type": "", 
    "validated": true
  }, 
  {
    "alterations": [
      281
    ], 
    "assertion_id": 490, 
    "created_on": null, 
    "description": "Deletion of 17p13 leads to LoH of TP53 and is considered a high-risk feature of multiple myeloma.", 
    "disease": "Multiple Myeloma", 
    "favorable_prognosis": false, 
    "last_updated": "2017-11-03 14:39:04.608770", 
    "old_disease": "Multiple Myeloma", 
    "oncotree_code": "MM", 
    "predictive_implication": "Level B", 
    "sources": [
      86
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "", 
    "therapy_sensitivity": null, 
    "therapy_type": "", 
    "validated": true
  }, 
  {
    "alterations": [
      282
    ], 
    "assertion_id": 491, 
    "created_on": null, 
    "description": "More frequent with complex karyotypes and del(5q).", 
    "disease": "Myelodysplasia ", 
    "favorable_prognosis": null, 
    "last_updated": "2017-11-03 14:39:04.623859", 
    "old_disease": "Myelodysplastic Syndromes", 
    "oncotree_code": "MDS", 
    "predictive_implication": "Level B", 
    "sources": [
      11
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "Lenalidomide", 
    "therapy_sensitivity": false, 
    "therapy_type": "Targeted Drug", 
    "validated": true
  }, 
  {
    "alterations": [
      283
    ], 
    "assertion_id": 492, 
    "created_on": null, 
    "description": "More frequent with complex karyotypes and del(5q).", 
    "disease": "Myelodysplasia ", 
    "favorable_prognosis": null, 
    "last_updated": "2017-11-03 14:39:04.636498", 
    "old_disease": "Myelodysplastic Syndromes", 
    "oncotree_code": "MDS", 
    "predictive_implication": "Level B", 
    "sources": [
      11
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "Lenalidomide", 
    "therapy_sensitivity": false, 
    "therapy_type": "Targeted Drug", 
    "validated": true
  }, 
  {
    "alterations": [
      284
    ], 
    "assertion_id": 493, 
    "created_on": null, 
    "description": "More frequent with complex karyotypes and del(5q).", 
    "disease": "Myelodysplasia ", 
    "favorable_prognosis": null, 
    "last_updated": "2017-11-03 14:39:04.646301", 
    "old_disease": "Myelodysplastic Syndromes", 
    "oncotree_code": "MDS", 
    "predictive_implication": "Level B", 
    "sources": [
      11
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "Lenalidomide", 
    "therapy_sensitivity": false, 
    "therapy_type": "Targeted Drug", 
    "validated": true
  }, 
  {
    "alterations": [
      285
    ], 
    "assertion_id": 494, 
    "created_on": null, 
    "description": "Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).", 
    "disease": "Myelodysplasia ", 
    "favorable_prognosis": false, 
    "last_updated": "2017-11-03 14:39:04.654820", 
    "old_disease": "Myelodysplastic Syndromes", 
    "oncotree_code": "MDS", 
    "predictive_implication": "Level B", 
    "sources": [
      11
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "Lenalidomide", 
    "therapy_sensitivity": null, 
    "therapy_type": "Targeted Drug", 
    "validated": true
  }, 
  {
    "alterations": [
      286
    ], 
    "assertion_id": 495, 
    "created_on": null, 
    "description": "Clofazimine was found to decrease cell survival in several pancreatic ductal adenocarcinoma cell lines.", 
    "disease": "Pancreatic Adenocarcinoma", 
    "favorable_prognosis": null, 
    "last_updated": "2017-11-03 14:39:04.665761", 
    "old_disease": "Pancreatic Cancer", 
    "oncotree_code": "PAAD", 
    "predictive_implication": "Level D", 
    "sources": [
      133
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "Clofazimine", 
    "therapy_sensitivity": true, 
    "therapy_type": "Drug", 
    "validated": true
  }, 
  {
    "alterations": [
      286
    ], 
    "assertion_id": 496, 
    "created_on": null, 
    "description": "Presence of mutant TP53 may suggest resistance to nutlin-3.", 
    "disease": "Gastric Remnant Adenocarcinoma", 
    "favorable_prognosis": null, 
    "last_updated": "2017-11-03 14:39:04.678667", 
    "old_disease": "Gastric Cancer", 
    "oncotree_code": "GRC", 
    "predictive_implication": "Level D", 
    "sources": [
      109
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "nutlin-3", 
    "therapy_sensitivity": false, 
    "therapy_type": "Targeted Drug", 
    "validated": true
  }, 
  {
    "alterations": [
      287
    ], 
    "assertion_id": 497, 
    "created_on": null, 
    "description": "Downmodulation of TPX2 and AURKA in the presence of 20q copy gain was shown to tumor growth", 
    "disease": "Colorectal Adenocarcinoma", 
    "favorable_prognosis": false, 
    "last_updated": "2017-11-03 14:39:04.689538", 
    "old_disease": "Colorectal Cancer", 
    "oncotree_code": "COADREAD", 
    "predictive_implication": "Level D", 
    "sources": [
      12
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "", 
    "therapy_sensitivity": null, 
    "therapy_type": "", 
    "validated": true
  }, 
  {
    "alterations": [
      288
    ], 
    "assertion_id": 498, 
    "created_on": null, 
    "description": "Loss of function mutations in TSC1, TSC2, or FLCN may predict sensitivity to mTOR inhibition", 
    "disease": "Anaplastic Thyroid Cancer", 
    "favorable_prognosis": null, 
    "last_updated": "2017-11-03 14:39:04.700012", 
    "old_disease": "Anaplastic Thyroid Cancer", 
    "oncotree_code": "THAP", 
    "predictive_implication": "Level B", 
    "sources": [
      80, 
      81
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "mTOR inhibitor", 
    "therapy_sensitivity": true, 
    "therapy_type": "Drug Class", 
    "validated": true
  }, 
  {
    "alterations": [
      289
    ], 
    "assertion_id": 499, 
    "created_on": null, 
    "description": "Loss of function mutations in TSC1, TSC2, or FLCN may predict sensitivity to mTOR inhibition", 
    "disease": "Anaplastic Thyroid Cancer", 
    "favorable_prognosis": null, 
    "last_updated": "2017-11-03 14:39:04.711140", 
    "old_disease": "Anaplastic Thyroid Cancer", 
    "oncotree_code": "THAP", 
    "predictive_implication": "Level B", 
    "sources": [
      80, 
      81
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "mTOR inhibitor", 
    "therapy_sensitivity": true, 
    "therapy_type": "Drug Class", 
    "validated": true
  }, 
  {
    "alterations": [
      288
    ], 
    "assertion_id": 500, 
    "created_on": null, 
    "description": "Loss of function mutations in TSC1, TSC2, or FLCN may predict sensitivity to mTOR inhibition", 
    "disease": "Bladder Urothelial Carcinoma", 
    "favorable_prognosis": null, 
    "last_updated": "2017-11-03 14:39:04.721162", 
    "old_disease": "Bladder Cancer", 
    "oncotree_code": "BLCA", 
    "predictive_implication": "Level B", 
    "sources": [
      80, 
      81
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "mTOR inhibitor", 
    "therapy_sensitivity": true, 
    "therapy_type": "Drug Class", 
    "validated": true
  }, 
  {
    "alterations": [
      289
    ], 
    "assertion_id": 501, 
    "created_on": null, 
    "description": "Loss of function mutations in TSC1, TSC2, or FLCN may predict sensitivity to mTOR inhibition", 
    "disease": "Bladder Urothelial Carcinoma", 
    "favorable_prognosis": null, 
    "last_updated": "2017-11-03 14:39:04.732238", 
    "old_disease": "Bladder Cancer", 
    "oncotree_code": "BLCA", 
    "predictive_implication": "Level B", 
    "sources": [
      80, 
      81
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "mTOR inhibitor", 
    "therapy_sensitivity": true, 
    "therapy_type": "Drug Class", 
    "validated": true
  }, 
  {
    "alterations": [
      290
    ], 
    "assertion_id": 502, 
    "created_on": null, 
    "description": "Loss of function mutations in TSC1, TSC2, or FLCN may predict sensitivity to mTOR inhibition", 
    "disease": "Anaplastic Thyroid Cancer", 
    "favorable_prognosis": null, 
    "last_updated": "2017-11-03 14:39:04.746734", 
    "old_disease": "Anaplastic Thyroid Cancer", 
    "oncotree_code": "THAP", 
    "predictive_implication": "Level B", 
    "sources": [
      80, 
      81
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "mTOR inhibitor", 
    "therapy_sensitivity": true, 
    "therapy_type": "Drug Class", 
    "validated": true
  }, 
  {
    "alterations": [
      291
    ], 
    "assertion_id": 503, 
    "created_on": null, 
    "description": "Loss of function mutations in TSC1, TSC2, or FLCN may predict sensitivity to mTOR inhibition", 
    "disease": "Anaplastic Thyroid Cancer", 
    "favorable_prognosis": null, 
    "last_updated": "2017-11-03 14:39:04.757817", 
    "old_disease": "Anaplastic Thyroid Cancer", 
    "oncotree_code": "THAP", 
    "predictive_implication": "Level B", 
    "sources": [
      80, 
      81
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "mTOR inhibitor", 
    "therapy_sensitivity": true, 
    "therapy_type": "Drug Class", 
    "validated": true
  }, 
  {
    "alterations": [
      290
    ], 
    "assertion_id": 504, 
    "created_on": null, 
    "description": "Loss of function mutations in TSC1, TSC2, or FLCN may predict sensitivity to mTOR inhibition", 
    "disease": "Bladder Urothelial Carcinoma", 
    "favorable_prognosis": null, 
    "last_updated": "2017-11-03 14:39:04.769033", 
    "old_disease": "Bladder Cancer", 
    "oncotree_code": "BLCA", 
    "predictive_implication": "Level B", 
    "sources": [
      80, 
      81
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "mTOR inhibitor", 
    "therapy_sensitivity": true, 
    "therapy_type": "Drug Class", 
    "validated": true
  }, 
  {
    "alterations": [
      291
    ], 
    "assertion_id": 505, 
    "created_on": null, 
    "description": "Loss of function mutations in TSC1, TSC2, or FLCN may predict sensitivity to mTOR inhibition", 
    "disease": "Bladder Urothelial Carcinoma", 
    "favorable_prognosis": null, 
    "last_updated": "2017-11-03 14:39:04.779222", 
    "old_disease": "Bladder Cancer", 
    "oncotree_code": "BLCA", 
    "predictive_implication": "Level B", 
    "sources": [
      80, 
      81
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "mTOR inhibitor", 
    "therapy_sensitivity": true, 
    "therapy_type": "Drug Class", 
    "validated": true
  }, 
  {
    "alterations": [
      292
    ], 
    "assertion_id": 506, 
    "created_on": null, 
    "description": "", 
    "disease": "Myelodysplasia ", 
    "favorable_prognosis": false, 
    "last_updated": "2017-11-03 14:39:04.794868", 
    "old_disease": "Myelodysplastic Syndromes", 
    "oncotree_code": "MDS", 
    "predictive_implication": "Level B", 
    "sources": [
      11
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "", 
    "therapy_sensitivity": null, 
    "therapy_type": "", 
    "validated": true
  }, 
  {
    "alterations": [
      293
    ], 
    "assertion_id": 507, 
    "created_on": null, 
    "description": "", 
    "disease": "Myelodysplasia ", 
    "favorable_prognosis": false, 
    "last_updated": "2017-11-03 14:39:04.806518", 
    "old_disease": "Myelodysplastic Syndromes", 
    "oncotree_code": "MDS", 
    "predictive_implication": "Level B", 
    "sources": [
      11
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "", 
    "therapy_sensitivity": null, 
    "therapy_type": "", 
    "validated": true
  }, 
  {
    "alterations": [
      294
    ], 
    "assertion_id": 508, 
    "created_on": null, 
    "description": "", 
    "disease": "Myelodysplasia ", 
    "favorable_prognosis": false, 
    "last_updated": "2017-11-03 14:39:04.816546", 
    "old_disease": "Myelodysplastic Syndromes", 
    "oncotree_code": "MDS", 
    "predictive_implication": "Level B", 
    "sources": [
      11
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "", 
    "therapy_sensitivity": null, 
    "therapy_type": "", 
    "validated": true
  }, 
  {
    "alterations": [
      295
    ], 
    "assertion_id": 509, 
    "created_on": null, 
    "description": "", 
    "disease": "Myelodysplasia ", 
    "favorable_prognosis": false, 
    "last_updated": "2017-11-03 14:39:04.829564", 
    "old_disease": "Myelodysplastic Syndromes", 
    "oncotree_code": "MDS", 
    "predictive_implication": "Level B", 
    "sources": [
      11
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "", 
    "therapy_sensitivity": null, 
    "therapy_type": "", 
    "validated": true
  }, 
  {
    "alterations": [
      296
    ], 
    "assertion_id": 510, 
    "created_on": null, 
    "description": "A phase II study of 32 colorectal cancer patients (and 9 noncolorectal cancer patients) found an association between mismatch repair deficiency (measured by MSI status) and both immune-related objective response rate (40% of patients with MSI-High vs. 0% in MSI-Low) and immune-related progression-free survival rate (78% of MSI-High patients at 20 weeks vs. 11% in MSI-Low). Post-hoc cohort comparison showed hazard ratio for disease progression or death of 0.10 and for death of 0.22.", 
    "disease": "Colorectal Adenocarcinoma", 
    "favorable_prognosis": null, 
    "last_updated": "2017-11-03 14:39:04.843843", 
    "old_disease": "Colorectal Cancer", 
    "oncotree_code": "COADREAD", 
    "predictive_implication": "Level A", 
    "sources": [
      112
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "Pembrolizumab", 
    "therapy_sensitivity": true, 
    "therapy_type": "Targeted Drug", 
    "validated": true
  }, 
  {
    "alterations": [
      296
    ], 
    "assertion_id": 511, 
    "created_on": null, 
    "description": "Patients with MSI-High colorectal cancer appear not to benefit from, and may be resistant to, 5-fluorouracil therapy.", 
    "disease": "Colorectal Adenocarcinoma", 
    "favorable_prognosis": null, 
    "last_updated": "2017-11-03 14:39:04.853679", 
    "old_disease": "Colorectal Cancer", 
    "oncotree_code": "COADREAD", 
    "predictive_implication": "Level B", 
    "sources": [
      21
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "5-Fluorouracil", 
    "therapy_sensitivity": false, 
    "therapy_type": "Targeted Drug", 
    "validated": true
  }, 
  {
    "alterations": [
      296
    ], 
    "assertion_id": 512, 
    "created_on": null, 
    "description": "Patients with MSI-High colorectal cancer often have a favorable prognosis.", 
    "disease": "Colorectal Adenocarcinoma", 
    "favorable_prognosis": true, 
    "last_updated": "2017-11-03 14:39:04.861800", 
    "old_disease": "Colorectal Cancer", 
    "oncotree_code": "COADREAD", 
    "predictive_implication": "Level B", 
    "sources": [
      21
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "5-Fluorouracil", 
    "therapy_sensitivity": null, 
    "therapy_type": "Targeted Drug", 
    "validated": true
  }, 
  {
    "alterations": [
      297
    ], 
    "assertion_id": 513, 
    "created_on": null, 
    "description": "A study involving 351 multiple myeloma patients associated t(4;14) with a median survival of 24.7 months.", 
    "disease": "Multiple Myeloma", 
    "favorable_prognosis": false, 
    "last_updated": "2017-11-03 14:39:04.870430", 
    "old_disease": "Multiple Myeloma", 
    "oncotree_code": "MM", 
    "predictive_implication": "Level B", 
    "sources": [
      134
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "", 
    "therapy_sensitivity": null, 
    "therapy_type": "", 
    "validated": true
  }, 
  {
    "alterations": [
      298
    ], 
    "assertion_id": 514, 
    "created_on": null, 
    "description": "A study involving 351 multiple myeloma patients associated translocations t(14;16)(q32;q23;17p13) with a median survival of 42.3 months.", 
    "disease": "Multiple Myeloma", 
    "favorable_prognosis": false, 
    "last_updated": "2017-11-03 14:39:04.883480", 
    "old_disease": "Multiple Myeloma", 
    "oncotree_code": "MM", 
    "predictive_implication": "Level B", 
    "sources": [
      134
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "", 
    "therapy_sensitivity": null, 
    "therapy_type": "", 
    "validated": true
  }, 
  {
    "alterations": [
      299
    ], 
    "assertion_id": 515, 
    "created_on": null, 
    "description": "A study involving 351 multiple myeloma patients associated translocations t(14;16)(13q14) with a median survival of 50.5 months.", 
    "disease": "Multiple Myeloma", 
    "favorable_prognosis": false, 
    "last_updated": "2017-11-03 14:39:04.901166", 
    "old_disease": "Multiple Myeloma", 
    "oncotree_code": "MM", 
    "predictive_implication": "Level B", 
    "sources": [
      134
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "", 
    "therapy_sensitivity": null, 
    "therapy_type": "", 
    "validated": true
  }, 
  {
    "alterations": [
      300
    ], 
    "assertion_id": 516, 
    "created_on": null, 
    "description": "", 
    "disease": "Multiple Myeloma", 
    "favorable_prognosis": null, 
    "last_updated": "2017-11-03 14:39:04.914261", 
    "old_disease": "Multiple Myeloma", 
    "oncotree_code": "MM", 
    "predictive_implication": "Level B", 
    "sources": [
      86
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "Thalidomide", 
    "therapy_sensitivity": false, 
    "therapy_type": "Targeted Drug", 
    "validated": true
  }, 
  {
    "alterations": [
      300
    ], 
    "assertion_id": 517, 
    "created_on": null, 
    "description": "Amplification of 1p21 increases the risk of multiple myeloma progression.", 
    "disease": "Multiple Myeloma", 
    "favorable_prognosis": false, 
    "last_updated": "2017-11-03 14:39:04.924796", 
    "old_disease": "Multiple Myeloma", 
    "oncotree_code": "MM", 
    "predictive_implication": "Level B", 
    "sources": [
      86
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "Thalidomide", 
    "therapy_sensitivity": null, 
    "therapy_type": "Targeted Drug", 
    "validated": true
  }, 
  {
    "alterations": [
      301
    ], 
    "assertion_id": 518, 
    "created_on": null, 
    "description": "del(5q) concurrent with symptomatic anemia is associated with sensitivity to lenalidomide. Patients with del(5q) may have a higher risk of concomittant TP53 mutations.", 
    "disease": "Myelodysplasia ", 
    "favorable_prognosis": null, 
    "last_updated": "2017-11-03 14:39:04.935863", 
    "old_disease": "Myelodysplastic Syndromes", 
    "oncotree_code": "MDS", 
    "predictive_implication": "FDA-Approved", 
    "sources": [
      11
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "Lenalidomide", 
    "therapy_sensitivity": true, 
    "therapy_type": "Targeted Drug", 
    "validated": true
  }, 
  {
    "alterations": [
      302
    ], 
    "assertion_id": 519, 
    "created_on": null, 
    "description": "Co-deletion of 1p and 19q is associated with oligodendroglial histology, and may indicate sensitivity to alkylating chemotherapy.", 
    "disease": "Glioma", 
    "favorable_prognosis": null, 
    "last_updated": "2017-11-03 14:39:04.950650", 
    "old_disease": "Glioma", 
    "oncotree_code": "GNOS", 
    "predictive_implication": "Level A", 
    "sources": [
      85
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "Alkylating Chemotherapy", 
    "therapy_sensitivity": true, 
    "therapy_type": "Drug Class", 
    "validated": true
  }, 
  {
    "alterations": [
      303
    ], 
    "assertion_id": 520, 
    "created_on": null, 
    "description": "Co-deletion of 1p and 19q is associated with oligodendroglial histology, and may indicate sensitivity to alkylating chemotherapy.", 
    "disease": "Glioma", 
    "favorable_prognosis": null, 
    "last_updated": "2017-11-03 14:39:04.965406", 
    "old_disease": "Glioma", 
    "oncotree_code": "GNOS", 
    "predictive_implication": "Level A", 
    "sources": [
      85
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "Alkylating Chemotherapy", 
    "therapy_sensitivity": true, 
    "therapy_type": "Drug Class", 
    "validated": true
  }, 
  {
    "alterations": [
      302
    ], 
    "assertion_id": 521, 
    "created_on": null, 
    "description": "Co-deletion of 1p and 19q is associated with oligodendroglial histology, and may indicate a favorable prognosis.", 
    "disease": "Glioma", 
    "favorable_prognosis": true, 
    "last_updated": "2017-11-03 14:39:04.975380", 
    "old_disease": "Glioma", 
    "oncotree_code": "GNOS", 
    "predictive_implication": "Level A", 
    "sources": [
      85
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "Alkylating Chemotherapy", 
    "therapy_sensitivity": null, 
    "therapy_type": "Drug Class", 
    "validated": true
  }, 
  {
    "alterations": [
      303
    ], 
    "assertion_id": 522, 
    "created_on": null, 
    "description": "Co-deletion of 1p and 19q is associated with oligodendroglial histology, and may indicate a favorable prognosis.", 
    "disease": "Glioma", 
    "favorable_prognosis": true, 
    "last_updated": "2017-11-03 14:39:04.983316", 
    "old_disease": "Glioma", 
    "oncotree_code": "GNOS", 
    "predictive_implication": "Level A", 
    "sources": [
      85
    ], 
    "stage": null, 
    "submitted_by": null, 
    "therapy_name": "Alkylating Chemotherapy", 
    "therapy_sensitivity": null, 
    "therapy_type": "Drug Class", 
    "validated": true
  }, 
  {
    "alterations": [
      304
    ], 
    "assertion_id": 523, 
    "created_on": "2018-08-21 16:35:23.444132", 
    "description": null, 
    "disease": "Anaplastic Thyroid Cancer", 
    "favorable_prognosis": null, 
    "last_updated": "2018-08-21 16:35:23.444150", 
    "old_disease": "Anaplastic Thyroid Cancer", 
    "oncotree_code": null, 
    "predictive_implication": "Level A", 
    "sources": [
      3
    ], 
    "stage": null, 
    "submitted_by": "nsmoore15%40gmail.com", 
    "therapy_name": null, 
    "therapy_sensitivity": null, 
    "therapy_type": "ASP8273", 
    "validated": false
  }, 
  {
    "alterations": [
      305
    ], 
    "assertion_id": 524, 
    "created_on": "2018-08-21 16:57:38.615497", 
    "description": null, 
    "disease": "Anaplastic Thyroid Cancer", 
    "favorable_prognosis": null, 
    "last_updated": "2018-08-21 16:57:38.615627", 
    "old_disease": "Anaplastic Thyroid Cancer", 
    "oncotree_code": null, 
    "predictive_implication": "Level B", 
    "sources": [
      3
    ], 
    "stage": null, 
    "submitted_by": "ericrkofman%40gmail.com", 
    "therapy_name": null, 
    "therapy_sensitivity": null, 
    "therapy_type": "ALK Inhibitors", 
    "validated": false
  }, 
  {
    "alterations": [
      305
    ], 
    "assertion_id": 525, 
    "created_on": "2018-08-21 17:00:06.851053", 
    "description": null, 
    "disease": "Anaplastic Thyroid Cancer", 
    "favorable_prognosis": null, 
    "last_updated": "2018-08-21 17:00:06.851108", 
    "old_disease": "Anaplastic Thyroid Cancer", 
    "oncotree_code": null, 
    "predictive_implication": "Level B", 
    "sources": [
      3
    ], 
    "stage": null, 
    "submitted_by": "ericrkofman%40gmail.com", 
    "therapy_name": null, 
    "therapy_sensitivity": null, 
    "therapy_type": "ALK Inhibitors", 
    "validated": false
  }, 
  {
    "alterations": [
      306
    ], 
    "assertion_id": 526, 
    "created_on": "2018-09-26 16:27:08.598662", 
    "description": null, 
    "disease": "Acute Lymphoid Leukemia", 
    "favorable_prognosis": null, 
    "last_updated": "2018-09-26 16:27:08.598787", 
    "old_disease": "Acute Lymphoid Leukemia", 
    "oncotree_code": null, 
    "predictive_implication": "Level A", 
    "sources": [
      3
    ], 
    "stage": null, 
    "submitted_by": "nsmoore15%40gmail.com", 
    "therapy_name": null, 
    "therapy_sensitivity": null, 
    "therapy_type": "ALK Inhibitors", 
    "validated": false
  }, 
  {
    "alterations": [
      307
    ], 
    "assertion_id": 527, 
    "created_on": "2018-09-26 16:45:42.210181", 
    "description": null, 
    "disease": "Anaplastic Thyroid Cancer", 
    "favorable_prognosis": null, 
    "last_updated": "2018-09-26 16:45:42.210199", 
    "old_disease": "Anaplastic Thyroid Cancer", 
    "oncotree_code": null, 
    "predictive_implication": "Level A", 
    "sources": [
      3
    ], 
    "stage": null, 
    "submitted_by": "nsmoore1%40gmail.com", 
    "therapy_name": null, 
    "therapy_sensitivity": null, 
    "therapy_type": "5-Fluorouracil", 
    "validated": false
  }, 
  {
    "alterations": [
      308
    ], 
    "assertion_id": 528, 
    "created_on": "2018-09-26 17:16:56.436512", 
    "description": null, 
    "disease": "prostate", 
    "favorable_prognosis": null, 
    "last_updated": "2018-09-26 17:16:56.436534", 
    "old_disease": "prostate", 
    "oncotree_code": null, 
    "predictive_implication": null, 
    "sources": [
      135
    ], 
    "stage": null, 
    "submitted_by": "a@a.com", 
    "therapy_name": null, 
    "therapy_sensitivity": null, 
    "therapy_type": "", 
    "validated": false
  }, 
  {
    "alterations": [
      308
    ], 
    "assertion_id": 529, 
    "created_on": "2018-09-26 17:39:59.881050", 
    "description": null, 
    "disease": "prostate", 
    "favorable_prognosis": null, 
    "last_updated": "2018-09-26 17:39:59.881188", 
    "old_disease": "prostate", 
    "oncotree_code": null, 
    "predictive_implication": null, 
    "sources": [
      135
    ], 
    "stage": null, 
    "submitted_by": "a@a.com", 
    "therapy_name": null, 
    "therapy_sensitivity": null, 
    "therapy_type": "", 
    "validated": false
  }, 
  {
    "alterations": [
      308
    ], 
    "assertion_id": 530, 
    "created_on": "2018-09-26 17:40:35.866092", 
    "description": null, 
    "disease": "prostate", 
    "favorable_prognosis": null, 
    "last_updated": "2018-09-26 17:40:35.866153", 
    "old_disease": "prostate", 
    "oncotree_code": null, 
    "predictive_implication": null, 
    "sources": [
      135
    ], 
    "stage": null, 
    "submitted_by": "a@a.com", 
    "therapy_name": null, 
    "therapy_sensitivity": null, 
    "therapy_type": "", 
    "validated": false
  }, 
  {
    "alterations": [
      309
    ], 
    "assertion_id": 531, 
    "created_on": "2018-09-28 12:44:48.398730", 
    "description": null, 
    "disease": "Acute Myeloid Leukemia", 
    "favorable_prognosis": null, 
    "last_updated": "2018-09-28 12:44:48.398745", 
    "old_disease": "Acute Myeloid Leukemia", 
    "oncotree_code": null, 
    "predictive_implication": null, 
    "sources": [
      136
    ], 
    "stage": null, 
    "submitted_by": "pageload", 
    "therapy_name": null, 
    "therapy_sensitivity": null, 
    "therapy_type": "Select therapy", 
    "validated": false
  }, 
  {
    "alterations": [
      310
    ], 
    "assertion_id": 532, 
    "created_on": "2018-10-11 13:31:00.153292", 
    "description": null, 
    "disease": "Acute Lymphoid Leukemia", 
    "favorable_prognosis": null, 
    "last_updated": "2018-10-11 13:31:00.153334", 
    "old_disease": "Acute Lymphoid Leukemia", 
    "oncotree_code": null, 
    "predictive_implication": "Level E", 
    "sources": [
      137
    ], 
    "stage": null, 
    "submitted_by": "nsmoore15%40gmail.com", 
    "therapy_name": null, 
    "therapy_sensitivity": null, 
    "therapy_type": "5-Fluorouracil", 
    "validated": false
  }
]
